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In 1991-92 a large collaborative post-mortem study of adults and children was
undertaken in the West African city of Abidjan, Cote d'lvoire, in order to
document the impact of human immunodeficiency virus (HIV) infection on the
already high mortality from infectious disease. As part of this original study,
brain tissue preserved in paraffin wax blocks was retained from 78 HIV
positive children (76 HIV-1 and 2 HIV-2) and 77 age-matched HIV-negative
children. The baseline neuropathological findings were published and the
material was stored as an archive at the Western General Hospital, Edinburgh.
Further study of this unique collection of cases was clearly warranted.
Hypotheses and Aims of the Present Study:
In the Initial Study, an attempt was made to quantify white matter cell
numbers using a small sample of the whole cohort. The hypothesis was that it
would be possible to obtain reproducible numbers for total cell counts in the
white matter of HIV negative children and that the numbers were likely to be
significantly higher in HIV positive children. The Main Study focussed on the
extent of inflammatory change in HIV negative and positive cases, with the
prediction that HIV positive children would show a higher level of
inflammatory infiltrate than HIV negative children, despite the high level of
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background brain pathology in the latter group, and that this would be
associated with evidence of greater white matter damage in the HIV positive
cases. Lastly in the Apolipoprotein E (APOE) Study, it was predicted that the
inflammatory response, particularly the degree of microglial activation would
be influenced by the APOE genotype, being most evident in children
possessing one or more APOE e4 alleles.
Materials and methods:
For the Initial Study, eight age-matched HIV negative and positive cases were
selected from the African cohort, together with an additional HIV negative
case at either end of the age spectrum. Four regions of the brain were selected
from each of these 10 cases, including cerebral convexity, hippocampus, basal
ganglia and the cerebellum. Sections were stained routinely with haematoxylin
and eosin, Luxol fast blue and by immunohistochemistry. Total cell counts
were performed in an area of one mm2, and subsequently for individual cell
types identified using a combination of simple morphology and
immunostaining for glial fibrillary acidic protein (GFAP). Although there is no
immunostain that reliably identifies all of the members of a particular glial
population, whether they be astrocytes, oligodendrocytes or microglia,
separation of these cell types was attempted on the basis of GFAP positivity or
on simple nuclear morphology. The results were tabulated in Excel.
In the Main Study 40 further cases from the African cohort were examined.
These included 20 HIV negative and 20 positive, chosen to represent three age
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groups, lower, middle and upper, up to the age of six years. The basal ganglia
and the hippocampus were selected for examination in these cases. In about
half of these cases, significant pathology other than HIV-associated changes
was present and the spectrum of CNS disease included malaria, meningitis and
non-HIV encephalitis. Sections were stained routinely with haematoxylin and
eosin, Luxol fast blue and by immunohistochemistry for inflammatory cell
markers (CD 14, CD 16 and CD68) or lymphocyte markers (CD8 and CD20).
Sections were examined by routine microscopy, and by simple quantitation or
image analysis.
In the APOE study genotyping was undertaken first on the forty cases used
in the main study. Twenty further cases were added subsequently, 10 HIV
positive and 10 negative, and within the same age range as those in the main
study. DNA was extracted from paraffin sections according to a standard
protocol and amplified using polymerase chain reaction (PCR). The degree of
inflammation, as detected by CD 16 and CD68 image analysis in these cases,
was correlated with the different APOE genotypes.
All cases used in this study were anonymised. Ethical permission was sought
and obtained for this study (LREC/2003/6/6).
Results:
The results of the Initial Study showed that the total cell numbers varied
from case to case in the HIV negative group, and from one brain region to
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another, but that these differences were not statistically significant. The total
cell counts also varied between individual HIV positive cases and these
differences were not statistically significant either. However, comparison of the
means for HIV negative cases with those of the HIV positive cases revealed
significant increases in the latter group. Despite the obvious limitations of the
morphological approach to individual cell typing, subset counts from the
cerebral convexity, basal ganglia, hippocampus and cerebellum, putatively of
astrocytes, oligodendrocytes, microglia and endothelial cells, showed
significantly higher levels in the HIV positive cases.
In the Main Study, changes in the white matter assessed by routine and
Luxol fast blue staining, and by immunohistochemistry for myelin basic
protein (MBP), P-amyloid precursor protein (BAPP) and GFAP, and graded
according to a simple system, showed only limited differences between HIV
positive and negative groups. A general increase in activation of
macrophage/microglial cells and of lymphocyte numbers was found in both
basal ganglia and hippocampus in the HIV positive group. This increase in the
HIV positive group was detected despite a reasonable balance of background
brain pathology between the HIV positive and negative subsets. In the case of
CD68 immunostaining, the increase was statistically significant for the grey
(p=0.002) and white (p=0.009) matter of the basal ganglia. For counts of CD8
positive perivascular cells, the increase was also significant in grey (p=0.001)
and white matter (p=0.000) of the basal ganglia, and in grey (p=0.002) and
white (p=0.000) matter of the hippocampus.
In the APOE study, DNA extraction was successful in 47 cases in total. The
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distribution of APOE s3 and s4 alleles in this group proved in accordance with
the known West African distributions where the s4 allele approaches a
frequency of up to 29%. In this study, though the case numbers are small, the
frequency of the e4 allele was 41% in HIV negative children and 23% in HIV
positive children (p=0.01). These rates were significantly higher than in most
Caucasian populations (p=0.001). Satisfactory immunostaining for
inflammatory markers was achieved in 44 of the genotyped cases. Correlations
with the degree of neuroinflammation in grey and white matter of the basal
ganglia were confined to APOE s3/e3 and APOE e3/e4 cases because of the
small numbers of cases with rarer APOE allelic patterns. For HIV negative
children, there was little difference for CD 16 or CD68 staining between APOE
e3/e3 and APOE e3/e4 cases, either in white or grey matter. For HIV positive
children, subjects with e3/e4 genotypes did show a trend for higher levels of
CD68 activation than those with 3/3 genotypes, particularly in the basal
ganglia white matter, but failed to reach significance (p=0.07 for white matter
and p=0.1 for grey matter).
Conclusions:
1. Although the results of the initial study are limited in their possible
application to any studies other than in this cohort, the increases in total
and individual cell counts in the HIV positive group are intriguing. The
limitations of a study based on morphological assessment are
recognised.
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2. In the main study the failure to demonstrate significant white matter
change in either HIV negative or positive groups may mean that there is
none, but wider sampling in each case and examination of a larger
number of cases would increase confidence in this result. It is noted
that incomplete myelination in these young subjects is a possible
confounding factor in this study. Inflammatory changes, both innate
and acquired, proved to be significantly greater in both grey and white
matter of HIV positive compared with negative cases, there being a
relative balance of co-existing disease in the two groups. This study
shows, as predicted, that HIV infection is accompanied by significant
microglial activation in these West African children, and that this
occurs even in the absence of productive viral infection in the brain.
This finding is in keeping with what is known in Western paediatric
populations infected with HIV.
3. APOE genotyping revealed a distinctive allele distribution especially in
respect of the s4 allele, which was found to be twice as common in this
African cohort as in the Scottish population. Although there was trend
for greater microglial activation in APOE c4 HIV positive children, the




In Rome, in the first century A.D., Pliny the elder wrote: "Semper aliquid
novum ex Africa" (there is always something new from Africa). The reference
was to the Greek observation concerning unusual forms of plant or animal life.
The latter included animals of ferocity or size such that, in gladiatorial combat
in the arenas, a public thirst for spectacle could be assuaged. It was not known
then, of course, that mankind itself had originated in, and spread from, Africa
and it could not have been foreseen, even by the Sybil, the ancient prophetess,
that something much smaller than a carnivore would emerge from Africa to
prove a more formidable foe; and take as its arena the whole world, rendering
the word 'decimation' redundant by several orders of magnitude. The most
recent estimates of numbers are 33 million infected with HIV/AIDS in 2007,
2.5 million became newly infected and 2.1 million deaths for the same year
(WHO 2007).
Chapter 1: General Introduction
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1.1 - HIV/AIDS - The Beginning:
Human immunodeficiency virus (HIV) infection was recognized for the first
time in 1981 in the USA when an epidemic of illness occurred in homosexual
men in New York, Los Angeles and San Francisco. They were found to be
suffering from immunodeficiency associated Pneumocystis pneumonia.
Within a year, further cases, with Central Nervous System (CNS) involvement,
were reported (Britton and Miller 1984). Though these, at post mortem,
showed encephalitis with Cytomegalovirus (CMV) or toxoplasma, an
additional pathological process was suspected.
Epidemiological studies of further populations of similarly afflicted
individuals suggested that a transmissible agent was responsible (Francis et al.
1983) and this was identified as a retrovirus (Barre-Sinoussi 1983). It was
shown to have a strong relationship on molecular hybridisation analysis
(Gonda et al. 1985) to another retrovirus, Visna virus, the causative agent of a
chronic nervous system disease of sheep (Sigurdsson et al. 1957).
Common features of this new human infection, such as oral candidiasis,
recurrent Herpes infections, Pneumocystis carinii pneumonia and Kaposi's
sarcoma suggested a defect in cellular immunity. Careful study revealed that
the natural history of the disease was one usually with a time course of some
years terminating with a variety of illnesses, all having as their basis severe
progressive impairment of immunity. The condition became known as the
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Acquired Immunodeficiency Syndrome (AIDS) and the associated terminal
conditions were referred to as AIDS defining illnesses.
Other sections of the community affected in smaller numbers were
haemophiliacs, intra-venous drug users and those with a history of recent blood
transfusion. These characteristics suggested a blood-borne and sexually
transmissible agent and, two years later, in France this was identified as a
retrovirus, and provisionally named lymphadenopathy associated virus
(LAV)(Barre-Sinoussi et al. 1983) or Human T-lymphotrophic virus III
(HTLV III). In 1986 the International Committee for the Taxonomy of Viruses
suggested the name Human Immunodeficiency Virus (HIV) that was adopted,
and is still retained as HIV -1.
Though initially it appeared that this was confined to America, and then
Europe as well, evidence accrued to demonstrate that at the outset it was
already present in four continents. Heterosexual transmission appeared to occur
as readily as homosexual, as was apparent in Africa. A second related
retrovirus was found in West Africa, and subsequently called HIV-2. It has
remained largely located there, whilst HIV-1 has a worldwide distribution and
is responsible for the pandemic now affecting some 33 million people.
1.2 -The Virus
Sub-Saharan Africa is now known to be the place of origin of the Human
Immunodeficiency Virus in its two distinct types HIV-1 and HIV-2. HIV is a
member of the family of viruses known as the retroviruses, which infect
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principally vertebrates, causing a spectrum of disease including malignancies,
immune deficiencies and neurological disorders. They share a common
structure, genome and mode of replication in which viral RNA is transcribed to
DNA, which is then incorporated into the host genome. HIV is further
classified into a sub-family known as the lentiviruses, which cause slowly
developing illnesses in animals - such as Equine Infectious Anaemia, Feline
Immunodeficiency Disease and Visna, a demyelinating disease of sheep. The
lentivirus diseases of primates, including Simian Immunodeficiency Diseases
(SIVs) and HIV-1 and HIV-2 show tropism for a cell-surface receptor on
lymphocytes designated Cluster of Differentiation 4 (CD4). Hallmarks of their
behaviour, apart from insidious disease onset and persistence, are latency and a
remarkable capacity for genetic variation. Disease transmission is both
horizontal and vertical.
The principal reservoir of African lentiviruses is in the family of Old World
Monkeys and most are species-specific (Hahn et al. 2000). Though termed
Simian Immunodeficiency Viruses (SIVs), because of their close similarity to
HIV-1, they do not cause disease in their natural hosts. When, in 1989, an
HIV-1 related lentivirus was detected in wild chimpanzees (Peeters et al.
1989), (Huet et al. 1990), the suspicion was that this could be the zoonotic
source of HIV. This virus, designated SIVchimpazee (cpz), appeared closer
antigenically to HIV-1 than to HIV-2 or the other SIVs. Subsequently this virus
was found rarely, and only in captive chimpanzees (Gao et al. 1999),
(Nerrienet et al. 2005). More recently extensive field studies in Cameroon,
using faecal specimens gathered from the forest floor and analysed for SIVcpz
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nucleic acids, have suggested that for the chimpanzee subspecies, Pan
troglodytes troglodytes,, community prevalence rates of infection are of 29-
35% (Keele et al. 2006).
Genetic analysis of HIV-1 and HIV-2 has allowed further classification of
HIV-1 into 3 main groups, M, N and O, of which type M is responsible for the
present pandemic; and HIV-2 into 6 subtypes, A-F (Human retroviruses and
Aids - Los Alamos 1998 ) (Hahn et al. 2000). HIV-1 group M is considered to
have evolved directly from SIVcpz, which itself is thought to have arisen as a
recombinant of ancestral forms of SIVs, currently infecting red-capped
mangabeys and Cercopithecus monkeys in West central Africa (Bailes et al.
2003). HIV-2 is thought to have arisen from the sooty mangabey monkey.
HIV-1 sequence analysis suggests the date of the last common ancestor of the
main group of HIV-1 to be 1931 (Korber et al. 2000). The species jump -
chimpanzee to man - is thought to have occurred in or near Cameroon, perhaps
as a result of blood exposure in the bush meat trade, and to have had as its first
staging post a large town, such as Kinshasa (Vidal et al. 2000).
A natural concern, frequently expressed, is that any of the many other SIVs
found in African monkeys today present a continuing zoonotic risk (Hahn et al.
2000), (Keele et al. 2006).
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Fig. 1.2.1 - The Organisation of the HIV Genome and Protein
Derivatives
transcriptase























Table 1.2.1 - The structural HIV genes and their proteins
Gene Protein Location/Function






Env gp41 Transmembrane envelope glycoprotein
gpl20 External envelope glycoprotein
Vpr p 15 Virus particle component
Table 1.2.2 - The regulatory HIV genes and their proteins
Gene Protein Function
Tat pl4 Transcriptional and post- transcriptional
regulator of gene expression
Rev pl9 Post-transcriptional regulator
Nef p27 reduces cell surface expression of the CD 4
receptor
Vif p23 Virus infectivity factor essential for
replication in macrophages and primary T
cells
Vpu pi 5 Membrane protein facilitating viral
maturation and release
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HIV is an enveloped retrovirus and the virion contains two copies of the
RNA genome (see Fig. 1.2.1) The inner core proteins, coded for by the gag
gene, are p9 - the nucleocapsid protein, pi7 - the matrix protein and p24 - the
capsid protein (see Table 1.2.1). The diagnosis ofHIV infection is based on the
finding of serum antibodies directed against gp41. The pol gene codes for three
key enzymes, protease, reverse transcriptase and integrase that are involved in
the replication cycle. The regulatory genes are shown in Table 1.2.2.
After entry into the body the process of infection begins when the envelope
protein, gpl20, binds to the main receptor CD4 on the surface of T4
lymphocytes. This results in a change in the gpl20 molecule such that gp41
becomes accessible to bind to the co-receptor CXCR4 and fusion of the viral
envelope with the cell membrane occurs. The virion then enters the cell and the
viral RNA is copied into DNA by the enzyme, reverse transcriptase.
The viral genome is then incorporated into the host cell genome through the
agency of the enzyme, integrase. The next step is the transcription of viral
genes into viral messenger RNA (mRNA) by host cell polymerase. Viral
assembly follows in the cytoplasm and the capsid proteins are elaborated by
the enzyme, protease. The virion then leaves the cell by budding, acquiring the
envelope from the cell membrane as it departs (see Fig. 1.2.2).
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1.3 -The Stages of HIV/AIDS
Several systems of classification have been used to describe the stages in the
natural history of HIV/AIDS. The Centers for Disease Control (CDC)
proposed a scheme based on clinical features with 4 principal groups:
1. Acute infection
2. Asymptomatic infection
3. Persistent generalised lymphadenopathy
4. Other disease
Group 4 is further divided into subgroups 4A-4E depending on the nature of
the illness and these are:
Group IV A HIV wasting syndrome (AIDS)
Group IV B HIV encephalopathy - AIDS/HIVE and
neurological disease
Group IV C 1 Major opportunistic infections specified as AIDS
defining
Group IV C 2 Minor opportunistic infections
Group IV D Cancers specified as AIDS-defining e.g. primary
CNS lymphoma
Group IV E Other conditions e.g cytomegalovirus pneumonia
In 1989 the World Health Organisation (WHO) offered a classification of
HIV infection in adults based on clinical criteria and lymphocyte counts, the
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groups ranging from asymptomatic individuals with CD4+ T-cell counts > 500
cells / cu. mm., to those terminally ill with counts < 200 cells /cu.mm. Now a
finer grading correlates diseases with counts < 200 cells/cu.mm, e.g.
Pneumocystis carinii, <100 cells/cu.mm, cerebral toxoplasmosis and < 50
cells/cu.mm, disseminated Mycobacterium avium intracellular.
1.4 - Viral Entry into the Body
Several routes are involved: in adults via the genital or rectal mucosa in sexual
intercourse, or by transfusion of infected blood or blood products, or through
intra-venous drug misuse. In the foetus it can occur by trans-placental spread
and at parturition; and in the infant, via the intestinal mucosa from maternally
infected milk.
The efficiency of genital or rectal mucosal transmission is determined by a
number of factors, not least being the HIV load in semen. Usually these mirror
blood levels and are lower, though may be higher, especially in the setting of
co-existent infection such as CMV (Sheth et al. 2006). Also the time with
respect to seroconversion is important, especially high levels in semen
occurring within the first two months after infection (Pilcher et al. 2004).
Studies using human cervico-vaginal organ culture systems have shown early
binding of virions to cervical mucosa with penetration to sub-mucosa within 3-
4 days (Maher et al. 2005). Cells infected had the morphology and distribution
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of macrophages, and yet even after 7 days CD 4+/CD3+ cells showed no
evidence of infection (Palacio et al. 1994).
However, several modes of viral uptake are possible and differing views are
expressed as to the main route. When cell-free virus is considered, infection of
the target cell is determined by its expression of co-receptor CD4 and
chemokine receptor CCR5 (Doms 2001). SIV infection in rhesus monkeys has
been used as a model to study the dynamics of initial infection, and these have
suggested, contrary to the above, that the earliest and most marked infection
occurs within CD4+ T cells of the mucosa (Stahl-Hennig et al. 1999) rather
than Langerhans dendritic cells (Veazey and Lackner 1998; Zhang et al. 1999;
Vajdy et al. 2000; Veazey et al. 2000). These latter cells not only are less
permissive for viral replication, but may actually inhibit viral replication
through the agency of the C-type lectin langerin (CD 207) expressed in the
Birbeck granules of Langerhans cells. Experimental blocking of langerin using
a monoclonal antibody rendered Langerhans cells more liable to HIV infection
and more efficient in transmission to CD4+ lymphocytes (de Witte et al. 2007).
Cell-to-cell transmission by viruses is considered much more efficient than
cell-free spread (Dimitrov et al. 1993) in terms of time - even within minutes
(Sato et al. 1992) - and survival, by relative shielding from the immune
response. For human T cell leukaemia virus type 1 (HTLV-1) it is the
principal pathway (Igakura et al. 2003) as infected lymphocytes release very
few HTLV-1 viral particles. The extent to which this mode of spread operates
in HIV infection is unknown but it occurs readily (Sherer et al. 2007).
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1.5 - The Immune System and Acute HIV Infection
The tissues of the body that bear the major brunt of HIV infection are the
immune system and the CNS. In the primary illness the clinical expression is
principally due to immune system involvement. Though the immune system is
covered in detail in a later section, a short introductory account of the
immunodynamics of early HIV infection is given here.
In the first 2-3 weeks following transmission, by whatever route, the virus
becomes established in the lymphoid tissues of the host (Haase et al. 1996).
Seroconversion, marked by the appearance of anti-HIV antibodies, to core and
envelope proteins, occurs within 3-8 weeks of infection. The chief cell
infected by HIV is the CD4+ lymphocyte, and to a lesser extent the CD4+
macrophage. As explained later in the introduction most circulating
lymphocytes, 60-70%, are naive or unprimed and a similar proportion is found
in the T-cell zones of lymph nodes and the spleen. These mature T
lymphocytes bear the CD 3 (cluster of differentiation) molecular complex,
known as the T-cell receptor, on their surfaces. In activation further molecular
complexes are expressed to give two main lymphocyte subsets, CD4+ and
CD8+ T cells.
The activities of the two types are quite distinct though not necessarily
entirely so. The majority of CD8 cells perform, in their activated state, a
cytotoxic function, especially in viral infections, where infected host cells
bearing viral products on their surfaces are identified and killed. The CD4
lymphocytes, also known as T helper or Th cells, produce, when activated,
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signalling molecules known as cytokines which influence the numbers and
activities of B-cells, cytotoxic T cells, and macrophages.
The HIV envelope glycoprotein, gpl20 , has a particular affinity for the CD4
molecule (also expressed by monocyte/ macrophages and dendritic cells), but
productive infection in the CD4+ cell was found to depend on the presence of
other receptors, known as co-receptors CCR5 and CXCR4 (Berger et al. 1999).
These chemokine receptors are used differentially by specific HIV strains,
predominantly CCR5 for macrophages and CXCR4 for T cells.
The details of viral binding and entry are complex but essentially involve
firstly the conjunction of gpl20 envelope glycoprotein and the CD4 molecule,
then the linkage of gpl20 to either of the co-receptors and finally, through the
agency of gp41, cell membrane fusion and viral entry (Littman 1998).
The sequelae depend on the state of activation of the invaded CD4+ T cell.
In inactive cells the virus may remain in pro-viral form in the cytoplasm, but in
dividing cells the virus enters the nucleus and becomes part of the genome.
Latency or productive infection, with cytolysis, may follow (McCune 2001).
The natural ligand for the CD4 molecule is the major histocompatability
complex (MHC) class II molecule, but its binding affinity is exceeded by that
of the HIV external envelope protein, gp 120.(The MHC is a complex of
genetic loci that encodes a family of cellular antigens. There two principal
classes that code for leucocyte antigens - human leucocyte antigens (HLA)
classes I and II. MHC class I peptides are expressed on the surfaces of all
nucleated cells and allow cytolytic T-cells to recognize cells infected with
pathogens. MHC class II molecules are expressed on B cells, dendritic cells
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and macrophages, that function as antigen presenting cells (APCs) for the
activation of CD4 helper T cells.) The effect of infection in the case of
lymphocytes is usually a cytopathic one, and eventually the replacement
capacity of the bone marrow is overcome, total CD4 lymphocyte levels fall and
a state of immunodeficiency supervenes. Some infected lymphocytes do not
succumb, and remain the site of active infection. Despite infection, the
numbers of monocytes and macrophages remain unchanged. The numbers
infected are relatively less than CD4 lymphocytes and the cytopathic effect
much less pronounced (Schnittman et al. 1989).
By the time seroconversion occurs, viral replication is both rapid and on a
very large scale - it is calculated that daily production of virions by infected
CD4+ T cells is in the order of several billions (Zhang et al. 1999), and some
10-100 million infected CD4+ T cells die daily (Wei et al. 1995). Resting
infected CD4+ T cells may number 1-100 million (Embretson et al. 1993), and
there is also a large reservoir of virion-associated follicular dendritic cells (Fox
and Cottier-Fox 1992). The profound state of immunodeficiency that later
develops has as a cornerstone the depletion of the CD4+ T lymphocyte
population as a direct result of infection, but related factors operate. Chronic
activation of uninfected cells may lead to their depletion by apoptosis
(Hazenberg et al. 2000). Also decreased production, by loss or interference
with maturation of precursor cells in the thymus (Wolthers et al. 1996), is
probably just as important.
The thymus is a lymphoid organ, situated in the upper mediastinum, that
reaches its maximum size in early adolescence with a weight of 30-40 gm.
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After that it gradually involutes, but maintains a degree of function into old
age. In the embryo, at about 8 weeks of age, it is invaded by immature
lymphocytes, the first from the yolk sac and the liver in their haemopoietic
phases, and then from the bone marrow. The major role of the thymus is in the
functional differentiation and selection or deletion of T-lymphocytes. The
immature lymphocytes in the cortex do not possess the T-cell receptors on their
surfaces - they are CD4 and CD8 negative. The maturation process is a
complex one and involves the agency of specialized cells, called thymic nurse
cells and thymic hormones. Lymphocytes reactive to self-antigens are
eliminated by apoptosis, and the mature CD4 and CD8 lymphocytes are
released into the general circulation.
Maldevelopment of the thymus, as in the Di George syndrome, is
characterised in childhood by a state of impaired immunity commonly
associated with death from infection (the role of the thymus in childhood HIV
infection is considered on page 82).
From the clinical point of view, in some 70% of cases there is a transient
glandular fever type illness within the first two to three weeks of infection and,
in a few, a neurological syndrome with a mild meningitis or encephalitis. In
the plasma the CD4 lymphocyte count falls from its normal level of about
1,000 per pi to 300-400 cells per pi and the plasma HIV-RNA level may rise
tol million copies/ml. The antibody to the envelope protein, gp41, persists
indefinitely and its detection is the basis for identification ofHIV infection.
By about 12 weeks the CD4 lymphocyte count has risen to near its original
value and the HIV-RNA level has fallen to a low stable level. These values,
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reflecting a balance between the host's immunity and the virulence of the
infecting HIV strain, were found to be an accurate predictor of the time course
in any particular individual until the onset of AIDS, and the onset of this steady
state has become known as the viral set point (Mellors et al. 1997). Recovery
from the illness of primary infection is usually complete and the illness itself
may be recalled only in retrospect.
1.6 -Asymptomatic Phase of the Infection
After the primary illness subsides, a long asymptomatic period ensues. The
median period from infection to the next stage is 5 -10 years.
Throughout the asymptomatic period persistent generalised
lymphadenopathy (PGL), defined as enlarged lymph nodes at two or more
extra-inguinal sites, is a variable feature. Plasma viral load in untreated
individuals remains elevated, and the fall in CD4+ T-cell levels may be in the
order of 150 cells/pl of blood per year.
During this latent stage of HIV infection, a number of factors operate that
may modulate the severity and rate of progression of the disease. On the one
hand, there is a small sub-set of individuals, termed "non-progressors" or "elite
controllers", who remain healthy despite being infected for many years. AIDS
associated alleles, (they are alternative forms of a gene pair that may be
associated with either an enhanced or suppressed rate of progression of HIV
infection) are described below. The key features of this group, in which the
host adaptive immune response is important through HIV-specific CD4+ and
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CD8+ T-cell actions (Pantaleo et al. 1995; Betts et al. 1999), are a low level
viraemia and a stable CD4+ T-cell population. Host and viral genetic factors
underlie the equilibrium - the prolonged survival of 28 - 40% of a group of
Caucasian HIV subjects to 10 or more years was associated with their being
fully heterozygous at HLA class 1 loci or their lack of AIDS-associated alleles
(Carrington et al. 1999).
The HLA class 1 system is of importance in viral infections for two reasons.
HLA class 1 has been shown to bind to viral peptides, thereby influencing the
activation of cytotoxic T lymphocytes and their action on the virus. Also class
1 molecules similarly interact with natural killer cells through their surface
receptors, resulting the elimination of virally infected cells .These two cell sets
therefore play a crucial role in the establishment or otherwise of early and
continuing viral infection.. Two of the HLA alleles that have been shown to
influence the course of HIV infection are, one, HLA-B*27, that is associated
with slow progression and the other, HLA-B*35 with a more rapid course
(Carrington and O'Brien 2003) A long quiescent period may be due to
deletions or mutations in the HIV nef gene. 'Controllers' showed higher
numbers of IL-2 producing CD4 + lymphocytes than do non-controllers (Emu
et al. 2005).
Age is a factor which influences the rate of progression - beyond an age of
about 50 years lire risk of progression increases by 40% for each decade of life
at the time of infection (Darby et al. 1996). The older the subject at infection,
the more likely a rapid course (Belanger et al. 1997).
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Eventually, in most members of this heterogeneous group, viral replication
increases and CD4+ T-cell numbers fall, due to several mechanisms including
abnormal signalling of CD8+ T cells, decreased stores of perforin, increased
HIV mutant escapes and abnormal B and T cell differentiation (Koenig et al.
1995; Goulder et al. 1997; Appay et al. 2000).
There also exists a very small group of people who remain uninfected despite
repeated exposure to HIV-1 through sexual contact, and this capability has
been shown to be due to their being homozygous for a deletion in the CCR-5
gene which encodes an essential co-receptor, now known as CCR-5 (Liu et al.
1996). The resultant defective protein is shortened, and is undetectable at the
cell membrane level.
The fact that productive infection of HIV occurs much more readily in
activated T-cells (McDougal et al. 1985; Zagury et al. 1986) suggested that
coexisting microbial disease might enhance progression. Support for this view
was obtained in serological studies involving HIV positive American
homosexual men and African sufferers of both sexes. Evidence of previous
exposure to diverse viruses such as HSV, CMV, EBV and Hepatitis B (all
known to perturb the immune system) was found in both groups compared
with controls (Quinn et al. 1987). Mycobacteria infections provoke the
secretion of large amounts of cytokines, including tumour necrosis factor alpha
(TNF-a), interleukin I beta (IL-1|3) and interleukin 6 (IL-6), which all
stimulate the replication of HIV in monocytes and macrophages (Poli et al.
1994). Mycobacterium avium infections commonly give rise to bacteraemia in
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AIDS sufferers in the USA, and in Africa M tuberculosis is one of the
commonest terminal opportunistic infections (Lucas et al. 1993).
The situation regarding African populations is of particular concern by virtue
of the enormity of the epidemic, where infection rates of 30% or more were
returned from several African countries (Merson 1993), with devastating
effects on infrastructure and economy. The background level of diverse
infection is higher in African populations compared to affluent communities
and the degree of associated immune activation, even in the HIV negative
population, is a notable feature (Bentwich et al. 1995). One very significant
contributor to this infective burden, and which is a chronic one, is helminth
infestation (Nahmias et al. 1993). Protozoan infection with Toxoplasma
gondii, Leishmania donovani and Plasmodium falciparum (Kublin et al. 2005)
are others.
The next stage of mildly symptomatic disease (CDC classification category
4B) is characterised by the appearance of conditions suggestive of mild
impairment of cellular immunity, and correlating with CD4 T-cell counts of
below 500 / cu.mm but greater than 200 /cu.mm. These conditions may be
general, such as weight loss, diarrhoea, fever and night sweats or specific, such
as oral hairy leucoplakia, cervical dysplasia and herpes zoster. Fungal and
bacterial skin conditions are troublesome and common.
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1.7 -AIDS
The terminal stage ofHIV infection (AIDS) is defined by the development of
conditions associated with severe immunodeficiency - CD4 cell counts of less
than 200 cells /cu.mm. There are a number of such specified conditions and
they include both common and unusual (opportunistic) infections, several types
of neoplasm including lymphoma, and several illnesses of the central nervous
system, for example:


















Primary Cerebral Lymphoma CNS
HIV Encephalopathy CNS
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The more important of these are now considered in relationship to the
systems they commonly affect.
Respiratory System
The first cases seen in 1981 suffered from an unusual pulmonary condition,
Pneumocystis carinii pneumonia, which is caused by an organism with fungal
and protozoal features. Patients present with shortness of breath of several
weeks' duration, malaise, fatigue and a dry cough, and x-ray may show some
peri-hilar shadowing. The differential diagnosis includes pneumonia caused by
bacteria, including tuberculosis (TB). The diagnosis is confirmed by sputum
cytology and treatment with co-trimoxazole is usually effective. Pneumocystis
pneumonia is still the commonest AIDS-defining illness, though triple anti-
HIV therapy and primary prophylaxis have reduced the incidence.
Pulmonary infection with Mycobacterium tuberculosis, causing TB, is a
major problem in the pandemic, as about a third of the 33 million HIV
sufferers are also infected with TB and most of these live in sub-Saharan
Africa. Access to treatment is limited and compliance often suboptimal.
Multi-drug resistance is common and the two diseases have an adverse effect
on each other. Bacterial pneumonias, due to S. pneumoniae and //. influenzae,
are more common in HIV infection and more severe.
The Gastro-lntestinal Tract
Several AIDS-defining conditions affect the gastro-intestinal tract.
Oesophageal candidiasis can be severe and cause dysphagia. Diagnosis is
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confirmed by barium swallow or endoscopy. Anti-fungal agents are an
essential part of treatment. Two groups of zoonotic protozoan parasites,
Cryptosporidium and Microsporidium, commonly cause severe diarrhoea and
malabsorption. Hydration and treatment with albendazole are important, but
success is limited unless highly active antiretroviral therapy (HAART) is used
to restore a low CD4 count.
Cytomegalovirus is implicated in gastro-intestinal tract disease if the CD4
count falls below 100 cells / cu.mm. It can cause oesophagitis and colitis and
without HAART the prognosis is poor. Another disease due to a
Mycobacterium, M. avium intracellular, which may originate in either the
gastro-intestinal or respiratory tracts, has a tendency to become disseminated
but the incidence has fallen appreciably with HAART.
The Nervous System
Apart from infection with HIV itself, both in the primary infection and in end
stage disease, the brain, spinal cord and peripheral nervous system (PNS) are
subject to several opportunistic infections and other conditions that are AIDS
related.
a. Meningitis or meningoencephalitis due to infection with the yeast
Cryptococcus neoformans is an AIDS-defining illness of subacute onset with
headache, fever and mild confusion. It occurs in about 5% of AIDS sufferers.
Raised intracranial pressure with papilloedema may be present. The organism
can be seen on direct film of the cerebro-spinal fluid (CSF) and obtained by
culture. Anti-fungal therapy may not prevent complications, such as deafness
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and blindness, and drainage procedures are indicated for raised intracranial
pressure. The death rate is between 5 and 10%.
b. Cerebral toxoplasmosis: the protozoan parasite, Toxoplasma gondii, has a
worldwide distribution. The natural host is the cat and transmission is by the
excretion of cysts that are subsequently eaten by other animals. On ingestion
tachyzoites are released from the oocyst and multiply intracellularly with the
formation of cysts, especially in skeletal muscle and brain, and which remain
viable indefinitely. Infection in the immunocompetent human is not
uncommon - seropositivity levels in adults can vary between 20-70% - and
results in a minor glandular fever-like illness. Transmission from an acutely
infected pregnant woman to her foetus can result in serious congenital disease.
In AIDS, waning immunity allows activation of any cerebral cysts, resulting in
local or diffuse disease with necrosis and abscess formation. The clinical
presentation is often an encephalitic one, and diagnosis may be difficult as the
scan appearances of cerebral toxoplasmosis and lymphoma may be
indistinguishable. A therapeutic trial of pyrimethamine may be conclusive but,
if not, biopsy is indicated. Despite HAART the outcome is often poor.
c. Cytomegalovirus (CMV): a member of the herpes group of viruses, is of
worldwide distribution and infects man and other mammals. In
immunocompetent hosts the illness of infection is trivial and short lived. The
virus can be found in most tissues and derives its name from its ability to cause
the cells in which it resides to become larger, and to show both nuclear and
cytoplasmic inclusions. It shares with other herpes viruses the habit of latency,
and of becoming reactivated under certain conditions; it can be found in all
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body fluids. Seropositivity in HIV positive groups varies between 50 and 75%,
and before the advent of HAART, CMV retinitis was common in patients with
CD4 cell counts belowlOO /cu.mm. Now a 90% reduction in incidence has
been recorded in patients on long-term HAART. CMV also causes
encephalitis and myelitis. Treatment with anti-viral agents such as ganciclovir
is imperative to reduce the risk of blindness.
d. Progressive multifocal Ieukoencephalopathy (PML) is a condition first
described in 1961 (Richardson 1961). This disease, characterised by
progressive multifocal demyelination, was suspected of having a viral
aetiology on account of inclusion bodies seen in pathological oligodendrocytes.
It tended to occur in people in the older age groups associated with
lymphoproliferative disorders or other neoplasms. In 1969 electron
micrographs showed an array of viral particles in the nuclei of infected
oligodendrocytes and these appeared similar to polyoma virions (Zu Rhein
1969).
In 1971 the virus was isolated from the brain of a patient with Hodgkins
disease who had developed PML (Padgett et al. 1971), and it was named JC
virus (JCV) after the initials of the patient. It was classified as a polyomavirus.
This virus is widespread in nature, with sero-conversion occurring in childhood
and some adult populations having a sero-prevalence rate as high as 90%.
PML remained a rare disease, though numbers increased with the advent of
organ transplantation and drug-induced immuno-suppression. Now, in AIDS,
the incidence can be as high as 5-10% and, pre-HAART, it was the AIDS
defining illness in 1-3% of cases. The prognosis is poor, most patients
33
surviving only a matter of months after diagnosis (by MRI scan) and despite
HAART and/or anti-viral therapy.
e. Primary CNS lymphoma: in immuno-suppressed individuals the
commonest CNS neoplasm is Primary CNS lymphoma (PCNSL) and it occurs
in approximately 5% of all AIDS cases. The presentation is a short illness with
headache, fever and increasing drowsiness - focal signs and seizures develop,
and in an HIV/AIDS setting the principal differential diagnosis is cerebral
toxoplasmosis. Failure to respond to anti-protozoal therapy, especially if
toxoplasma serology is negative, suggests the diagnosis and, if imaging is
unhelpful, brain biopsy may be required. The lymphoma is usually a single
mass with oedema, but it may be multifocal. Histology shows most PCNSLs
to be high grade B-cell neoplasms and there is a very strong association with
Epstein-Barr virus, the genome of which can be found in 90% of lymphoma
masses and in virtually 100% of PCNSLs in AIDS. Treatment with
chemotherapy and /or irradiation is of little avail and life expectancy, like that
of PML, is measured in months.
f. HIV-associated dementia (HAD): characterised by global cognitive
deterioration and associated motor abnormalities, occurs late in HIV infection,
when the CD4 count is generally less than lOOcells / cu.mm. Its incidence has
fallen considerably since the introduction of HAART. Cerebral atrophy is
present and this is detectable on magnetic resonance imaging.
g. Spinal cord involvement: the spinal cord may be affected by a condition
called vacuolar myelopathy - similar in symptomatology to subacute combined
degeneration of the cord associated with pernicious anaemia but showing, in
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addition to demyelination, symmetrical vacuolation. Vitamin B12 levels are
normal and no virus is detectable.
h. Peripheral neuropathy: a distal sensory neuropathy develops in 30% of
cases of AIDS when the CD4 cell count falls to below 200 cells/cu.mm.
Treatment is relatively ineffective and the problem may be compounded by
drug related side effects
i. Proximal myopathy: muscle disease occurs in the later stages of
HIV/AIDS. A specific myopathy can develop, but skeletal muscle may also be
affected by toxoplasmosis, lymphoma and Kaposi's sarcoma. A drug-related
myopathy occurs with zidovudine.
AIDS Related Neoplasms
a. Kaposi's sarcoma: this once rare tumour, which was seen only in a few
restricted populations such as transplant recipients and young adults in Sub-
Saharan Africa, came into prominence with the initial wave of AIDS sufferers
in 1981. It has since appeared to segregate in certain sub-sections of HIV-
infected individuals, namely male homosexuals and bisexuals, but also in sub-
Saharan Africa amongst the general HIV infected population. Epidemiological
studies suggested a transmissible agent and a novel herpes virus, human herpes
virus 8 (HHV8), was identified as the responsible organism (Chang et al.
1994). The initial lesion is often a purple skin patch, which then enlarges and
forms a plaque and later becomes nodular. Any internal organ may be
involved and the pace of the illness is often determined by co-existing
pathology. The tumour has a rather variable histological appearance with
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endothelial cells, fibroblasts and spindle cells arranged in sheets, in the dermis
and subcutaneous tissues. Frequent mitoses are seen in the more aggressive
nodular types. Combination therapy has reduced the incidence of the disease
and may, in previously untreated cases, result in regression. Simple excision,
radiotherapy and chemotherapy all have a part to play in treatment.
b. HIV-associated lymphoma: including PCNSL. The risk of developing
both Hodgkin and non-Hodgkin lymphoma in HIV infection is increased and
correlates with the degree of immunosuppression, most presenting when the
CD4 cell count is about 50 cells / cu.mm. It is the AIDS-defining condition in
5-10% in some cohorts. HAART is considered to have effected a 40%
reduction in incidence. Standard chemotherapy is used with a remission rate of
about 50%.
c. Ano-genital neoplasms: anogenital cancer is more frequent in HIV
infected people and the risk is associated with increased incidence of human
papilloma virus infection.
d. Invasive cervical carcinoma: this is also an AIDS-defining condition.
1.8 - Normal Brain Constituents.
Neurons
The neuronal population, which resides in the grey matter, is diverse both in
terms of its distribution and the morphology of its individual cell subsets. An
example of this is in the cerebellar cortex, where the small relatively
featureless granular cells are seen side-by-side with the large distinctive
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Purkinje cells. In humans, neurons are estimated to number 100 to 200 billion
and they vary in size from 4p (e.g. the smallest granular cells of the
cerebellum) to 140p in diameter (e.g. the largest motor neurons of the spinal
cord).
Each neuron has a cell body, termed the perikaryon, and a number of
processes known as dendrites or axons. The axon is generally single, larger
and longer than the dendrites and is dealt with separately below.
The nucleus is generally centrally located and its size varies according to the
cell size, from 3p lo 18p. A darkly staining nucleolus serves to identify the
larger neurons. The cytoplasm is basophilic, and with appropriate staining, and
under the light microscope can be shown to contain neurofibrils and deeply
staining granules known as Nissl substance. These were identified under the
electron microscope as clusters of endoplasmic reticulum. The dendrites
appear as simple extensions of the cell body and branch extensively within the
immediate vicinity of the cell.
The function of the neuron, very simply defined, is to do with the receipt of
information, its processing or retention and its transmission. Input and output
are achieved through two modalities - electrical and chemical. The details of
action potentials and their propagation are not considered here, but in the
resting neuron the interior of the neuron is maintained at 70-90 mV negative
potential with respect to the extracellular space. In activity ionic shift occurs
with the entry of sodium ions and an action potential is generated. The
propagation of action potentials is along the axon and the rate depends on the
diameter and thickness of the myelin sheath, which may attain a velocity of
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120 metres /sec. The dendrites are part of the afferent system of the cell and
form receptor sites with neighbouring synapses and adjacent neuronal cell
membranes.
The axon arises at a special site in the perikaryon, a dome-shaped
prominence known as the axon hillock, and which is completely devoid of
Nissl substance, as is the axon itself, in contrast to the dendrites. The axon
contains mitochondria, neurofilaments and microtubules. Axons over lp in
diameter are usually myelinated (see oligodendrocyte section below) and may
attain a length of a metre or more in the human - from the Pyramidal cells of
the cerebral cortex to the lumbar cord - and of course much longer in other
animals, such as the giraffe! At their distal ends the axons of the CNS form
synaptic contact with other neurons, as with the anterior horn cells of the spinal
cord. In addition to the conduction of impulses the axon is responsible for the
elaboration and release of neurotransmitters. Many of these are produced in
the synaptic terminals of the axons, but the enzymes and other molecules
required for their synthesis are made in the cell body and conveyed along the
axon by a process called axoplasmic transport at a rate which varies, fast
transport at a rate of 400mm/day and slow at l-5mm/day. Apart from the
neurotransmitters and their components, other particles are also carried
including membrane-bound vesicles and, in a retrograde direction, metabolites
and, in pathological settings, viruses, such as the herpes viruses and rabies
virus.
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The Macroglia - oligodendrocytes, astrocytes and ependyma
In the CNS, as opposed to other tissues and organs, there is no connective
tissue, and early investigators tended to view the non-neuronal elements simply
as a supporting framework, calling them neuroglia - the nerve glue of Virchow
(Rudolf Virchow, German Pathologist 1821-1902) It soon became clear,
through the detailed studies of Ramon y Cajal (Santiago Ramon y Cajal,
Spanish neurohistologist 1852 -1934) and others, and more recently from
electron microscopy and molecular biology, that the glia were very important
functional elements. Numerically the glia outnumber the neurons by 10 to 50
times depending on the region, and are estimated to constitute about half the
volume of the human brain.
a. Oligodendrocytes: named because they were seen to have fewer processes
than astrocytes - are considered to be the most numerous glial cell in white
matter, contributing about 80% of the total. In routinely stained sections they
appear as round nuclei, less dense and smaller than astrocytes, and cytoplasm
is not generally apparent. Three classes are recognized on the basis of nuclear
morphology under the light and electron microscope - dark with nuclear size
3.5-5p, medium of nuclear size 4-7p and light of nuclear size 6-8.5p (Mori and
Leblond 1970).
They may also be classified according to their location. They are found in
the grey matter closely associated with neurons and are termed perineuronal
satellite cells. In the white matter they are disposed in rows along the fibres
and are known as interfascicular cells.
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Oligodendrocytes are responsible for the formation and maintenance of
myelin. The process is complex and involves the encirclement of segments of
adjacent axons by tongues of cell membrane, and further coiling, so that a
multilayered section is produced - the internodal segment or internode, the
typical length ofwhich is approximately 200p.
The short gaps between adjoining segments are known as nodes of Ranvier
and are 0.8-1.1p in length. A single oligodendrocyte may contribute segments
to as many as fifty axons and the final thickness of each segment depends on
the diameter of the axon. Myelin in its fresh state appears white, and at
ultrastructural level the sheath is seen to be composed of alternate concentric
layers of lipid and protein.
Myelination correlates directly with brain volume and its progress may be
inferred by the facts that at birth the brain is approximately 25% of its volume
in adult life and by the end of the first year it has reached 75% of the final adult
volume, which is reckoned to occur in the seventeenth or eighteenth year of
life. Different tracts myelinate at different times and detailed post-mortem
studies have provided data that illustrate this variation (Brody et al. 1987). At
birth myelination in the cerebellum was well advanced. At the end of the
second post-natal year though myelination was still found to be incomplete in
the spinal cord the majority of cerebral white matter tracts were almost
completely myelinated including the internal capsule and the temporal lobe
white matter. Currently MRI scanning is contributing to our knowledge of
white matter maturation, which is shown to continue throughout childhood and
adolescence (Paus et al. 2001).
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Oligodendrocytes express the following molecules - galactocerebroside
(gal c), carbonic anhydrase 11 (CA11), myelin basic protein (MBP) and
transferrin. Antibodies to these may be used in immunocytochemistry to aid
their identification but a fully comprehensive marker awaits discovery.
Oligodendrocytes react to a wide range of metabolic and toxic insults by
acute swelling. A sub-set in adult life retains a limited capacity for
proliferation, as is seen in the periphery ofMS lesions (Morris et al. 1994).
b. Astrocytes are the largest of the glial cells, having a perikaryon of 10-20p,
and a nucleus of approximately lOp, in diameter. In number they constitute
10-15% of the total glial population of white matter. Under the light
microscope and in routinely stained sections their cytoplasm is not usually
visible, and in normal white matter the only clues to their identity are nuclear
size and dispersed nuclear chromatin. In the early days of silver staining in
neurohistology the astrocytes in grey matter were distinguished from those in
white matter by having fewer and shorter processes. The former were termed
protoplasmic, and the latter fibrous astrocytes - the name of the cell referring
to its stellate shape. Both fibrous and protoplasmic astrocytes contribute to the
almost complete covering of the capillary by their end feet (see BBB below).
Both likewise participate in the formation of the CNS surface covering and
interface with the pia, its basal lamina and their end-feet or cell bodies - the
glia limitans.
The fibrils first noted in silver stains appear at ultrastructural level to be
hollow structures, which are about 10mm. in diameter and bearing some
resemblance to neurofilaments. They occur in both the perikaryon and
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processes as compact bundles, and their main constituent is an intermediate
filament protein known as glial fibrillary acidic protein (GFAP) that has a
molecular weight of 27.000 kD. They are found in protoplasmic astrocytes as
well but are far fewer in number. Astrocytes have a capacity to change rapidly
in morphology that occurs without alteration in the cytoskeletal proteins
(Safavi-Abbasi et al. 2001) (cell culture study).
Since 1972 GFAP has been used as a marker for astrocytes (Bignami et al.
1972) using polyclonal, and now monoclonal, antibodies. There has been
general acceptance that resting protoplasmic astrocytes do not show significant
staining and the fibrous astrocytes of young animals are also less well stained.
Furthermore in the adult animal a proportion of cells having astrocytic
morphology remain unstained.
Astrocytes perform a number of functions in health. The idea of the early
histologists that the main purpose of astrocytes was to provide support for the
neuronal population is inseparable from what is now known of the micro¬
architecture of the astroglia - their attachment to the fine vessels of the
neuropil and their formation of the glia limitans. Astrocytes play an essential
part in the induction and maintenance of the Blood Brain Barrier (Flayashi et
al. 1997). In embryogenesis they provide a framework for migrating
neuroblasts. Ultra structural studies have revealed that almost all synapses are
covered by the fine processes of astrocytes (Nedergaard et al. 2003).
Protoplasmic astrocytes are known to absorb neurotransmitters from the
synaptic cleft (Anderson and Swanson 2000). Another important function is
the uptake of extra-cellular potassium (Walz 2000). Astrocytes are involved
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in energy metabolism and store glycogen (Forsyth 1996), but the precise
mechanism of glucose transport from blood to neuron and the role of the
protoplasmic atrocity remains incompletely explained.
A wide variety of conditions are associated with a rapid change in astrocytic
morphology and function. An early and easily recognisable change seen in
routinely stained sections under the light microscope is swelling of the cell
body, with abundant eosinophilic cytoplasm and displacement of the nucleus.
This change is seen in response to generalised conditions such as hypoxia, or
local ones such as in the proximity of tumours or acute multiple sclerosis (MS)
lesions. If widespread and severe the problem of cytotoxic brain oedema may
arise, with its metabolic and pressure effects. A more profound change, which
may be associated with any conditions causing acute swelling, is known as
astrogliosis (Eng and Ghirnikar 1994). This may be defined as an acute
reactive state of astrocytes in which there is both hypertrophy, as evidenced by
an increased cell GFAP content, and hyperplasia. However, research has
suggested that in the acute reaction the impression of an increase in numbers of
astrocytes is actually due to the upregulation of GFAP in previously GFAP
negative ceils, rather than local proliferation or migration of nearby astrocytes
(Eddleston and Mucke 1993).
c. The ependyma is a single layer of cuboidal cells lining the central canal of
the spinal cord and the ventricles of the brain. The cells have microvilli on their
apical surfaces. Their basal processes, which extended in the embryo to the
surface of the neuraxis, in postembryonic life remain as vestigial remnants,
which intertwine with a layer of astrocytes to form the sub-ependymal or
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internal limiting glial membrane. In contrast to most other epithelia, no
basement membrane is present. The ependymal cells are joined to each other
by the usual epithelial junctional complexes and there is no functional barrier,
akin to the blood brain barrier (BBB), between the CSF and the brain. Indeed
the ependyma is believed to have absorptive and secretory functions.
Ependymal cells in the adult have no regenerative capacity.
The Microglia and Perivascular Cells
These two cell types are both considered to be of monocyte/macrocyte
lineage.
There is general acceptance that the microglia in the mature nervous system
are directly derived from a population of monocytes which moved into the
foetal nervous system, adopted a universal, but not necessarily uniform,
distribution, lost their amoeboid nature and became the typical resting ramified
cells in the neuropil.
The terminology of the perivascular macrophages or perivascular cells
remains the subject of debate, but certain features separate them, in their
resting state, from the microglia and any other vessel-associated cells. In
position they are outside the parenchyma of the CNS, being situated between
the basal lamina of the endothelial cells in capillaries or the adventitia of larger
vessels and the glia limitans of the parenchyma (Graeber et al. 1992). They are
relatively large, lack the dendritic morphology of the microglia and express
antigens not detectable on resting microglia (Franklin et al. 1986). It is thought
that monocytes entering the nervous system are not eligible to become
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microglia but, experimentally, blood monocytes may adopt a microglial
morphology when cultured with astrocytes (Sievers et al. 1994).
Resting microglia have a very low rate of population turnover - less than 1%
over nine months and longer- but perivascular cells may cycle up to 30% of
their population over three months (Hickey et al. 1992). This may play an
important part in HIV entry.
In terms of distribution microglia are arranged in the brain and spinal cord in
close proximity to one another but without overlap of their spatial domains.
They constitute some 5-10% of the total glial population and are probably
found in equal numbers in grey and white matter. Microglia, in their resting or
ramified state, are difficult to identify with certainty in routinely stained
sections under the light microscope, but generally the nucleus is round, dense
and small - between 5-8p in size. Staining with heavy metals shows that the
cell body is smaller than the other glia, is bipolar, and has two or three
branches extending from either end, each of which is subdivided into finer
branches.
The most effective immunostains for the microglia are anti-CD 68, anti
HLA-DR and anti-CD 45, and for the perivascular cells, anti-CD 14 and anti-
CD 45. The state of activation, as indicated by cell surface antigens, does not
necessarily correlate with morphology, i.e. whether the cell is in its ramified or
amoeboid state (Dickson et al. 1991).
Though the microglia show a down-regulated phenotype with ramified
morphology in the CNS of healthy animals, they are the first cell to respond to
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even subtle molecular signals, either locally, or as a manifestation ofminor and
remote systemic disease (Perry et al. 1993), (Perry 2007).
Microglia when activated, apart from their phagocytic function, also produce
numerous molecules, some of which are potentially cytotoxic. Amongst these
are nitric oxide (NO), free oxygen intermediates, proteases, excitatory amino
acids and cytokines. The involvement of some of these is considered later in
this section, but here it may be noted that the pro-inflammatory cytokine TNF-
a may cause damage in multiple sclerosis, and free oxygen radicals have a
neurotoxic effect on neurons in co-cultures (Thery et al. 1991). Apart from
their role as cytotoxic effector cells, microglia may exert a protective influence
in reducing post-inflammatory gliosis by secretion of TGF-(31.
Choroid Plexus
The choroid plexus is a highly vascular frond-like structure in four parts,
located in the lateral ventricles, the third ventricle and the fourth ventricle. It
arises in the embryo as an invagination of the ependymal roof plate into the
ventricular cavities by the pial blood vessels. Its function is the production of
the CSF, both by ultra-filtration and secretion.
It is produced at the rate of approximately 0.35mls /min. and measures in
volume in the adult 140 mis. A blood-CSF barrier exists in the same way as
the blood brain barrier and is located at the cuboidal epithelium that covers the
surface of the choroid plexus. Tight junctions join these cells.
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Vascular Endothelium
The Vascular endothelium of the CNS plays an important part in the
pathogenesis of many diseases affecting the brain and spinal cord. As it is of a
special nature, some detail of normal capillary structure and function is
included here. The typical capillary wall is a single layer of the endothelial
cells (which line the entire vascular system), arranged on a basal lamina. Other
cells called pericytes are associated with capillaries. The capillary diameter is
5-8p, allowing blood cells to pass in single file with some transient deformity.
Their length is between 200u and 1 mm. and the pressure within 25mm Hg.
The entry to the capillary system is through arterioles, the immediate pre¬
capillary arteriole having a single layer of muscle cells and contraction of
which can deny entry of blood to the capillary network. The exit is provided
by the confluence of several capillaries to form a vessel of up to 30p in
diameter, known as a post-capillary venule. This has a thin adventitia of
collagen fibres but has no muscle coat or elastic lamina. This is probably (see
below) the principal site of leucocyte migration and certainly the chief site of
protein rich fluid escape in neurogenic inflammation. The intraluminal
pressure drops from 25mm to 5 mm ofmercury in these vessels.
The endothelial cells are flat and thin, being 2-3 p at central nuclear level and
0.2 u peripherally. The junctions between neighbouring endothelial cells are
classified as to the degree of adhesion - adherens, communicans and occludens
- of which the last is the most secure and which is found in the almost all of the
capillary networks in the CNS. Another specific feature of capillaries in the
CNS is that their surface is almost completely enveloped by the end feet of
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astrocyte processes. Endothelial cell functions vary in different parts of the
body but in general they contain numerous enzyme and transport systems, they
secrete clotting factors and express adhesion molecules to attract leucocytes.
In the endothelial capillary cells of the CNS the nucleus shows homogenous
chromatin. Mitochondria are more numerous than in endothelial cells
elsewhere. True pinocytotic vesicles and lysosomes are rare in normal health.
CNS endothelial cells can be identified by immuno -cytochemistry, using
antibodies to Factor 8 related antigen (Von Willebrand protein) and anti-ZO-1,
an antibody to zona occludentes.
The Leptomeninges
The leptomeninges, known as pia mater and the arachnoid mater are the fine
layers inside the tough outer dura mater that cover the brain. They are
intimately related to each other. The arachnoid, the outer of the two, is a
delicate non-vascular membrane that overlies the vessels on the surface of the
brain and bridges over the sulci. The pia is a vascular membrane, intimately
attached to the surface of the brain and composed of reticular and elastic fibres.
On its upper surface it is connected to the arachnoid by trabecular strands and
on its under surface it is continuous with the end feet of astrocytes. The CSF
circulates in the space between these two membranes, known as the sub¬
arachnoid space, and is absorbed into the superior sagittal sinus by passing
through the arachnoid granuations, glomerular shaped structures that penetrate
the dura mater, to enter the sinus. The pia invests arteries which pass into the
brain, becoming fenestrated before blending with the vessel at pre- or capillary
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level. Such a space as exists between the vessel and pia is continuous with the
perivascular space on the surface of the brain.
The pia and arachnoid are mesodermal derivatives and, in contrast to the
CNS parenchyma, neutrophil access is unrestricted.
The Blood Brain Barrier (BBB)
Before examination of the detailed dynamics of viral and CNS interactions,
the structure and concept of the Blood Brain Barrier (BBB) is considered in
some detail. In the context ofHIV infection its importance lies in the mode of
viral entry, the constraints on immune cell access and restriction on the transfer
of some of the major therapeutic agents.
In 1885 Ehrlich (Paul Ehrlich, German medical scientist and pioneer of
immunology 1854-1915) observed that certain dyes injected into the blood
stream of experimental animals, with a view to determining oxygen
consumption, stained all tissue and organs except the brain and spinal cord.
The concept of the Blood Brain Barrier developed in the early 1900s in studies
on the administration of drugs via the CSF route (Lewandowski 1900) Since
then it has been the subject of numerous experiments (Davson and Oldendorf
1967). The understanding now is that the principal barrier is at the levels of
the endothelial cells of the cerebral capillaries and the post capillary venules.
As opposed to most capillaries elsewhere in the body, the borders between the
endothelial cells of the cerebral capillaries are sealed by the extension of tight
junctions.
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In some special locations of the CNS, the pineal body, the neurohypophysis
and the median eminence of the hypothalamus, these are lacking. Also known
as zonulae occludentes. tight junctions are present as short segment areas of
fusion between the endothelial cells in most capillaries of the body, but
intervening clefts are present - gap junctions. The studies of del Rio Hortega
(Pio del Rio Hortega, Spanish histologist 1882-1945) had shown that the
abluminal surface of CNS capillaries was almost completely covered by
astrocyte endfeet.
In health, transport of molecules through the endothelial cell itself is strictly
regulated. Lipid solubility, hydrogen bonding and molecular weight are the
principal determinants of simple diffusion (Oldendorf 1974). Transport
systems exist for most essential substances, including nutrients ((Davson and
Oldendorf 1967). In certain disease states, especially those in which hypoxia,
toxic chemicals or physical factors are present, the integrity of the endothelial
cell is compromised, and passage of normally excluded molecules occurs. This
process, known as adsorptive endocytosis (AE), has been studied using
molecules such as the toxic glycoprotein, wheatgerm agglutinin (WGA),
conjugated with horseradish peroxidase (Broadwell 1993). AE may provide a
mechanism whereby viral entry is facilitated (Banks et al. 1999).
Therapeutic attempts using hyperosmotic solutions to "open" the BBB to
allow enhanced access of chemotherapeutic agents, as in the treatment of brain
tumours, produce multifocal lesions in association with serum protein seepage
(Salahuddin et al. 1988).
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Current views on immune cell entry are considered below and in the final
discussion section - chapter 6.
In summary, the principal functions of the blood brain barrier are:
1. Protection of the brain from the blood milieu
2. Selective transport of various substrates or factors which are required
for neuronal or glial acitivites
3. Metabolism or modification of blood- or brain-borne substances (Risau
and Wolburg 1990).
1.9 - Immune System and the Brain: Neuroinflammation
Reference to one of John Hunter's observations serves as a reminder that
inflammation is a response, not a disease in itself, or even a cause of disease:
he wrote, in the introductory chapter to his Treatise on the Blood,
Inflammation and Gunshot Wounds, published in 1793:
"Inflammation must have some exciting cause, and the same cause will
produce an effect under one circumstance, which it will not under another."
Before considering the immunodynamics of the CNS in detail in health and
disease, the concept of immune privilege or immunologically privileged sites is
briefly mentioned. In the early days of experimental tissue transplantation it
was discovered that grafts of foreign tissue would survive in certain locations
in the recipient, whilst being rapidly destroyed by immune reaction in others
(Medawar 1948). The brain was found to be one such site, the eye and the
testis others. Now the understanding is that this is a relative, rather than an
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absolute, privilege and is subject to certain conditions. Though the separate
determinants of this exclusiveness are considered below and elsewhere, the
most important factors, in respect of the CNS, may be summarised:
1. The presence of the BBB excludes large molecules, for example IgG.
2. Its endothelial cells are specialized in their pattern of cytokine
secretion.
3. The CNS is devoid of antigen-presenting cells.
4. The parenchymal cells of the CNS do not express MHC class I and
class II molecules.
5 Neurons have immunosuppressive actions on glial cells.
6. Glial cells themselves express immunosuppressive cytokines.
Immune reactions in the CNS can be thought of as innate, associated with
changes in microglia and astrocytes, or acquired as the result of movement of
cells, lymphocytes and monocytes, into the brain compartment.
The CNS has no lymphatic vessels although drainage occurs in an indirect
fashion - see below. Immune cell traffic through the brain is normally low in
health. The normal CSF contains fewer than 5 cells/ml, of which 70% are
lymphocytes and 30% are macrophages. In infection, the cell count rises to 25-
500/ml in mumps meningitis, and to > 10,000 in bacterial meningitis. In
chronic inflammatory disease, such as multiple sclerosis (MS), it is seldom
more than 40/ml.
In the previous section reference was made to the surveillance function of the
immune system, which is in effect a detection and early warning system of
change in the tissues, whether due to neoplasia or the presence of foreign
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material of any kind. All tissues and organs are continuously patrolled and the
brain parenchyma is no exception but the numbers of cells and their transit
pace are strictly controlled by a number of factors, most of which operate at
BBB level. The physical nature of the interface has long been recognized, but
in recent years molecular biology has revealed the subtleties and complexities
associated with capillary wall physiology. An example of this is the expression
of adhesion molecules necessary for leucocyte migration, and which are
normally expressed at low levels (Bart - 2000).
The relationships between the various cells of the immune system and the
CNS are now separately considered.
Dendritic Cells
Dendritic cells are not normally found in the brain or spinal cord, but in the
rat a very small population may be found in the meninges (Matyszak and Perry
1996), and they may rarely be detected in the choroid plexus (McMenamin
1999). Perivascular cells, microglia and astrocytes can all subserve an antigen-
presenting function.
T Lymphocytes
T lymphocytes are known to traverse the normal CNS in very small numbers
(Hickey - 1999). They do so in apparently random fashion but activation
appears to be a condition of entry (Fritz et al. 2000). The adhesion molecule P-
selectin has been shown to be involved in lymphocyte access (Hickey 2000).
In the absence of an antigenic encounter, the fate of T4 lymphocytes in the
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neuropil is unknown. Apoptotic death has been observed in inflammation
(Bauer et al. 1998), and the notion that the neural micro-environment is hostile
to lymphocytes has been expressed (Hickey 2001). The probable underlying
immunological mechanism to account for this apoptotic fate is the fact that
astrocytes and neurons in the rat and human brain express fas ligand (fasL).
Fas is an apoptosis-inducing protein which can react with the fas receptor of a
trafficking lymphocyte (Bechmann et al. 1999)
B Lymphocytes
The relationship between B-lymphocytes and the CNS in health had been
studied in the late 1970s. An animal model system was used to test the
responses to antigen, to which the animal was already sensitisedand which was
introduced behind an intact BBB through a very fine cannula (Cserr et al.
1978). Antigen-specific B cells and plasma cells were then found around the
cannula tip providing evidence of a normal micro-inflammatory response. The
question as to whether or not B lymphocytes might be found in normal brains,
however, remained unanswered until a post-mortem study in 2003 comparing
normal brains with those of several groups of HIV-infected individuals
(Anthony et al. 2003). B lymphocytes, bearing the activation marker CD 23,
were found in small numbers in all parts of the normal brains. Relatively
increased numbers of B cells were detected in the brains of late pre-
symptomatic (that is after a course of several years) HIV infected individuals
but the numbers were found to be reduced in AIDS cases.
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The Monocyte/Microglia/ Macrophage System
Monocytes, which may be up to 20p. in size, comprise 2-10% of the
circulating white blood cells. They are the antecedents of macrophages, which
they become on entering the tissues after spending the first few days of their
life in the bloodstream.
In the tissues, having become macrophages, two populations are encountered
- fixed and free - the former being referred to as histiocytes and sometimes
named specially according to their locations by their first describers, e.g.
Kuppfer cells of the liver and Langerhans cells in the skin. The macrophage,
like the neutrophil, is a motile and actively phagocytic cell.
The process of phagocytosis is complex but in essence it consists of particle
engulfment, facilitated if the particle is already coated with a host-derived
protein known as an opsonin.
The monocyte-macrophage lives for many months and as some bacteria, in
particular pathogenic mycobacteria, have evolved evasion strategies to enable
continued life within the cell (Nguyen and Pieters 2005), this presents
considerable problems for the host. Equally devastating is the same practice of
some viruses, such as HIV, as will be seen below.
Neutrophils are short-lived and rarely enter the brain, though in the meninges
rapid and major influxes occur in response to bacterial infection.
Monocytes have been known to enter the perivascular spaces in the brain
since rat chimaera studies in 1988 (Hickey and Kimura 1988), there to become
known as perivascular cells or perivascular microglia. Parenchymal microglia
are similarly derived from blood cells circulating form the bone marrow in
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early fetal life. The entry of monocytes into the brain is continuous in the
healthy animal but their time of exit, if at all, is uncertain. They are efficient
antigen-presenting cells and one study suggested that they did leave the CNS to
return to the lymphoid tissues (Broadwell et al. 1994). Other studies using
paitieulate antigen failed to demonstrate an immune response (Matyszak and
Perry 1996). The relative stability of the population of perivascular cells
suggests they either exit or die by apoptosis since there is no evidence to
suggest that they move into parenchymal microglial territory in healthy adult
life.
Factors Affecting Immune Cell Access
Cytokine modulation is an important mechanism whereby immune cell access
is regulated. An important molecule, which enhances entry, is transforming
growth factor-[3 (TGF-|3). This is a homo-dimeric protein widely distributed in
mammals, and which controls lymphocyte activation, growth and
differentiation. Like IL-10, TGF-[3 can down regulate lymphocyte activation.
It is produced by platelets, endothelial cells, lymphocytes and macrophages. It
is normally present in health at low levels in the CSF (Johnson et al. 1992).
Glial Cell Participation in Immune Reactions
In vitro studies have suggested an important possible role in T-cell mediated
immune responses. Not only is it considered possible that microglia and
astrocytes may act, in addition to the dendritic cells of the meninges and
choroid plexus, as antigen presenting cells (Aloisi et al. 2000), but that they
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can also stimulate the T helper subsets, Thl and Th 2. The cells of these
subsets operate in contrasting ways. Thl cells when activated produce
predominantly pro-inflammatory cytokines (IL-2, IFN-y, TNF- a and TNF-|3)
and Th 2 cells produce IL-4, IL-5, IL-6 and IL10 (Mosmann and Sad 1996).
These are associated with responses, respectively, the former to elicit
phagocytic defence against infections and to activate CD8 T-cells, and the
latter to promote B-cell maturation and antibody production. There is interplay
between the two processes and the initiation and outcome depend on signalling
from local or remote sources. TGF-|3 can act in an autocrine fashion
suppressing both phagocytic and cytotoxic behaviour (Merrill and Zimmerman
1991)
1.10 - HIV and the Brain - pre-AIDS and AIDS, untreated
and treated
Viral Entry into the Brain
The possible routes of entry of HIV into the Central Nervous System (CNS)
are of considerable interest, not least because of the immunologically
privileged status of the brain (Barker -1977), the variable access to therapy and
its role as a sanctuary for the virus. The viruses that are known to infect the
CNS gain entry in a variety of ways. Some, such as the picornaviruses
(Couderc et al. 1990), and parvoviruses(McClure 1992) infect the capillary
endothelial cells and gain entry in this way. Others, for example, coxsackie and
mumps virus, infect the meninges. Neural spread is recognized as a route for
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rabies virus (Murphy et al. 1973) and offers a conduit for many other virus
families including herpesviruses and polioviruses, but does not appear to
participate in HIV entry.
An early observation that HIV might infect CNS endothelial cells (Moses et
al. 1993) has not been confirmed. This finding, which was for a lymphotrophic
strain, would be at variance with the demonstration that in early HIV infection
the macrophagetropic HIV is the predominant viral phenotype (Zhu et al.
1993). The choroid plexus has been shown to harbour HIV infection in both
asymptomatic and AIDS patients (Petito et al. 1999).
However, the most likely and important route for HIV entry into the CNS is
considered to be within blood-derived monocyte/macrophages (Nottet and
Gendelman 1995), and its immediate place of residence in the perivascular
spaces within the perivascular macrophages (Koenig et al. 1986). The precise
molecular mechanisms enabling entry to the CNS remain unclear, but the first
step seems to be the rolling of the infected cell on the endothelium. This is
mediated by the interaction of the endothelial adhesion molecule E-selectin
and oligosaccharides present on the monocytes (Varki 1994). This process is
likely to operate later in the AIDS phase as the expression of E-selectin is
considerably increased in demented compared with non-demented cases
(Nottet et al. 1996). Another factor which may aid entry is the production by
HIV-infected cells of NO, a potent vaso-active molecule which could slow the
capillary bloodstream.
The possible routes from capillary lumen to perivascular space are still a
matter of debate and recent papers examine the matter critically (Engelhardt
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and Wolburg 2004), (Bechmann 2006) (and see below - BBB). In essence the
cells could migrate in the capillary section, either through the endothelial cell
itself, or in between cells in the tight junction region and the astrocyte end
feet, or distal to the capillary through the wall of the post-capillary venule.
The fate of the infected perivascular cells after the initial inflammatory
reaction of acute HIV infection is debateable; most seem to disappear, either
dying or passing out in the CSF. A few remain, but these may not necessarily
contribute to the protracted second wave that heralds the onset of pre-AIDS. In
this phase there are high levels of circulating cytokines, such as TNF-a and IL-
1(3, which alter BBB permeability (Quagliarello et al. 1991), and these induce
the expression of endothelial adhesion molecules E-selectin and vascular
adhesion molecule-1 (ICAM-1) (Nottet et al. 1996). The BBB in this terminal
infection is probably further damaged by the monocytes' secretion of super
oxide anion and NO, which can combine to form the highly toxic compound
perioxynitrite (Boven et al. 1999). An allied compound, nitrotyrosine, can be
demons Lialed by immunocytochernistry in the perivascular areas of demented
AIDS patients. Infected monocytes also have the capacity to digest basement
membrane. The factors affecting HIV- infected macrophages' migration
within the CNS parenchyma and their preferential location in the cerebral
white matter remain unclear, but a spectrum of chemoattractant molecules is
likely to be involved (Nottet - 1997), including TGF-1 and macrophage
inflammatory protein-a (MIP- la), both of which are found in higher levels in
AIDS brains compared with controls. An association with astrocytes may be
significant.
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The Neuropathology of HIV/AIDS
The neuropathology, as related to the stages of the disease and the conditions
outlined above, is now considered. The CSF abnormalities already noted
suggest that from the primary infection until death, when as many as 90% of
patients dying of AIDS will have detectable CNS changes at necropsy (Kure et
al. 1991) (Gray et al. 1988), HIV maintains a presence in the CNS which is
clinically silent for much of the time.
At the time of the acute primary infection much of what happens in the
human brain is speculative, but a single case report (Davis et al. 1992) allows
insight into what may be the universal situation. A 68 year- old man, infected
as a result a therapeutic error, died two weeks later. Blood culture for HIV-1
had become positive just before death. At necropsy a mild lymphocytic
meningitis and a minor degree of perivascular cuffing was present. No focal
abnormalities were noted. HIV was obtained by culture and HIV gp41 viral
antigen was detected in sparse perivascular and sub-pial cells. Several other
organs sampled showed no signs of viral presence. In the light of accumulated
knowledge of HIV infection and simian studies (Chakrabarti et al. 1991) it
seems reasonable to suppose that this represents the usual state of CNS
involvement in the early weeks after infection.
The long asymptomatic stage of HIV infection is marked by continued viral
activity in the lymphatic system and CD4 lymphocyte depletion, and
opportunities to study other organs are infrequent but are provided by cases of
accidental death, related to substance abuse, suicide or haemophiliacs dying of
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complications. Several studies have reported the general and CNS pathology
in these pre-AIDS individuals. In one study of four cases no significant
abnormality was seen (Budka 1991). In others a low grade lymphocytic
meninigitis and perivascular infiltrate was observed, but microglial nodules
and multinucleate giant cells were not (Esiri et al. 1989) (Bell et al. 1993),
(Gray et al. 1996). Astrogliosis and microgliosis were noted. The presence and
timing of active viral replication remains uncertain with respect to the pre-
AIDS stage (An et al. 1996), but a marker of transition to HIVE may be the
increase in B and T cell numbers in the perivascular compartment of the brain
(Anthony et al. 2003).
The neuropathology of the final stages ofHIV infection - AIDS - was of
interest from a very early stage in the epidemic as CNS manifestations such as
dementia and motor abnormalities were of frequent occurrence (Snider et al.
1983), (Jordan et al. 1985)
In 1985 a post mortem study of 15 patients, adults and children, dying with
AIDS-related encephalitis showed varying neuropathology (Shaw et al. 1985).
In addition to focal lesions, due to CMV or Toxoplasma, other features were
cerebral atrophy, scattered microglial nodules and vacuolar myelopathy. One
brain appeared normal. Histological abnormalities did not consistently
correlate with the degree of dementia. Detailed Southern blot analysis and in
situ hybridisation confirmed the presence of HTLV-III DNA in the brains of
five of the cases and in four of these viral-specific RNA was found (Shaw et al.
1985), suggesting that the virus itself might play a major part in the genesis of
the encephalopathy. It was noted that the features of this condition contrasted
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strongly with those of Visna, in which there was a strong mononuclear
inflammatory response in the brain but which occurred in the absence of the
profound immunosuppression present in HIV/AIDS.
Other studies in the same year, 1985, showed that HIV could be isolated and
grown from the CSF and other CNS tissues (Levy et al. 1985).
In 1986, the cellular localisation of HTLV-III (which had just been renamed
HIV) was investigated in the brains of twelve AIDS cases (Wiley et al. 1999).
Using the technique of in-situ hybridisation, nine of the brains were shown to
be significantly infected with HIV and the cells involved were capillary
endothelial cells, mononuclear inflammatory cells and giant cells. White
matter was more severely affected than grey matter. Only one case, with severe
and extensive involvement, showed evidence of weak infection of neurons and
astrocytes; the important conclusion drawn was that features of AIDS-related
encephalopathy were more likely to be due to an indirect effect of the virus
than compromise of neurons or astrocytes by direct infection (Wiley et al.
1986).
In the 20 years that have elapsed since then, many aspects of the
neuropathology of HIV/AIDS have been explored, and imaging studies have
contributed to our understanding of the extent of the disease process in treated
and untreated patients, and those in special risk groups such as drug abusers.
The hallmark of productive HIV infection in the CNS remains the presence of
HIV positive, macrophage-derived giant cells, signalling the presence of HIV
encephalitis (HIVE).
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In general the naked eye appearances of the brain may be unremarkable. The
reduced brain weight noted in childhood HIV infection (Bell et al.
1997)((Kozlowski et al. 1997) has not been systematically reported for adults.
The meninges do not usually show any obvious gross abnormality. A minor
degree of gyral atrophy and, on sectioning, some ventricular dilatation may be
present. MRI imaging studies confirm these findings in AIDS subjects (Everall
et al. 1997).
The changes seen on microscopy vary considerably and there may be no
correlation between the appearances and the degree of dementia noted in the
months before death. Some parts of the brain are generally affected more than
others - the cerebral cortex is less involved than the deep grey matter, and the
central white matter of the cerebrum more than that of the cerebellum (Gray et
al. 1988). The commonly reported finding of white matter pallor in
haematoxylin and eosin or Luxol fast blue stained sections may have as its
basis significant white matter pathology with myelin loss and astrocytic
activation (Budka et al. 1987). Perhaps more commonly, it may be a reflection
of underlying oedema, or even an artefact related to poor fixation. White
matter pathology was originally considered to be of two distinct kinds - HIVE,
in which there were multi-focal infiltrations of inflammatory cells with only
minor focal areas of myelin damage, and HIV leuco-encephalopathy (HIVL),
which was characterised by diffuse or focal loss of myelin, sometimes with
axonal loss as well, and in severe cases, frank necrosis. Associated with this
latter change was microglial/macrophage infiltration and astrocytic activation.
Now the justification for considering these two conditions as separate entities
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seems less, and it is supposed that they may represent different stages on a
continuous spectrum of white matter damage (Grassi et al. 1997).
The cellular elements respond in different ways to HIV infection, and it is
not always clear whether they are reacting to local or remote influences.
Neuronal loss, initially sought as a cause of, or correlation with, HAD is
generally quite modest (Everall et al. 1993) and may not be detectable
(Seilhean et al. 1993) Although HIV-specific nucleic acid has been
demonstrated in neurons by in situ polymerase chain reaction (in-situ PCR),
productive infection has not been demonstrated in these cells.
Astrocytes respond to HIV infection, as they do to most environmental
perturbations in the CNS, by upregulation of GFAP and proliferation. Though
they lack the surface receptor CD4 they have been shown to become infected
in small numbers (Epstein et al. 1984), and have been shown to support
productive infection in tissue culture (Brack-Werner 1999). Productive
infection of astrocytes in vivo is considered to be limited (Saito et al. 1994);
but more important are the possibilities of associated malfunction of important
homeostatic functions of this cell, including maintenance of the BBB, and its
potential capacity as a reservoir of the virus.
The role of the oligodendroctye in HIV infection is uncertain. It is not known
to become infected, but certainly participates in the general white matter
disturbance. Its numbers were found to be increased in HIVL (Esiri et al.
1991). The damage to myelin may be due to a direct effect of toxic molecules,
or an indirect one through the agency of the oligodendrocyte.
64
Macrophages, giant cells and microglia play the principal part in the
pathogenesis of HIVE. All of these cells have been shown by
immunocytochemistry to be productively infected (Budka 1990). The
sequence of infection of these cells and their relative numbers is probably not
as important as the relationship between the number of giant cells and the
proviral load (Bell et al. 1996) Giant cells are thought to originate from fusion
of infected macrophages (Michaels et al. 1988; Moses et al. 1993). Microglial
nodules are common in HIVE but are non-specific (Kato et al. 1987). They are
found more commonly in the white matter.
There is a difference in the neuropathology between different risk groups.
Haemophiliacs show less advanced change associated with HIVE and fewer
opportunistic infections (Esiri et al. 1989). They are however more prone to
suffer from cerebral haemorrhage.
HIV infected drug misusers were shown to have a higher incidence of HIVE
than homosexual men, but the reverse relationship was found with respect to
primary cerebral lymphoma (Bell 1998).
The Neurological Syndromes Associated with HIV Infection
Involvement of the CNS in HIV infection, considered in part in the
beginning of this section, was common in the early years of the epidemic.
Some 39% of AIDS patients had neurological abnormalities (Levy et al. 1985).
Even in the absence of symptoms or of recognisable signs, examination of the
CSF may show elevated protein levels, pleocytosis and the presence of viral
RNA as well as anti-HIV antibodies.
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In adults (for children see section 2.5) the main clinical syndromes are:
• Meningitic syndrome
• Seizure disorder
• Motor and sensory disorders
• Cognitive disorder
• Ophthalmic Disease (with visual compromise)
Meningitic syndrome: this syndrome occurs in the course of the primary
infection in about 10% of cases (Carne et al. 1985) (Schacker et al. 1996). It
may be accompanied by a rash and lymphadenopathy and lasts 2-4 weeks. It is
indistinguishable on clinical grounds from other causes of aseptic meningitis,
but HIV-RNA can be found in blood and CSF.
It can also develop at any other time prior to the onset of AIDS, and the fact
it is very uncommon in AIDS is thought to signify that it may have an immune
basis (Fauci 2001).
Seizure disorder: although seizures may occur occasionally in the meningitic
illness of primary infection, most instances occur in AIDS either as a
manifestation of direct HIV infection, such as sub-acute encephalitis (7-50%),
or in the course of secondary CNS disease, for example cerebral toxoplasmosis
(15-40%). When a seizure is the presenting symptom of HIV infection, an
underlying mass lesion is the commonest cause, usually due to toxoplasma
infection or to lymphoma.
Motor and sensory disorders: these are principally determined by disease in
the spinal cord, and to a lesser extent, in the spinal nerve roots and peripheral
nerves. Spinal cord involvement is confirmed by finding degeneration of the
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dorsal and lateral columns on histological examination - a condition known as
vacuolar myelopathy. This is found in 5-30% of AIDS cases (Petito et al.
1986) (Henin et al. 1992). The vacuoles, which are symmetrically disposed,
appear at ultrastructural level to be intramyelinic swellings with splitting of the
lamellae. Generally axons are preserved, except in association with Wallerian
degeneration secondary to severe vacuolation. The condition is maximal in the
thoracic cord. There is no gliosis and/or inflammatory infiltrate apart from
some debris containing macrophages. Viral antigen is not generally found and,
if it is, the more correct appellation would be myelitis (Henin et al. 1992), As
previously noted, though the condition resembles sub-acute combined
degeneration of the cord, vitamin B12 levels are normal.
Cognitive disorder: Soon after the recognition of AIDS in 1981 it became
apparent that there was an associated dementing illness, and that this could be
the presenting condition in some 3% of AIDS sufferers. In the terminal stages
of the disease it is present in at least 25% (Fauci 2008). Originally this
condition was termed "sub-acute encephalitis" then subsequently HIV-
associated dementia, AIDS dementia complex and most recently HIV-
associated major cognitive/motor disorder. AIDS dementia complex (ADC) is
currently used most commonly and is taken to be synonymous with HAD.
Its onset is insidious, with mental slowing, apathy, difficulty in concentration
and poor memory. Psychological testing has suggested that the onset of HAD
in AIDS corresponds to a CD4 count of below 350/cu.mm (Harrison et al.
1998). Features such as dysphasia and dyspraxia, which are common in
Alzheimer type dementia, are infrequent, as is impairment of conscious level.
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Motor and behavioural problems develop in the course of the condition, which,
if untreated, lasts less than a year.
CSF findings show a raised protein level and cell count. HIV-RNA and
specific antibodies can be detected, and the virus itself cultured, but there is no
correlation between this and the presence of HAD. A spectrum of molecules is
also present, including neopterin and quinoleic acid, in addition to
inflammatory cytokines and these are all suspected of being pathogenic for
CNS damage, in addition to HIV itself.
Imaging by CT-scan or MRI helps to exclude the presence of additional
pathology - for example toxoplasmosis or lymphoma - and generally shows a
degree of cerebral atrophy. Treatment with HAART usually results in a rapid
improvement in cognitive function, suggesting that structural change is not the
sole basis for cognitive decline.
Ophthalmic conditions: evidence of eye involvement is found in about half
of the cases with advanced AIDS. CMV retinitis is a serious cause of visual
loss and occurs when the CD4 count falls below 100/cu.mm. Intensive
treatment with intravenous anti-retroviral therapy is mandatory to prevent
impairment of vision. Toxoplasmosis and lymphoma may less commonly
affect the retina.
1.11 -HIV/AIDS -treatment
In 1981, the first sufferers of what was to become known as HIV/AIDS were
afflicted by illnesses symptomatic of underlying severe immunodeficiency,
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including cryptococcal meningitis, Kaposi's sarcoma and Pneumocysts carinii
pneumonia. Initial treatment was of necessity directed towards these
conditions. The life expectancy of such patients was approximately 2 years
(Rothenberg et al. 1987) and little therapeutic yield was achieved. In 1983, the
identification of the virus, HIV (Barre-Sinoussi et al. 1983), and the later
introduction of an antibody test (Silberner 1985), paved the way for the
development and approval of the first anti-HIV drug, zidovudine (AZT). This
preparation exploited the early stage of HIV entry, where the viral RNA is
transformed by the enzyme reverse transcriptase to double-stranded DNA prior
to its incorporation into the host DNA. Zidovudine is a nucleotide analogue
which inhibits reverse transcriptase (Ezzell 1987) (Furman and Barry 1988).
Another nucleotide reverse transcriptase inhibitor (NRTI), didanosine (DDI),
was released in 1991 but by 1994 it was recognized that this form of treatment
was insufficient (Volberding et al. 1995) on its own to halt the progression of
HIV infection to AIDS.
However, also in 1994, a significant success associated with zidovudine
therapy was recorded, and that was a reduction in the rate of mother-to-child-
transmission from a quarter to just under a tenth of cases (Connor et al. 1994).
The next development in anti-HIV therapy was an intervention in a later
stage of intra-cellular life history of the virus - that of protein assembly in the
viral particle in its pre-exit maturation phase. Core protein chains at this point
are shortened by enzymatic cleavage involving viral protease, inhibition of
which precludes maturation to infectious virions (Venaud et al. 1992) (Dorsey
et al. 1994). Drugs such as indinavir and ritonavir were approved for general
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treatment in 1996. It soon became apparent that, when protease inhibitors were
used alone or intermittently, drug resistance emerged in a matter of months.
Trials of different drugs given together then followed, and a combination of
two reverse transcriptase inhibitors and a protease inhibitor was found to be
particularly effective. An alternative approach was to use another type of drug
of a class called non-nucleoside reverse transcriptase inhibitors (NNRTIs), of
which vivirapine, introduced in 1996, is an example, in combination with an
NRTI and a protease inhibitor.
This form of treatment became known as highly active anti-retroviral
therapy, or HAART. and suppression of plasma viral load, as measured by RT-
PCR for HIV-1 RNA, was shown to remain below detectable limits (Gulick et
al. 2000).
HAART is still the mainstay of therapy. Other drugs, such as fusion
inhibitors, have been developed. The quest for a vaccine continues and the
pessimistic view in 2008 is that an effective agent is still at least 10 years
away.
The problems of drug resistance, especially in view of the pronounced
tendency of the virus to genetic variation, and the side effects of these drugs,
are encountered in therapy, as with other anti-microbial agents. Generally the
search for anti-HIV drugs has been constrained by the fact that the virus uses
many host molecules, which cannot be used as targets, and current therapy is
effective only whilst the virus is replicating. Latent infection in lymphocytes
(Wong et al. 1997) and monocyte/macrophage reservoirs (Pomerantz 2001)
remain a major obstacle in attempts to eliminate virus by drugs. Furthermore
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the drug levels achieved in the CSF may be sub-optimal, e.g DDI concentration
in the CSF is only about 20% of that in plasma and the presumption that
plasma levels reflects those in brain tissue may be false.
In summary, treatment for HIV has been surprisingly effective in
transforming a uniformly fatal disease to a chronic illness but there are still
many limitations, some outlined above. However the principal concerns on a
global scale are those of accessibility and compliance in poor countries,
especially in parts of Africa.
The HAART era
Since 1995, when HAART was introduced, the lives ofmost HIV sufferers in
the Western world have been transformed, and for them the prospect is that of
living with a chronic disease rather than a uniformly fatal one. However, for
the majority in the developing world the situation remains bleak, especially in
respect of the dependency and suffering imposed by the devastating impact of
the CNS involvement by HIV/AIDS. The success of HAART in most
recipients has tended to obscure certain limitations that are now briefly
considered.
For some, treatment is started after a degree of neural damage has occurred
and this persists. In others, side effects of therapy dictate cessation, and in yet
others a paradoxical and serious worsening of cerebral symptomatology
occurs, for reasons not yet well understood. Moreover there is the increasing
problem of the emergence of drug-resistant strains. Also, the limited
penetration of protease inhibitors into the CNS and viral reservoirs are as yet
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unresolved issues. The failure rate in therapy may be as high as 50%
(Fatkenheuer et al. 1997). The overall yield is a 50% decline in AIDS death
rate, decreased maternal-infant transmission rates, reductions in the rates of
opportunistic infections and a 40-50% decrease in the incidence of HIV-
associated dementia (Brodt et al. 1997) (Sacktor et al. 2001).
However, the incidence of minor cognitive-motor disorder remained
unchanged with HAART, and the prevalence was recorded as running at
approximately 30% in two major cohorts of high risk individuals (Sacktor et al.
2002). This was a disappointing finding especially as CSF studies showed
effective clearance of HIV-1 RNA over a three month period (Foudraine et al.
1998).
As regards post-mortem findings in the HAART era, the incidence of
opportunistic infections has declined (Mamidi et al. 2002), but HIVE was
found in 25% of cases in one autopsy study (Masliah et al. 2000). In another
study apparently inactive HIV encephalitis (HIVE) lesions were found,
suggesting at least temporary respite from disease progression (Gray et al.
2003). A rather different situation has been reported in some cases in the last
few years. This has occurred in patients receiving HAART with established
neurological disease and who died with worsening symptoms. In a small study
of seven cases, post mortem examination revealed active and extensive
demyelinating leucoencephalopathy associated with marked perivascular
inflammatory cell infiltrates (Langford et al. 2002). A more recent report on
two patients with advanced HIV infection and who, under treatment, had
shown rising CD4 cell counts and falling viral loads, revealed that both died
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with acute encephalopathies. Detailed post mortem examination showed in
one, HIVE, and in both, widespread microglial hyperplasia and very extensive
perivascular and parenchymal infiltration with CD8+/CD4- lymphocytes.
HIV-RNA was detectable by PCR in both brains (Miller et al. 2004).
The explanation offered for the findings in these cases is that the abrupt and
selective recovery of the CD8 lymphocyte population in the periphery allows a
surge into the relatively unprotected CNS and profound tissue damage follows.
This phenomenon of HAART-related adverse immune response has been
termed the immune reconstitution inflammatory syndrome (IRIS).
A very important aspect in the development of HIV-associated dementia is
the question of the final common pathway - would it develop irrespective of
conditions prevailing elsewhere in the body, or is the "driver" in the final phase
resident in a locus such as the bone marrow (Gartner 2000), and thereby
offering hope of prevention by new systemic treatments?
1.12 - Paediatric AIDS
1.12.1 The General Western Population - with reference to
that in the developing world
HIV/AIDS in Children
The upper age limit of childhood is variously defined, but for the purposes of
this study the term "children" is used to apply to those under the age of 15
years.
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The first cases of AIDS in childhood were reported in 1982, in the USA, at
varying locations from San Francisco to New York. By 1996 it had become the
seventh leading cause of mortality in the 1-4 years age group in the USA
(Ventura et al. 1997)
Now it is estimated that there are 1,500 new infections daily worldwide and
2.1 million children are currently infected. The number of children estimated
to have died worldwide in 2007 is 290,000 (270,000 -320,000)
(UNAIDS/WHO 2007).
Also of note is that in resource-poor countries, where the major mode of
spread in adults is by heterosexual intercourse, a consequence is that some 15-
20% of all new cases are paediatric (Kuhn and Stein 1995).
In the worst affected countries AIDS is now the biggest single cause of death
in the under 5 age group. The prognosis for African children infected
perinatally with HIV-1 is very poor. In a meta-analysis of seven randomized
mother-to-child-transmission intervention trials, 32% had died by one year and
52.5% by two years (Newell et al. 2004).
Modes of Transmission
In the first report of immuno-compromised children in the USA, the social
and sexual habits of their mothers raised the possibility of a vertically
transmissible agent (Oleske et al. 1983). Following the discovery of HIV, its
detection in amniotic fluid and products of conception made this mode of
transmission almost certain. The further isolation of the virus in breast milk
and vaginal secretions pointed to additional routes of perinatal infection. By
74
1987, when it was already known that the virus could also be spread by
contaminated blood or blood products, it was estimated that of the population
of childhood AIDS in the USA, some 80% was due to vertical transmission,
and the remaining 20% to transfusion of blood or blood products (Rogers et al.
1987). Now, since screening of blood and blood products is universal in
developed countries, almost all childhood HIV infection is due to mother-to-
child-transmission (MTCT). In less fortunate countries, such as those in
Africa, infection by contaminated blood or syringes still occurs and by another
mode, particularly in the case of young girls, that of sexual abuse (WHO
2007).
Mother-to-child (MTCT) or Vertical Transmission
Estimates for rates of MTCT in the absence of any therapeutic intervention
vary, but reasonably reliable figures are 15-20% in Europe and the USA, and
up to 25-30% in some African populations (Prendergast et al. 2007). The
transmission rate for HIV-2, even without any intervention, is much lower -
less than 2% (Adjorlolo-Johnson et al. 1994) underscoring the limited
pathogenicity of HIV-2 compared with HIV-1. A large number of factors
influence the risk of vertical transmission. The more important of these
include maternal viral load and CD4 count (Burns et al. 1997), prematurity,
duration of rupture of the membranes and mode of delivery.
The timing of transmission has been the subject of many studies and
differing views are held as to the relative importance of the various time
"windows" - pre-confinement, intranatal or perinatal and post-natal. In a study
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of spontaneous abortion in HIV positive women, HIV-1 was found in 7 out of
14 foetuses by in-situ hybridisation (Langston et al. 1995). Thus, though
transmission may occur in the early weeks of pregnancy, evidence from
prospective longitudinal studies suggests that the most important time period is
either in the short period before, or actually during, birth and this may amount
to as much as 80-90% in developed countries. The studies, which involved
estimation of HIV-RNA levels at birth and after, showed that only 12-16% of
infected infants were positive at birth, which is consistent with intra-uterine
transmission (Shearer et al. 1997). Furthermore, the RNA levels in such
positive neonates tended to rise rapidly in the first 2-4 weeks of life, signifying
possible recent intra-uterine infection. Another study, based on perinatal
virology and serology, estimated that of those considered to have been infected
in utero, the median time between infection and delivery was 14 days (95% CI
5-75%), and the 95th percentile was estimated as 59 days before delivery
(Rouzioux et al. 1995).
The post-natal transmission risk, that is the risk associated with breast
feeding, was accurately defined in African women who became infected in the
post partum period and were shown to transmit infection in their milk at rates
of up to 30% (Van de Perre et al. 1992). The overall risk from breast feeding
in die transmission ofHIV is estimated from a meta-analysis to be in the range
from 7-22% (Dunn et al. 1992).
The time periods of probable transmission in African populations have been
studied, and for general transmission rates of 25% the proportions have been
estimated at: 20-25% in the early intra-uterine period, i.e. before 28 weeks of
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gestation; 50-60% in the period from 28 weeks to 7 days post-partum; and 15 -
20% in the post-natal period to 24 months (Simonon et al. 1994). The results
of this and other studies were in accordance with the study quoted above (Dunn
et al. 1992).
Another important factor influencing MTCT is a genetic one - mother-child
class 1 HLA concordance increases the risk (MacDonald et al. 1998).
Rates of mother to child transmission are much higher in sub-Saharan Africa
than in Europe (Kuhn and Stein 1995), and several factors are probably
responsible for this disparity, for example the higher the maternal viral load,
the more likely the possibility of transmission (Kamara et al. 2005). Co¬
existent maternal disease, such as malaria in sub-Saharan African populations,
is also known to increase the risk (Brahmbhatt et al. 2008)
Modulation of MTCT Risk by Intervention
In Europe and the USA a number of interventions are available which have
been shown to reduce the risk of transmission substantially. Zidovudine
therapy given before 28 weeks' gestation can minimize the risk of intra-uterine
infection (Lallemant et al. 2000). In the absence of breast feeding, zidovudine
given during pregnancy and labour, and to the newborn infant for 6 weeks, can
reduce the transmission rate from 25 to 8% (Connor et al. 1994). In women on
triple therapy with an undetectable viral load the risk may be as low as 1%
(MMWR - 1998). Delivery by Caesarian section, which is known to confer
significant benefits in reduction of transmission (Kind 1995), may be indicated
in some circumstances In less favoured settings the options are fewer, but
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zidovudine in short courses, or nevirapine given as a single dose to the mother
in labour and to the infant during the first three days of life, have reduced
transmission rates by up to 40%. This has been shown to be a very cost
effective intervention (Sweat et al. 2004).
The question of advice on breast feeding for mothers in developing countries
is often problematic, and from a pragmatic point of view the infant may be at
less overall risk from its mother's milk than other risks such as malnutrition or
gastroenteritis from contaminated water supplies.
One simple and inexpensive intervention is the provision of vitamin A
supplements for pregnant women. Vitamin A deficiency is common in African
populations and is a recognized risk factor for MTCT (Semba et al. 1994).
In considering the impressive advances made in the developing world in the
recognition and prevention of MTCT, mention should be made of a parallel
adverse situation in respect of vertically transmitted syphilis, another sexually
related disease,. In Europe and the USA, antenatal screening for this condition
has been standard for fifty years or more, and though there has been a slight
increase in reported cases in the general population in recent years, congenital
syphilis remains a rarity. However, the position with respect to prevalence and
incidence in less fortunate countries, such as Africa, is quite different. In sub-
Saharan Africa between 4 and 15% of pregnant women have syphilis, and an
estimated 492,000 infants die of congenital syphilis every year worldwide
(Schmid 2004).
Despite the great investment of foreign aid in MTCT prevention
programmes, this has not been matched by equivalent screening for, and
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treatment of, maternal syphilis. This intervention is both simple and cheap.
Syphilis in pregnancy causes spontaneous abortion, intra-uterine growth
retardation, pre-term delivery, stillbirth and congenital abnormality in up to
50% of cases (Schulz et al. 1987). In Tanzania, 51% of stillbirths, 24% of pre¬
term live births and 17% of all adverse pregnancy outcomes could be attributed
to syphilis. The plea is made that a concerted effort by the relevant agencies
could help to avert the tragedy of children escaping HIV infection only to
succumb to syphilis (Peeling et al. 2004).
Transmission through Blood Products
The first reports of haemophiliacs presenting with severe immunodeficiency
were in 1982, in the USA, when three cases of P. carinii pneumonia in patients
who had received factor V111 concentrate were identified. In December of
that year, an infant with severe immunodeficiency and who had received a
blood transfusion was reported. Inl985, universal blood and blood product
screening was introduced, the causal relationship with HIV having been
established. The number of children with haemphilia children who contracted
HIV through infected blood products thereafter steadily decreased in the USA
(Seliketal. 1993).
1.12.2 - Natural History of HIV Infection in Childhood
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In about a third of HIV infected pregnant women, transmission to the infant
will occur in the absence of any intervention, yet in most cases the neonate
appears normal.
The prognosis for the untreated infected infant is poor, especially in
developing countries, where the mortality rate for the first two years of life is
45-69% (Obimbo et al. 2004). In Europe and the USA the comparable rate
was 10-20% (European Collaborative Study 1994). In untreated infants
(USA), a minority sub-set of about 15-20% was found to have developed
AIDS-defining illnesses by the age of 12 months (Blanche et al. 1990).
The introduction of HAART, in 1997, and anti-microbial prophylaxis, where
available, has transformed the picture of paediatric HIV infection so that, in the
UK, the progression to AIDS has been reduced by 50% and mortality by 80%
(Gibb et al. 2003). An association was found with advanced maternal disease
and infection in-utero (Ioannidis et al. 2004). A presentation at about three
months of age with severe respiratory illness - due either to Pneumocystis
pneumonia or cytomegalovirus - is common and carries a high mortality. By
12 months some 70% of infected infants will have become symptomatic and
the median age of progression to AIDS is 6 years. A few may not present until
early in the second decade. Generally disease progression in untreated children
is faster than in adults. In the resource-rich world, HAART, and Pneumocystis
prophylaxis, have transformed the prognosis for childhood HIV infection, but
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elsewhere the situation remains uncertain, though one of the Millenium
Development Goals was to halt and reverse the spread of HIV/AIDS.
Diagnosis of HIV Infection in Childhood
Because maternal antibodies acquired through transplacental passage can
persist for 18 months, all infants born to HIV positive mothers are themselves
antibody positive. Suspected diagnoses in neonates must be confirmed by the
demonstration of active infection - either by viral culture or the detection
(Yanase et al. 1986) by PCR of viral RNA or DNA (Burgard et al. 1992).
Positive results should be repeated at least once, and negative ones checked by
serial tests at regular intervals (Husson et al. 1990).
1.12.3 - Immunopathogenesis in Childhood
In general the immuno-pathogenesis of HIV infection is the same in
childhood as in the adult, namely, the infection of cells bearing the CD4
surface marker and, in particular, helper lymphocytes and cells of
monocyte/macrophage lineage.
The situation in early childhood with respect to the response to HIV infection
differs from that in adults in several ways. Firstly circulating blood levels of
lymphocytes are higher in the first few years of life - 6-7 x 109 /L are normal
levels in the early months, in contrast to the adult counts of 1-3 x 109 /L. For
reference, in adults with HIV infection a lymphopenia (< 800 cells/mm3) is
found in 18%, and in 70% of patients with AIDS (Treacy et al. 1987). 30-70%
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of the total lymphocyte count in infants is made up of CD4 cells. The normal
CD4:CD8 ratios are 3:1 in the newborn, 2-3:1 in infants aged one to two and 1-
2:1 for children over the age of two (Yanase et al. 1986). The high initial viral
loads - commonly at 1 x 105 —1 x 106 HIV-RNA copies/ml of plasma - do not
seem to be associated with HIV-specific CD8 lymphocyte activity, and the
marked fall in viral load following initial infection that occurs in adults is not
seen. The rate of progression may be slower in the presence of HLA alleles
B27 and B57 (Feeney et al. 2004). The immunodynamics of HIV infection in
infancy and childhood, especially with regard to the rate of progression, may
be related to the degree of involvement of the thymus in HIV infection. There
is some evidence that involvement of the thymus can occur soon after HIV
transmission to the foetus and, indeed, may contribute to early miscarriage.
Abnormalities were found in the thymus of three out of thirty seven foetuses
aborted by HIV positive women. These were a degree of lymphocyte depletion
and though there was no evidence of any extensive HIV infection it was
thought likely that the changes were related to HIV infection (Papiernik et al.
1992). Detailed examination of the thymus of an HIV positive infant, dying at
3 days of age, showed the presence of infection of thymocytes, by in situ
hybridisation, and selective depletion of some thymocyte subsets (Rosenzweig
et al. 1993).
In a cohort of 59 HIV infected infants, 17 showed depletion of CD4+ and
CD8 + T cells suggestive of thymic compromise and 5 infants with the Di
George syndrome, who were also part of the study, showed a more rapid
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course to AIDS and a higher early death rate than the other HIV positive
children (Kourtis et al. 1996).
The other side of the coin is that, if there is no early compromise of thymic
function, there is an advantage for children compared with adults in the
possession of a relatively larger and more active thymus. This obtains in the
apparently greater ability to challenge viral escape mutations with a greater
repertoire of cytotoxic T lymphocyte (CTL) responses (Shearer et al. 1997).
Another apparent relative benefit is in the regeneration of HIV specific T-
helper activity which follows treatment with HAART in children (Rosenberg et
al. 2000), but which declines with similar treatment in adults (Lichterfeld et al.
2004)
As regards monitoring, both the plasma viral load and the CD4 count are
used, as in adults (Palumbo et al. 1998). However, in view of the declining
CD4 counts (absolute CD4 counts are much higher in infancy) which occur
normally, a preferable index is the CD4 %, i.e. percentage of total lymphocytes
that are of CD4 lineage until the age of five (Waecker et al. 1993). Above this,
absolute CD4 counts become as reliable a marker as in adults. In resource-
poor settings, clinical examination and simple haematological indices, such as
haemoglobin level and total lymphocyte count, may be the only markers
available.
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Haematology Findings in Childhood HIV Infection
Bone marrow abnormalities are common in children who suffer from HIV
infection, but tend to be non-specific and may not necessarily help in the
elucidation of haematological problems (Mueller et al. 1996).
Anaemia (10 gm./l or less) is common in childhood HIV infection and a
haematocrit of less than 25% is often associated with a poor prognosis
(Ellaurie et al. 1990). The anaemia is commonly hypochromic and microcytic
and associated with iron deficiency. Rarely is it macrocytic or haemolytic. An
association with AZT therapy exists and may be dose-dependent (Englund et
al. 1997).
Neutropenia with less than 1,500 white cells / mm3 has been reported in 43%
of previously untreated children with HIV infection (Pizzo et al. 1988) The
neutropenia may be isolated, or associated with anaemia and
thrombocytopenia. Aetiological factors are bone marrow involvement by HIV
or opportunistic infections and, in the case of therapy, AZT.
Thrombocytopenia as an HIV-related phenomenon was noted in 1982, at the
start of the epidemic. In a paediatric population a platelet count of less than
50,000 /mm3 was found in 19% (Butler et al. 1991). The aetiology of
thrombocytopenia in childhood HIV infection is not well understood and the
response to therapy is variable.
One of the first blood findings in infected infants is B-cell hyperactivity
associated with elevation of one or all immunoglobulins (IgG), with IgA and
IgM elevated at three months. IgG levels may rise to lgm/L in the first year
and even to 4gm/L later. Despite these levels there is a widespread
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abnormality of antibody responses as evidenced by early susceptibility to
bacterial infection.
CD8 T-cells, cytotoxic/suppressor lymphocytes, are not depleted until very
late in HIV infection. They are considered to play an important role in specific
HIV immune response (Borrow et al. 1994), and this is supported by evidence
from simian immunodeficiency studies (Schmitz et al. 1999) (Mphatswe et al.
2007).
1.12.4 - Clinical Features - Neonatal Period and Early Infancy
In considering the clinical aspects of HIV infection in children, compared
with those of adults, two general points are worth making. The first, which is
self evident, is that childhood is a time of somatic and intellectual growth and
these attributes are therefore susceptible to interference. The second is that the
long asymptomatic period in adults does not have an exact counterpart in
childhood for various reasons, not least because childhood is naturally a time
of first encounters with common environmental pathogens, but also because
significant problems tend to arise before the advent of severe
immunosuppression.
The prognosis for the untreated infected infant is poor, especially in
developing countries, where the mortality rate for the first two years of life is
45-69% (Obimbo et al. 2004). In Europe and the USA the comparable rate
was 10-20% (ECS - 1994). The introduction of HAART in 1997, and anti¬
microbial prophylaxis where available, has transformed the picture of
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paediatric HIV infection so that, in the UK, the progression to AIDS has been
reduced by 50% and mortality by 80% (Gibb et al. 2003).
Bimodal Distribution in Early Childhood
In 1988 an analysis of 215 infected infants in New York City suggested two
at-risk populations with respect to incubation periods. In the first, designated
rapid progressors comprising some 12% (± 7%), a very short incubation period
of median 4.1 months was present and for the remainder, the slow progressors,
a median of 6.1 years was identified (Auger et al. 1988). The clinical and
immunological status of 267 infected neonates (total population born to
infected mothers was 1,386) was the subject of a prospective, multicentre trial
(Mayaux et al. 1996), which served to identify the markers of susceptibility for
the early severe form ofHIV in infancy (Blanche et al. 1990) .
Within 2 weeks of birth, using viral culture or HIV PCR, 35% of the cohort
was identified as being infected, and was observed to differ from the remainder
both in terms of clinical features and laboratory investigations. The infants in
this group were twice as likely to have a birth weight below 2500gm, and also
had a 1cm. smaller head circumference on average. They were three times
more likely to have lymphadenopathy or hepatosplenomegaly. They had a
lower mean CD4 count (2.57 vs. 3.49 xl09/L), a higher IgM level and a lower
platelet count.
This group comprised 61% of the infants with the early severe form of the
disease - that is infants suffering from wasting, encephalopathy and recurrent
severe infections occurring within the first year of life. As virus detection by
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PCR or culture at birth is considered to indicate pre-existing intra-uterine
infection, the implication is that this is one of the main determinants of early
disease. The authors pointed out that additional mechanisms must operate to
account for the other cases in this group and also that some infants, infected at
birth by blood transfusion, also developed early severe disease (Jones et al.
1992).
The Clinical Course of Rapid Progressors
Non-specific conditions such as hepatosplenomegaly, lymphadenopathy,
dermatitis and parotitis are common to both groups, but they occur earlier in
the rapid progressors and are more severe.
In the absence of treatment some 15-20% of infected infants will have
developed an AIDS-defining illness within one year. Commonly the first
illness is a respiratory one at about three months of age and due to
Pneumocystis carinii (now jirovecii) pneumonia. This illness occurred in up to
53% of children with AIDS (Rogers et al. 1987) and carried a high mortality
(and still does even with treatment) (Williams et al. 2001). Another common
respiratory illness is lymphoid interstitial pneumonitis (LIP), or pulmonary
lymphoid hyperplasia (PLH), which occurs in about 20-30% of vertically
infected children. It is a disorder in which there are diffuse infiltrates of
lymphocytes in the lung parenchyma. It can occur in infants as young as 2
months but is more commonly encountered in the one plus age group. The
aetiology is uncertain, it may represent an unusual response to Epstein-Barr
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virus (Andiman et al. 1985), or an exaggerated response to an inhaled or
circulating antigen.
Examination of lungs removed at post-mortem has shown a pleomorphic
lymphoid infiltrate of which 46% were B cells, 25% CD4+ T cells and 40%
CD8+ T cells (Joshi et al. 1985). The course of the condition is quite variable.
It is an AIDS defining condition (CDC classification Group IV E). In some it
remains relatively asymptomatic; in others a wheezing condition develops; and
in yet others progressive pulmonary disease develops with a bronchiectasis-like
syndrome. Treatments tried in addition to standard anti-retroviral therapy are
pulmonary toilet with aerosol administration, oxygen and physiotherapy. Its
incidence has remained relatively constant at approximately 20% of all
patients.
Pulmonary TB is more often a problem in Africa (see section 2.5.3). Gastro¬
intestinal problems are common and one of the most important, an AIDS-
defining condition, is oesophageal candidiasis. (Cello 1988). A degree of
hepatosplenomegaly is present in the majority of children with HIV infection.
Bacterial (Bernstein et al. 1985) and viral (Jura et al. 1989) infections are
common, frequently severe and were the presenting condition in 20% of
infants in one series (Krasinski et al. 1988). The particular susceptibility to
infectious disease is considered due in the main part to the B-cell defects
associated with CD4 T-cell depletion; although hypergammaglobulinaemia is
frequently present, antibodies are generally non-functional.
Cardiovascular disease contributes a small but significant burden to
paediatric AIDS sufferers. A study of 433 children with AIDS showed a 6.5%
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incidence of cardiomyopathy with a relative risk of dying of 2.8%, compared
with other children with AIDS (Tovo et al. 1992).
1.12.5 - The Central Nervous System in Childhood HIV Infection
The Clinical Manifestations of Paediatric HIV Infection
With regard to neuropsychological development, HIV infected children can
be conveniently considered in three sub-sets - those with encephalopathy,
those with some CNS compromise and those with no apparent deficit of CNS
function (Working Group 1991). The first group, that of encephalopathy, can
be further sub-classified into subacute progressive, plateau and static. The
subacute progressive course is most common in infants and young children - in
this there is actual regression of function, where previously acquired skills are
lost. In the plateau group new skills are scarcely gained but existing ones are
retained, and in the static group there is a continued delay in progress. In the
more severe cases of encephalopathy there may be moderate to severe
psychomotor difficulties.
The HIV-related compromise group fall within the normal range but there is
impairment of some neurocognitive functions.
The apparently normal function group do not differ from their fellows in any
specific way or show decline over time.
A degree of correlation between cognitive function and HIV disease state
was noted in the pre-treatment era, using laboratory markers such as CD4
counts and p24 antigen levels (Brouwers et al. 1994).
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Almost half (Mason et al. 1990) of the rapidly- progressing infant sub-set
will acquire an encephalopathy, within three years, characterized by hypertonic
diplegia and developmental delay - especially in respect of motor skills and
language (Lobato et al. 1995). Dementia may supervene. CT imaging may
show a degree of atrophy and calcification in the basal ganglia. The median
survival from onset is 11 months (Scott et al. 1989) . The very high mortality
rates quoted above - 32% in first year and 52% in the second - mean that
many will die before the possible expression.
In children with a later onset of AIDS at a median age of 6.1 years (Scott et
al. 1989), the spectrum of disease is similar to that outlined above.
A general phenomenon in HIV infection in children is disturbance of growth,
which is manifest at all ages. Inextricably linked to the problem of growth and
development in HIV-infected children, certainly in the developing world, is
malnutrition. This condition - specifically protein calorie malnutrition (PCM)
- is the most common cause of immunodeficiency worldwide. Indeed, before
HIV infection was recognised, Kaposi's sarcoma and Pneumocystsis carinii
pneumonia were described in malnourished, but otherwise healthy, children
and adults, in resource-poor settings (Hughes et al. 1974).
The Neuropathology of Paediatric HIV Infection
Much of what is known of the neuropathology of childhood HIV infection is
derived from the American experience of the epidemic. In some of the
literature the ethnic background of the study population is detailed, but often it
is not. The incidence of HIV infection in America has been unevenly
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represented in the population sub-sets - in the general population the main
racial groups are distributed thus: 56% white, 20% black and 21% Hispanic.
Of the 7629 children in America reported to CDC by December 1996, 58%
were black, 23% were Hispanic and 18% were white (Centers for Disease
Control and Prevention 1996). Genetic influences may play a part in
determining the susceptibility to, severity of, and rate of progression of HIV
related CNS pathology. Another point in considering the results of studies is
whether or not there could be a bias in favour of one or other arms of the
bimodal distribution (Auger et al. 1988) which clearly existed before treatment
was available to modify transmission.
a. Cerebrovascular disease: this is a cause of morbidity and mortality in
childhood HIV infection. Arteries affected by an inflammatory process were
seen in the brains of children with HIV encephalopathy (Joshi et al. 1990). Of
seven children with HIV infection who developed strokes, six of them were
found at autopsy to have a thrombotic cause associated with vascular disease,
and two showed aneurysmal dilatation of the circle of Willis (Park et al. 1990).
The pathogenesis of vessel pathology in HIV infection is uncertain. Direct
infection of the endothelium, though detected by some investigators, has not
been a universal finding (Lipshultz et al. 1990). Circulating cytokines have
also been postulated as an aetiological factor (Weiss et al. 1993)
b. CNS opportunistic infections: as noted above, children are generally less
liable to opportunistic infections than adults and this was reflected in the
relatively low incidence (11 out of 114 cases) in a multi-centre post mortem
study of children with AIDS (Kozlowski 1990).
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CNS lymphoma in childhood is uncommon (Epstein et al. 1988).
The HIV specific abnormalities once frequently observed in the CNS are now
seen much less commonly. HIVE was seen in over 50% of infected children in
the early days (Belman et al. 1988) but became uncommon in the USA and
Europe a few years later (Tardieu et al. 1995).
c. Microcephaly: before the introduction of antiretroviral therapy, this was the
most frequent abnormality in paediatric AIDS, seen in 63% of necropsies
(Kozlowski et al. 1997). Microcephaly refers to a small head size for the age of
the individual and implies small brain volume. In effect this phenomenon was
equivalent to growth retardation. A detailed study of 12 brains from children
suffering from AIDS and 7 control brains was performed in 1997(Kozlowski et
al. 1997). The AIDS brains showed significant differences in volume when
compared with both the control brains and the standard reference values for
normal children of similar ages. The reduced volumes were shown to affect
both the total of the hemispheres and of the individual structures, including
separately the whole of the cortex, the white matter and the basal ganglia. The
negative weight differences for the AIDS brains ranged from 13.2-55.2% when
compared with normal brains of the same age. Cerebral atrophy had also been
demonstrated by CT scanning, and in a systematic unbiased study (DeCarli et
al. 1993) of children with symptomatic HIV disease in 1993, ventricular
enlargement and widening of sulci were seen in 78% of cases, and attenuation
of the white matter in 27%.
d. Cerebral vascular calcification: this is a common finding in childhood
HIV infection, especially in the basal ganglia. It is not seen in adults (Kure et
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al. 1991) and tends to be a feature of vertically infected children. In a CT scan
study it appeared more than twice as common in vertically infected children
compared with transfusion infected ones, 36% vs. 14% (Brouwers et al. 1994).
Furthermore as calcification was rarely seen in premature infants infected by
transfusion after 34 weeks, the implication was that it might indicate
intrauterine infection and, possibly, local breakdown of the blood brain barrier
(Belman et al. 1986; Kinney et al. 1988).
e. Inflammatory cell infiltrates: both perivascular cuffs and parenchymal
collections of macrophages, with giant cells, were common, especially in
infants with progressive encephalopathy, signifying a high prevalence of HIVE
in Western paediatric populations (Dickson et al. 1989). These changes were
found mostly, but not exclusively, in the deep white matter and basal ganglia.
f. Neuronal loss and apoptosis: this was reported to occur in the younger age
group with encephalopathy (Wiley et al. 1991) but was not confirmed in other
studies (Brouwers et al 1994).
g. White matter pallor with astrocytosis: this was found in most paediatric
AIDS cases in the pre-treatment era, on staining brain sections with Luxol fast
blue (Epstein et al. 1986) (Kozlowski et al. 1997). It may be hard to interpret
myelin pallor in the first two years of life, when myelination is still active,
especially if there is delay due to adverse conditions, (Kinney et al. 1988).
Delay, or arrest, of myelination may be a major component of the substrate of
encephalopathy. The spinal cord may also show delay in myelin maturation but
in some AIDS cases, axonal injury co-exists (Dickson et al. 1989).
1.12.6 - Treatment of HIV/AIDS in Children -
developing World
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in the developed and
In general the approaches to treatment of HIV infection in childhood are
broadly similar to those used in adults. The three chief determinants are the
presence of symptoms, the CD4+ T cell count and the viral load.
Treatment should be started in symptomatic children regardless of CD4+ T
cell count or viral load and, conversely, since the CD4+ T count and/or the
viral load are predictive of disease progression and death, treatment may be
indicated even in the absence of symptoms. The guidelines vary slightly
between Europe and the USA and according to age. For children under a year,
values which should prompt treatment are a CD4+ count of 20% or less and a
viral load ofHIV-RNA 1,000,000 copies/ml of plasma or greater; for children
over a year, a similar CD4+ T cell count or a viral load of greater than HIV
-RNA 100,000 copies/ml of plasma.
A combination of two reverse-transcriptase inhibitors and a protease
inhibitor is considered optimal therapy (MMWR - 1998). Therapy can
suppress viral loads to undetectable levels and restore CD4 counts (Fraaij et al.
2005). The problems of drug resistance and side effects encountered in the
treatment of adults also occur in childhood, and additional difficulties are those
of appropriate formulations and volumes, coupled with an often relatively
larger dosage requirement.
Continuous monitoring is required at three monthly intervals and
unfavourable indices, or symptoms suggesting intolerance, indicate the need
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for a review of therapy. Since HAART became an integral part of the
management of HIV infected children in the developed world, most affected
individuals survive into adulthood.
In the developing world, treatment programmes are in the early stages of
implementation, and the G8 target of universal availability is set for 2010.
Initial studies, based on a start date of 2004 and investigating children in Cote
d'lvoire, Kenya and South Africa, have shown promising results (Rouet et al.
2006), (Nyandiko et al. 2006) and (Reddi et al. 2007).
1.12.7 -The Future for Paediatric HIV/AIDS
The great advances in prevention of mother-to-child-transmission and
treatment with HAART, achieved in the developed world, provide a yardstick
against which progress in poorer countries can be measured. The aims must be
wider access to testing for pregnant women, with pre- and post- confinement
intervention as necessary. Likewise early diagnosis in the neonate with
appropriate treatment should be a goal. There is increasing goodwill among the
young people of the richer nations, "Live-AID" for example, and the hope is
that, with the provision of adequate finance and encouragement, poorer
countries will able to start reversing the burden of paediatric HIV infection and
AIDS.
95
1.12.8 - Differences between HIV Infection in Adults and Children
An absolute difference is in the integral nature of somatic and intellectual
growth in childhood, and the possibility of its impairment. Also related to the
development of the child are the first-time encounters with environmental
pathogens and the associated increased risk of meeting these with impaired
immunity. For example, the association of LIP with Epstein-Barr infection.
This of course means that the illnesses seen in adult AIDS as a result of
reactivation of past and previously quiescent disease, for example, herpes
simplex, CMV, and toxoplasma (cerebral or other site), generally have no
counterpart in the spectrum of paediatric AIDS. Primary lymphoma of the
brain occurs infrequently (Epstein et al. 1988). Malignancy is uncommon in
childhood and accounts for less than 2% of AIDS-defining illness. Kaposi's
sarcoma is extremely rare (Joshi et al. 1990). The fairly clear-cut bimodal
disease distribution of childhood does not occur in adult HIV infection.
Other differences emerge in laboratory investigations. For example, anaemia
in childhood HIV infection is commonly hypochromic and microcytic, whereas
anaemia in adult HIV infection is typically normochromic and normocytic.
Lymphocyte counts are physiologically higher in the first few years of
childhood and the hypergammaglobulinaemia which is common in children is
infrequent in adults. The initial viral load is higher in children.
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1.13 - What is known of Paediatric African AIDS?
HIV Infection in Africa
The HIV/AIDS epidemic in Africa differs from that in Europe and North
America in several ways. It is mainly transmitted heterosexually, with a male
to female ratio of 1:1 and the homosexual and drug abusing risk groups are
probably of negligible proportions. The prevalence rate for adults in sub-
Saharan Africa is much higher. All of the 14 countries estimated by WHO to
have rates of infection greater than 5% are in sub-Saharan Africa. The overall
rate in Africa was 8.8% in 2000, of which 55% was female. Infection may be
facilitated by a higher incidence of co-existing sexually transmitted disease, eg
syphilis, and by different sexual customs, for example, intercourse at a younger
age for women.
In women attending ante-natal clinics, in East and South Africa, rates of
between 14-33% have been recorded. The mother-to-child transmission rate
without intervention is higher and ranges from the previous (untreated) rate of
15-30% in Europe to 25-40% in sub-Saharan Africa (Nesheim et al. 1994).
Transmission by contaminated blood or needles may still be a problem in some
parts of sub-Saharan Africa. The progression to AIDS may be more rapid in
the presence of other tropical diseases - for example malaria and helminth
infection.
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The Clinical Course in African Children
The high prevalence of HIV/AIDS for adults in sub-Saharan Africa has a
significant impact on the rate of vertical transmission. In some parts of Africa
the proportion of women of childbearing age who are HIV positive reaches
35% or more (Newell et al. 2004). This is reflected in the high incidence of
paediatric HIV infection (18.3% for children in a hospital setting) (Blantyre)
(Molyneux et al. 2003). In this study the commonest causes for admission
were gastroenteritis, pneumonia, TB and malaria. In cases of malnutrition,
62% were HIV positive and in cases of probable TB a rate of 58% was
recorded. The aim of the study was to compare the effect of HIV infection on
the management of bacterial meningitis, which had previously been shown to
account for 2.7% of all admissions (Molyneux et al. 2000). Out of 598 cases
of meningitis 459 were tested for HIV status and 157 (34%) were found to be
HIV positive. The overall mortality rate was 65% in the HIV positive group
and 36% in the HIV negative group.
The data shown above serve to illustrate the spectrum of illness in sub-
Saharan Africa. Without treatment the mortality rate for HIV infected children
at two years is estimated to be 45-59% (Dabis et al. 2001), against that in
Europe and the USA before treatment of 10-20% (European Collaborative
Study 1994). In one study of perinatally HIV infected children in Central
Africa, 89% had died by the age of 3 years (Taha et al. 2000).
Limited resources, in even simple matters such as access to clean drinking
water, mean a higher background level of gastro intestinal disease. Social
deprivation imposed by orphan status and malnutrition compound the desperate
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situation for even HIV negative infants; the mortality risk for HIV positive
children is ten times greater (Newell et al. 2004).
The bimodal expression of HIV disease is similar in African populations but
disease progression in both sub-sets appears more rapid. Diarrhoea is the
commonest cause of death and rotavirus the usual pathogen. The risk of death
in chronic diarrhoea is eleven times greater for HIV positive infants (Thea et
al. 1993).
Respiratory Illness
Pulmonary infectious disease is a particularly important cause of morbidity
and mortality in African children. Reference is made to this in the original
Abidjan study, and a further post-mortem study, conducted in Zambia and
specifically applied to lung disease, is particularly instructive (Chintu et al.
2002). In this study of 264 children, aged between 1 month and under 16
years, 137 were male (93 HIV- 1 positive and 44 HIV-1 negative) and 127
were female (87 HIV-1 positive and 40 HIV-1); examination was confined to
the lungs.
Multiple pulmonary diseases were common, but overall the four main
conditions were: acute pyogenic pneumonia - 39.1%, Pneumocystis carinii
pneumonia - 27.5%, cytomegalovirus - 20.2% and tuberculosis - 18%. In the
HIV-1 positive group the three commonest conditions were: acute pyogenic
pneumonia (41%), P. carinii pneumonia (29%) and CMV (22%) and for the
HIV-1 negative group, acute pyogenic pneumonia (50%), tuberculosis (26%)
and interstitial pneumonia (18%). Of the 10 cases in which LIP was detected, 9
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were HIV-1 positive. TB was common in all age groups, even in the very
young, and irrespective of HIV-1 status. It was found as the sole pathology in
25 cases.
The high incidence of TB is a matter of great concern, and its intimate
relationship (worldwide, as well as in Africa) with HIV is a formidable
partnership from a public health point of view (Chintu et al. 2002). The
percentage of HIV positive children in South Africa co-infected with TB
approaches 50% (Jeena et al. 2002). HIV is estimated to increase the risk of
contracting pulmonary TB by up to 20-fold (Madhi et al. 2000). Diagnosis is
difficult and treatment complicated by differing regimes, side effects and the
emergence of resistant strains.
Malaria
The relationship of HIV infection with malaria, once thought to be a
mutually neutral one, is now considered to be disadvantageous with respect to
the incidence and severity ofmalaria and the HIV viral load.
Plasmodium falciparum is the species most likely to cause severe disease,
with cerebral complications. There are reckoned to be 515 million cases of
malaria in the world each year, of which over 70% occur in Africa and mostly
affect children. Infants are less susceptible to malaria in the first six months,
despite being infected, because of maternal antibodies. Seizures are a common
presenting feature of cerebral malaria. Severe anaemia, hypoglycaemia and
coma are other manifestations. A longitudinal study in 1991 found that
children with AIDS had an increased incidence of malaria and higher parasite
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densities than pre-AIDS or non-infected children (Greenberg et al. 1991).
Another study showed that HIV-1 infection was associated with an increase in
severe malaria with coma and the prospect of neurological sequelae
(Grimwade et al. 2003).
A prospective study in adults showed that infection of HIV-1 positive
individuals with P.falciparum malaria led to significant increases in HIV-1
RNA, which was thought possible both to accelerate disease progression and
facilitate transmission (Kublin et al. 2005). A prospective trial of
cotrimoxazole prophylaxis, anti-retroviral therapy and insecticide-impregnated
bed nets found a significant reduction in malarial episodes in HIV-1 positive
adults (Mermin et al. 2006).
Mathematical modelling on a Kenyan population suggests that recurrent
infection with malaria in HIV-1 positive individuals is a significant factor in
enhancing transmission (Abu-Raddad et al. 2006). Perhaps it should be added
that it is still thought unlikely HIV-1 transmission could occur by mosquito
bites.
1.14 - Background to the Present Study
The present investigation arises from a study undertaken in 1995-6 in
Abidjan, Ivory Coast, by Lucas and Bell (Lucas 1996, Bell 1997) which was
based on a series of children coming to autopsy and designed to reveal the
contribution of HIV infection to causes of death as compared with local
mortality in HIV negative children. Virtually no clinical information was
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available for these children who were moribund or dead on arrival at the
hospital. Conclusions as to cause of death were based on post mortem HIV
serology and autopsy findings. Consequently CD4 counts were unavailable.
This study was the first to document accurate pathology findings in an African
population in contrast to other studies that have inferred pathology from
clinical data alone (Valdez and Lederman 1997). Furthermore, the very
difficult conditions under which the necropsies were conducted should not be
underestimated.
Of the 408 children arriving in the mortuary during the study period, 80
(20%) were found to be HIV positive (two of them HIV-2 rather than HIV-1
positive). Children aged one month or older, and up to 12 years, often selected
on size since age was not actually known, were included in the study after the
HIV status was determined. 78 HIV positive and 77 HIV negative children
were studied in full autopsies. Infective illnesses were the cause of death in
almost all HIV negative and positive children, as determined at post mortem
examination. The spectrum of disease was similar, except that certain
conditions, such as Pneumocystis carinii pneumonia (8 cases all under one
year), lymphocytic interstitial pneumonitis (1 case), cerebral toxoplasmosis (3
cases) and multinucleate giant cell encephalitis (2 cases), were seen only in
HIV positive children. AIDS-defining conditions were found in 24 of the 36
(67%) children under the age of 15 months, and 12 of the remaining 42 (29%).
Respiratory tract diseases were the dominant causes of death in all children
underlining the importance of respiratory illness in the inpatient paediatric
population, HIV positive and negative, in Abidjan (Vetter et al. 1996).
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Measles was the cause of death in thirteen HIV positive children and five HIV
negative children. Miliary tuberculosis was seen only in one 18-month-old
HIV positive child and two HIV negative children of 36 months and 8 years.
Enteric illness children was listed as the cause in six HIv positive and four HIV
negative children. Purulent meningitis accounted for the deaths of eleven HIV
positive children and nine HIV negative children. Apart from the cases of
HIVE and was listed as the cause of death in six HIV positive and four HIV
negative toxoplasmosis mentioned above, two other cases of encephalitis were
seen, one due to measles and the other to cytomegalovirus. Malaria was
present in six HIV positive and twenty-three HIV negative children, and was
thought to be the cause of death in three and eighteen respectively.
In discussion of the systemic pathology the authors commented on several key
findings. The prevalence of Pneumocystis pneumonia, at 31% in HIV positive
children, contrasted strongly with the rate of 3% in HIV positive adults at post¬
mortem in Abidjan (Lucas et al. 1993) , and yet was comparable to that found
in Europe and North America. Though measles was common, HIVE and
tuberculosis were not, probably reflecting a rapid progression to death in these
vulnerable children.
The neuropathology findings in this paediatric cohort were described in 1997
(Bell et al. 1997). The cases were divided into those aged one to fourteen
months and those older than fifteen months. Comparison of brain weights
between HIV positive and negative children showed the mean weights for both
younger and older HIV positive groups to be less than their HIV negative
counterparts. For those under fifteen months the mean weights were 786 gm.
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for HIV positive, and 940 gm. for HIV negative cases (p = < 0.005). For those
aged fifteen months and over, the respective weights were 1,119 gm. and 1,
211 gm. (p = <0.001). However ventricular dilatation was not a significant
feature of HIV positive cases and cerebral atrophy was not noted. Florid
meningitis was visible in twenty brains, one of which proved on microscopy to
be tuberculous, in an HIV negative child. Eight brains showed haemorrhages in
association with malaria. One tumour was found in the cerebellum of an HIV
negative three year old and was later shown to be a medulloblastoma. The
brains were sampled comprehensively for histology. All brain sections were
examined with routine stains and in HIV-1 positive children were screened for
HIV-1 p24 antigen. Immunocytochemistry was used only in very selected
cases for glial fibrillary acidic protein (GFAP); and for specific cell markers
for microglia or macrophages (CD68) and lymphocyte subsets - CD45
(leucocyte common antigen LCA), CD3 (a marker for CD4+ and CD8+
lymphocytes), MT1 (which stains the surface membranes of all T cells,
immature B cells and histiocytes) and L26 (a marker for CD20 lymphocytes).
HIVE was found in the brains of four children. Two of these cases, one aged
five and a half years and the other six years, had HIV p24 positive giant cells in
their white matter. The other two, both aged four months, showed foci ofHIV
p24 positive microglial cells without giant cells. Leucoencephalopathy was
present in three out of the four, and in another brain affected by CMV
encephalitis. Toxoplasmosis was present in three brains (including one of the
two with HIV encephalitis). Severe necrotizing encephalitis in a five year old
was confirmed as due to measles by immunohistochemistry. Other conditions
104
present in both HIV positive and HIV negative children included micronodular
encephalitis which was found more often in HIV positive cases than in HIV
negative cases. Basal ganglia mineralization was more pronounced in the HIV
positive group, especially in younger children. Non-specific inflammatory cell
infiltrates were of variable degree in both groups. White matter pallor and
gliosis was twice as common (26 cases) in HIV positive children compared
with HIV negative children (13 cases). Acute bacterial meningitis was equally
represented in both groups but malaria was more common in HIV negative
children (11 cases) than in positive cases (n=2). One three-year old HIV
negative child was thought to have trypanosomiasis. Another feature common
to both HIV positive and negative children was the presence of meningeal and
perivascular lymphocytic infiltrates, found in 26 HIV positive but in only 11
HIV negative children. It is of note that low grade lymphocytic infiltrates in the
CNS are a typical feature of presymptomatic HIV infection and it is important
to note their occurrence in HIV negative children in this series. A pleomorphic
lymphocytic infiltrate was present in two other HIV negative children and
shown by immunohistochemistry to be due to Epstein-Barr virus. In Africa
this infection is commonly acquired in the first year of life, as opposed to
throughout childhood in the developed world. Of the two HIV-2 positive
children, the younger child, aged two months, showed micronodular
encephalitis of indeterminate cause and the seven year old showed an
apparently normal brain.
When correlating the neuropathology findings with the systemic pathology
several pertinent points were noted. The four cases of HIVE occurred
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independently of AIDS-defining illness elsewhere in the body, the cause of
death being pyogenic pneumonia in all. Pneumocystis carinii pneumonia was
the cause of death in both cases of CMV encephalitis and in the two children
with the Epstein Barr positive meniongeal infiltrate. The causes of death in the
twenty-four HIV positive children with low-grade lymphocytic meningitis
were measles-associated pneumonia in seven, and bacterial pneumonia in the
remainder.
In discussing these findings, the authors stressed that the presence of CNS
abnormalities in 64% of HIV negative children formed a standard against
which findings in HIV positive African children could be assessed. The
naturally high infant mortality in Africa was considered a possible reason why
the bimodal distribution of HIV infection, observed in American children, was
not displayed in the population studied in Abidjan. The spectrum of disease,
however, was not dissimilar if allowance was made for the superimposition of
tropical disease. In particular, bacterial disease was common to both locations.
However a major difference between the African and American cohorts was in
the prevalence of HIVE - 6% in the Abidjan paediatric population and 38% in
the EfS series (Kozlowski 1990). The higher infant mortality in Africa and a
possible autopsy selection bias in America were thought possible contributors
to this discrepancy. However, it is of interest that the rate of HIVE
encephalitis in Abidjan adults was also low (3%) (Lucas et al. 1993). The
finding of lymphocytic meningitis in 34% of HIV positive children was
potentially a marker of pre-AIDS, as in adults (Bell et al. 1993), but the similar
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finding in HIV negative children was considered to diminish the potential
usefulness of this approach.
The comparable incidence of opportunistic infections between the African
and American populations was noted, though toxoplasma had not been found
in American paediatric AIDS series. However there is a high environmental
incidence of this parasite in Africa, and cerebral toxoplasmosis was found in
about 15% of adults dying of AIDS in West Africa (Lucas et al. 1993).
Cytomegalovirus (CMV), found systemically in 3.1% of HIV positive children
in the series, was also detectable by serology in 77% of mothers in Abidjan
(Lucas et al. 1993). Tuberculosis, in contrast to its low expression in the HIV-
positive children in the series, was detected in 11% of adult in-patients with
AIDS in Abidjan (Lucas et al. 1993) although later studies found the
prevalence to be even higher (Chintu et al. 2002). HIV infection did not appear
to influence the likelihood of developing acute bacterial meningitis. In contrast,
malaria appeared to be more common in HIV-negative children. The reduced
brain weight seen in HIV infected children in America is also seen in those in
the West African study. Various mechanisms have been invoked in the
pathogenesis of impaired brain growth, including neuronal apoptosis (Gelbard
et al. 1995), (Adle-Biassette et al. 1995), defective methylation (Surtees et al.
1990), astrocytic infection (Saito et al. 1994) and cytokine expression
(Elovaara 1995).
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1.15 - The Present Study: Hypotheses and Aims
The previous studies of the African paediatric cohort were limited to basic
neuropathological descriptions with no detailed investigation of cellular
reactions in the brain. Given the high level of pathology in the brains of the
HIV negative children, careful comparison with HIV positive brains is clearly
vital, but it is accepted that study of these cases cannot reflect the normal state
of African paediatric brains and conclusions should be suitably cautious. So
little is known of African neuropathology, and paediatric cases in particular,
that this cohort warranted further investigation, at the very least with a wider
immunohistochemical panel to investigate CNS cellular sub-sets. Although the
affinity of HIV for microglia and also for astrocytes is well known, and both
cell types display an activated phenotype in the HIV infected brain, the
contribution to cell populations of hyperplasia, hypertrophy, increased cell
entry (in the case of monocytes becoming microglia), cell division and
apoptosis is not well understood. Variations in the Apolipoprotein E (APOE)
genotype are known to influence neuroimmune mechanisms and response to
CNS injury, and has been investigated in the context of HIV infection in
Caucasians but never in African populations.
Accordingly, the following hypotheses were formulated:
1. That there would be significant differences in the glial cell numbers
between HIV positive and negative children, specifically a likely
increase in the numbers ofmicroglia and astocytes in the former group.
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2. That the HIV positive children would show a higher level of activated
microglia and infiltrating lymphocytes than shown by the HIV negative
children, despite the high level of background brain pathology.
3. That the degree of inflammatory response would vary according to the
individual APOE genotype, with likely maximum response in individuals
carrying APOE s4 alleles.
In order to address these hypotheses, the present study is presented in three
parts, outlined in Chapters 3, 4 and 5.
In the Initial Study (Chapter 3), a quantitative assessment was made of
different cell sub-sets in selected areas of the white matter in age matched HIV
positive and negative children.
In the Main Study (Chapter 4), microglia/macrophages (innate neuroimmune
system) and lymphocytes (adaptive neuroimmune response) were quantified
and compared in selected HIV positive and negative children.
In the APOE Study (Chapter 5), APOE genotype was determined and related
to the degree of microglial activation in each case.
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Chapter 2: General Materials and Methods
2.1 - Source of Cases
The material for this study was obtained from a comprehensive post-mortem
survey of children who died in the community, or in the largest hospital, in the
capital city of the West African country of Cote d'lvoire, Abidjan. This survey
was undertaken between August 1991 and May 1992 by Sebastian Lucas,
Professor of Histopathology, Guy's and Thomas's Medical School, London,
with the aim of documenting the range of HIV and associated disease in
African children. Jeanne Bell, Neuropathologist at the Department of
Pathology, University Medical School, Edinburgh, completed the
neuropathological examinations in this cohort.
The selection of cases was as follows - all children brought to the mortuary
were serologically tested for HIV, and consecutive necropsies were performed
on all those found to be, or suspected of being, HIV positive. Post-mortems
were also performed on a randomly selected cohort of HIV negative children,
matched for age and height. The age of the children was not always available
and for these an estimate was made from measurement of crown-heel length
and comparison with a previously constructed chart of height and age.
Children aged one month or older were included in the study - a length of 56
cm or less was taken to indicate an age of less than one month (Schulz et al.
1962). The upper age and height limit was 12 years and 140 cm. As regards
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the antecedents to death, very little clinical, laboratory or radiological
information was available.
HIV testing was performed on autopsy blood samples using mixed antigen
assay for HIV-1 and HIV-2, enzyme-linked immunosorbent assay (ELISA) and
Western blotting. For children under the age of 15 months the influence of
maternal antibodies was discounted by Western blotting for HIV-IgA - in all
for 51 children nominally under the age of two.
The study population was composed of 78 HIV positive and 77 HIV negative
children with median ages of 18 months (range 3 months - 8 years) and 21
months (range 3 months - 12 years) respectively. The total number was 155, of
whom 78 were male and 77 were female (Table 2.1.1).








> 15 42 48
Totals 78 77
Of the 78 HIV positive children, two were HIV-2 positive. Of the 36
children aged 1-14 months and apparently HIV positive, eight proved to be of
indeterminate status by HIV IgA Western blotting.
Complete necropsies, apart from removal of the spinal cords, were performed
within 24 hrs of death. The brains were fixed in formalin for two to three
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weeks before weighing and dissection. The causes of death and general post¬
mortem findings have been published (Lucas et al. 1996) and the general
neuropathology findings have been studied (Bell et al 1997). The naked eye
appearances of the brains were recorded prior to sampling from the frontal,
parietal, occipital and temporal lobes, the thalamus, the basal ganglia and the
cerebellum - all on both sides - and the mid-brain, pons and medulla.
The present study is based on more detailed examination of some of the
blocks of brain tissue from this cohort, now held at the Wilkie Building,
University of Edinburgh. The study was undertaken in three parts. For the
histological studies four regions of the CNS were chosen for study - the
cerebral cortex, the hippocampus, the basal ganglia and the cerebellum.
The Initial Study (Chapter 3) was directed to the white matter and to older
cases where myelination was likely to be well underway. Accordingly the
blocks were selected to include areas of the brain with well-defined
longitudinal fibre orientation, such as the anterior commissure or the internal
capsule. The plan was to sample white matter within the chosen section where
the preferred orientation of fibres was in longitudinal, i.e. linear or curvilinear,
array. However despite careful examination of previously stained sections from
the original study, and the blocks themselves, it was apparent that this was not
possible for all cases because of the variation of original sampling at post¬
mortem or that the requisite blocks were not available. In the case of the
internal capsule the oblique cut of fibres dictated a departure from this plan but
contrary to expectations satisfactory results were obtained. In the case of the
cortical sections, because of varying availability, frontal or parietal cortex was
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used. Initial examination was of the original haematoxylin and eosin (H&E)
sections, or fresh sections cut at 5pm and stained in the same way, and also
with Luxol fast blue (LFB). Immunohistochemistry for glial fibrillary acidic
protein (GFAP) was undertaken and case selection is detailed in Chapter 3.
The Main Study (Chapter 4) focused on inflammatory changes in both grey
and white matter, using a range of special stains and antibodies. Cases were
selected from a wider age range in the cohort (details in Chapter 4) as
compared with the Initial study and blocks from the basal ganglia and
hippocampus were examined. Details of histological and immunohistochemical
methods are detailed below.
In addition, a study was undertaken of APOE genotyping, the APOE Study
(Chapter 5). For this study the cases used in the Main Study were selected
together with a small extra sub-set from the original cohort. Case selection is
detailed in Chapter 5. Methods for DNA and APOE genotyping are provided
below.
2.2 - Immunohistochemistry
Immunohistochemistry was undertaken using the antibodies shown in Table
2.2.1. and either the Avidin-Biotin Complex (ABC) or Tyramide Signal
Amplification (TSA) protocols, copies of which are filed in the appendix.
Sections were counterstained with haematoxylin.
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Table.2.2.1 - Antibodies and protocols used in the present study





















CD8 CD8 T-cells Novocastra EDTA
Pressure cooker
1/50 ABC
CD20 B-Cells Dako Citric acid m/w 1/300 ABC
GFAP Astrocytes(Most) Sertotec None 1/1,500 Polyclonal ABC





Dako Citric acid m/w 1/500 Polyclonal ABC
Transferr
-in
Oligodendrocytes. Dako None 1/200 Polyclonal ABC
HIV p24 HIV-1 Infected
Cells.











Endothelial Cells Dako Citric acid m/w 1/400 TSA
Key to Table 2.2.1: EDTA is ethylene-diaminetetracetic acid - a chelating
agent. Details of methods for Avidin-Biotin-Complex (ABC) and Tyramide
Signal Amplification (TSA) are included in the Appendix..
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Notes on Individual Immunostains
CD68 is a highly glycosylated membrane protein expressed strongly in the
cytoplasm of cells of monocyte/macrophage lineage, and whilst the antibody
detects activated microglia readily, resting microglia are less susceptible
(Falini et al. 1993).
The human leucocyte antigen (HLA) system was discovered as a result of a
transfusion reaction. The main role of the HLA-DP, DQ and DR molecules is
to present antigenic peptides to CD4+ T cells and they are expressed on antigen
presenting cells such as B-lymphocytes, monocytes and dendritic cells. In the
context of neuropathology, the antibody is used as a marker for perivascular
macrophages and activated microglia (Vinci et al. 1984).
CD14 - the CD 14 molecule has a molecular weight of 55kD and is expressed
on certain cells of monocyte/macrophage lineage. It has been proposed as an
exclusive marker of perivascular macrophages in the brain (Grimm, MC -
1966).
CD16 - the CD16 molecule has a molecular weight of 50-70 kD and is
expressed on natural killer cells, granulocytes and activated macrophages
(Venneker, GT- 1994).
The CD8 molecule is a polypeptide composed of two chains and has a
molecular weight of 32kD. It is found on a T-cell subset of normal
cytotoxic/suppressor cells and serves as a receptor for class 1 MHC molecules
(Ledbetter et al. 1981).
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The CD20 molecule is a transmembrane non-glycosylated protein expressed
on B-cells and B-cell precursors but is lost on their transformation to plasma
cells. T-cells are not labelled (Mason et al. 1990).
Glial fibrillary acidic protein (GFAP) is a 52 kD intermediate filament
found almost exclusively in glial cells or cells of glial origin (e.g. astrocytes,
ependymal cells and Schwann cells). There is no cross reactivity of GFAP
antibody with vimentin, neurofilaments, cytokeratins or desmin (Eng et al.
1971).
P Amyloid precursor protein (pAPP) is widely expressed in the brain and
body. It is also detectable in axons as a marker of early injury in brain trauma
or infective disease, moving to the site(s) of axonal injury by fast axonal
transport and accumulating where the cytoskeleton is disrupted (Sherriff et al.
1994).
Myelin basic protein (MBP) is produced by oligodendrocytes, is located in
myelin and accounts for 30% of the total myelin protein. The staining pattern
is similar to that obtained with Luxol fast blue (Hardy et al. 1996).
Transferrin is a plasma protein involved in iron metabolism. In the brain it
is stored selectively in oligodendrocytes (Gerber and Connor 1989).
HIV p24 - a marker of HIV infected cells - p24 is a nucleocapsid protein
(Kaluzaetal. 1992).
Ki 67 - is a cell proliferation marker - the Ki-67 antigen is expressed during
all active phases of the cell cycle but is absent in resting cells (Cattoretti et al.
1992).
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Von Willebrand factor - is composed of a series ofmacro molecules which
are synthesised in capillary endothelial cells and megakarycytes, and which are
essential for efficient blood clotting. The first step of this is adhesion of
platelets to the vessel wall. Von Willebrand disease is a genetic disorder
transmitted in autosomally dominant manner, and in which there is deficiency
of one or more components of the factor. In immunocytochemistry it is useful
as an endothelial cell marker (Sehested and Hou-Jensen 1981).
Note: CD4 immunostaining was not attempted in this study as it has been
found to produce sub-optimal results in paraffin-wax preserved tissue
(McCrossan et al. 2006).
2.3 - Microscopy and Quantitation
The white matter was examined using the following stains: haematoxylin and
eosin, Luxol fast blue (LFB) and immunostains. For LFB, the sections were
laid out in case number sets, in random order, on a light box (X-ray viewing
box) and scanned at a distance to judge the overall degree of staining and to
compare in a very approximate way the difference between cases. Sections
were then examined under the light microscope, first under the x4 objective
lens to assess the general appearance of the tissue and then, under the higher
power lenses, to note detail of any diffuse or focal abnormalities. The results
were then tabulated.
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Immunostained sections were examined under the light microscope and the
presence or absence of positivity, or pattern of staining, was recorded. Areas of
white matter were selected in the cortical blocks in the short arcuate fibres
(CNS region 1), in the core of one or more gyri (CNS region la), and in the
core of the parahippocampal gyrus (CNS region 2), as well as in the fasciculi
of the internal capsule (CNS region 3) and at the bases of the folia in the
cerebellum (CNS region 4). For the purposes of the Initial study in which cell
counts were undertaken, image analysis software, Image-Pro 4.5 supplied by
MediaCybernetics and coupled to an Olympus BX40 microscope, was used to
capture images, using the x40 objective lens. At this magnification the single
frame dimensions were: width = 164.18p, height = 123.29p and area =
20,243.8 sq.p. Sections were examined blinded to age, sex and HIV status.
More detail is provided in the Initial Study, Chapter 3 and in the Main Study,
Chapter 4
2.4 - DNA Extraction from Paraffin Embedded Tissue
Qiagen DNeasy kits (cat no 69506) were used for all DNA extractions using
the following protocol.
1. 2x 15pm sections were cut from paraffin blocks from each case (for case
selection see Chapter 5) and placed in a 1.5ml eppendorf tube. A clean
microtome blade was used for each sample to avoid risk of contamination
of tissue.
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2. 2ml of xylene was added and the tube was allowed to stand for 5 minutes.
Samples were then centrifuged in a microcentrifuge at 20,000 x g for 5
minutes.
3. Supernatant was then removed and 1.2ml of 100% ethanol was added.
Samples were then centrifuged at 13000 rpm for 5 minutes. Supernatant
was removed and this step was then repeated twice.
4. Tubes were incubated at 37°C for 15 minutes with the lid open to
evaporate remaining ethanol.
5. Tissue was then re-suspended in 180pl of buffer ATL and then 20pl of
proteinase K. Overnight incubation was undertaken at 56°C.
6. Samples were vortexed briefly, then 200pl of buffer AL was added, and
vortexed again before 200pl of 99% ethanol was added and mixed by
vortexing.
7. The mixture was pipetted into a DNeasy Mini spin column and the
centrifuged at 6000 x g for 1 min. The flow-through was discarded.
8. The DNeasy Mini spin column was placed in a new 2 ml collection tube
and 500 pi Buffer AW1 was added. It was centrifuged for 1 min at 6000
x g and the flow-through discarded.
9. The DNeasy Mini spin column was placed in a new 2 ml collection tube
and 500 pi Buffer AW2 added. It was then centrifuged for 3 min at
20,000 x g to dry the DNeasy membrane. The flow-through was
discarded.
10. The DNeasy Mini spin column was placed in a clean eppendorf
tube,200 pi Buffer AE was pipetted directly onto the DNeasy membrane. It
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was ncubated at room temperature for 1 min, and then centrifuged for 1 min at
6000 x g to elute.
2.5 - APOE Genotyping
The polymerase chain reaction (PCR) reaction was carried out in a total
volume of 50pl of mixture. The final concentrations of the PCR reaction
reagents are given in table 2.5.1.
Table 2.5.1 - Reagents for APOE PCR
Reagents Final Concentration
10 x PCR Buffer minus Mg (Invitrogen) lx
MgCh 50mM (Invitrogen) 1.8 mM
dNTP 1 OmM (Invitrogen) 0.2 mM
Betaine 2.6M (sigma) 1.3 M
Primers (each) 0.1 mM
Taq DNA polymerase 1.25 units
DNA l-5pg
H2O to a volume of 50pl
PCR primer sequences:
5' - ACA GAA TTC GCC CCG GCC TGG TAC ACT GCC A - 3'
5' - TCC AAG GAG CTG CAG GCG GCG CA - 3'
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The PCR reaction was carried out under the following conditions.The PCR
mixture was initially denatured at 95°C for 3mins, followed by 40 cycles
running at 94°C for lmin, 60°C for lmin, 72°C for 2min. A final extension
was undertaken at 72°C for 8 minutes.
15|R of PCR product were then removed and run on a 3% agarose gel at 120v
for 1 hour to visualise the 220bp APOE gene. The remainder of the PCR
product was subjected to restriction enzyme digest using Hhal (New England
Biolabs). The digest was carried out at 37°C for 2 hours. Digested products
were then run on a 4% metaphor agarose gel at 120v for 1.5 hours.
Results of DNA extraction and separation of APOE alleles is shown in Chapter
5
2.6 - Statistical Analyses
Statistical analyses were performed using the statistical software Minitab and
the individual tests used are indicated in following Chapters - the Initial Study,
the Main Study and the APOE study. The advice of a statistician was sought
and followed on the methods used.
2.7 - Ethical Approval
All cases used in this study were anonymised. Ethical permission was sought
and obtained for this study (LREC/2003/6/6).
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Chapter 3: Initial Study
3.1 - Introduction
The focus of this initial study is the attempted quantitation of cell populations
in the in the white matter ofHIV negative children and their responses in HIV
infection.
Normal White Matter- Anatomy and Physiology
In Chapter 1 the normal brain components were described, including the
structure and function of the axon and the oligodendrocyte. Here an account of
the white matter with particular reference to its organisation and the biology of
myelin is presented.
In the adult human brain the white matter contributes just under 50% of the
volume of the cerebral hemispheres (Miller et al. 1980). Although the
demarcation between grey and white matter is largely distinct there are loci
where this is blurred, as in the basal ganglia. The arrangement of the fibre
tracts in the hemispheres is best displayed by blunt dissection of the formalin
fixed brain. The fibres of the white matter may be considered in three main
systems according to their connections and directions
1. The commissural fibres connect corresponding areas of the two
hemispheres.
2. The long and short arcuate fibres connect different cortical areas within
the same hemisphere.
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3. The projection fibres connect the cerebral cortex with the grey matter of
the basal ganglia, brain stem and spinal cord.
Cellular Components of White Matter
The linear arrays of oligodendrocyte nuclei are a familiar sight in routinely
stained sections of central white matter tracts such as the corpus callosum. The
oligodendrocyte population in normal white matter is heterogenous with three
main classes described according to nuclear size and tinctorial properties -
dark nuclei with a nuclear size of 3.5-5jj.m, nuclei of medium shade with a
nuclear size of 4-7pm and light nuclei of nuclear size 6-8.5 pm(Mori and
Leblond 1970). This study was based on examination of the corpus callosum of
the rat. Mitotic activity could be detected in all except in dark nuclear group.
Other studies have confirmed the mitotic potential of oligodendrocytes (Suzuki
and Raisman 1992) and especially the capacity of fully differentiated, myelin
bearing oligodendrocytes to proliferate.
The spatial correlates of oligodendrocytes were the subject of a study of the
adult rat fimbria, in 1992 (Suzuki and Raisman 1992) (the fimbria is the
efferent pathway of the hippocampus and contains both projection and
commissural fibres). The tract was studied in both longitudinal and transverse
planes and showed arrays of oligodendrocyte nuclei were more or less
continuous in the long axis but interposed with astrocytes, so that a run of 8 or
so oligodendrocytes would be followed by a single astrocyte. In the transverse
plane these oligodendrocytes "cores" were separated from each other in a
regular way and at a mean distance of 15.7pm. Each core of oligodendrocytes
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was associated with a surrounding shell of fibres, estimated to number some
1,200, of which approximately 800 were myelinated. Previous studies have
suggested that a single oligodendrocyte might contribute segments of myelin
on up to 50 separate, but neighbouring, axons (Peters 1964) (Butt and Ransom
1989) and that most of these were at some distance, up to 40pm in some cases,
from the oligodendrocyte cell body. The mean inter-node length, that is the
length of each myelin segment, was estimated to be about 200pm and the
width of the node (node of Ranvier - see below in section on myelin) 0.8 -
1.1pm (Hildebrand et al. 1993). Apart from the linear arrays of
oligodendrocytes, these cells were also seen to run in a different direction as
they accompanied capillaries in their courses through the white matter.
Oligodendrocytes maintain contact through tight junctions (specialised parts of
the plasma membranes of adjacent cells that are in such close contact that the
extracellular space is excluded). The chief function of oligodendrocytes is to
ensheath axons. For larger axons this is by means of a myelin sheath. The
derivation of myelin from oligodendrocytes is covered in chapter 1. In early
studies, myelin was considered to be a relatively simple and static substance
composed largely of proteins and lipids. Advances in molecular biology have
shown it to be more complex and surprisingly dynamic in its biology, with a
relatively high metabolic rate (Persson et al. 1992).
Some 70-80% of myelin is lipid in nature and the principal lipids, which
make up some 65% of the total (Norton 1984) are galactolipids, including
cerebrosides and sulphatide, cholesterol and ethanolamine phosphoglyceride.
Cerebroside is used as a marker probe for myelin and oligodendrocytes. The
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principal proteins of myelin are myelin basic protein (MBP), proteolipid
protein (PLP), myelin associated glycoprotein (MAG) and 2', 3'-cyclic
nucleotide 3'-phosphodiesterase (CNP). MBP has a molecular weight (mw) of
20 kDa and is mainly associated with the intra-cytoplasmic membrane region
of myelin, which corresponds to the major dense line seen in electron-
micrographs. It is considered to be a major determinant of the compaction of
mature myelin and mice lacking the MBP gene (mouse mutant shiverer) show
defective lamellar structure ofmyelin with frequent splitting at the major dense
line (Benjamins et al. 1984). A sequence in its molecule renders it
encephalitogenic and this forms the basis of the model of experimental allergic
encephalitis (EAE)(Waksman and Adams 1962). Antibodies to MPP are used
as myelin markers in studies of myelin development and integrity. PLP has a
molecular weight of 25 kDa, similar to MBP, and is thought to participate in
securing the structure of myelin (Moscarello et al. 1973)The mutant Jimpy
mouse that has a genetic defect in the gene coding for PLP manifests a severe
myelin abnormality (Sprinkle 1989) PLP shares the antigenic properties of
MBP (Brostoff and White 1986). MAG has a molecular weight of 100-110
kDa and is involved in cellular interactions such as adhesion between neurons
and oligodendrocytes (Kucherer et al. 1987). CNP, which constitutes 2% of all
myelin proteins, is thought to be involved in myelinogenesis and myelin
maintenance(Braun et al. 1990). Another myelin protein, myelin-
oligodendrocyte-associated glycoprotein (MOG), of molecular weight 51-54
kDa, is of interest because experimental administration of anti-MOG serum
provokes demyelination (Schluesener et al. 1987).
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Generally astrocytes possess three kinds of processes - radial, longitudinal
and vascular. The radial processes, which are thick and tapering, extend in the
transverse plane, i.e. at right angles to the long axis of the tract, and for
distances of up to 100pm. The longitudinal processes are thin and unbranched,
up to 30pm in length and run in amongst the fascicles. The vascular processes
extend for variable distances to make contact with capillaries and each
astrocyte may contribute one or more end-feet to a capillary The separation of
astrocytes in the cores varies from 35 to 70pm. The spatial arrangement and
degree of separation of astrocytes has been investigated and shown to be non-
random (Distler et al. 1991), and to be determined by astrocytes alone, without
reference to surrounding structures or cells (Tout et al. 1993).
The arrangement of the radial processes of astrocytes, is considered to
provide a significant scaffold for the white matter (Distler et al. 1991).
Communication between neighbouring astrocytes exists via gap junctions (a
specialised part of the plasma membranes of adjacent cells where the surfaces
are separated by a gap of 2-4 nanometres (nm) and across which protein
filaments of connexion pass, allowing communication between the cytoplasm
of the cells), thereby providing a form of syncytium (Suzuki and Raisman
1992). This is in contrast to the gap junctions used by oligodendrocytes.
Astrocytes are intimately involved through their processes in the nodal regions
of axons, where they appear to have an active role in ionic homeostasis by
means of sodium and potassium channels (Hildebrand et al. 1993).
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Astrocytes also make contact with oligodendrocytes through gap junctions.
In health, astrocytes are key determinants of homeostasis. Through their end
feet on the microvasculature they have been shown to influence blood flow
(Koehler et al. 2006) and their participation in the maintenance of the blood
brain barrier (BBB) is essential to its function as gatekeeper (Abbott et al.
2006). The importance of their intimate contact with synapses and their uptake
of glutamate in health precludes accumulation of this neurotransmitter, that is
excitotoxic in excess (Anderson and Swanson 2000). Their close relationship
with neurons underscores not only essential inter-cellular signalling but also
involvement in energy transfer in circumstances where oxygen/glucose
delivery is sub-optimal (Pellerin and Magistretti 2004). The natural storage of
glycogen by astrocytes allows emergency supplies of this energy substitute to
be used by neurons and also by axons through astrocyte end-foot contact at the
node of Ranvier (Brown et al. 2002).
The interdependence of oligodendrocyte, astrocyte and axon is well
demonstrated in experimental studies in which disruption of axonal integrity is
followed by oligodendroyte loss and astrocyte disarray (David et al. 1984).
Microglia are distributed throughout the white matter, both within the linear
arrays of oligodendrocytes and elsewhere amongst the fibres, and in a peri¬
vascular position, where they are distinct from perivascular cells or
macrophages. In health, as the CNS arm of innate immunity, they express a
low level of immune of surface molecules and, like astrocytes, have a
supportive role in respect of neuron physiology through their secretion of nerve
growth factor (NGF)(Streit et al. 1988). Neurons interact with microglia and
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can suppress activation of these cells (Neumann et al. 1996). Microglia are
considered further in chapter 4.
The proportions of glia in the mature rat have been estimated to be -
oligodendrocytes 70-75%, astrocytes 17.5-20% and microglia 3.5-5% (Ling
and Leblond 1973). As regards the territories of individual cells, there is
considerable overlap in the fields of individual oligodendrocytes and also those
of astrocytes but in the case of microglia there is seen to be a strict demarcation
of territory and this is supported by very recent work using micro-imaging
techniques in vivo (Jinno et al. 2007).
Nervous tissue is highly dependent on a continuing supply of oxygen and
glucose and the demands of white matter are scarcely less than those of grey
matter. The resting cardiac output of an average sized human adult at rest is 5
litres a minute, of which the brain receives 800 mis/minute, or about a seventh.
Total oxygen consumption of the brain is approximately 3.5mls per 100 gm. of
brain tissue per minute. The capillary bed of the brain is not fed by end-
arteries as they are in other tissues, and the brain capillaries form frequent
anastomoses before uniting to form venules (Peters 1961). In this way nervous
tissue is protected as far as possible from fluctuations in blood flow. However,
the point is made that the benefits that the myelin sheath confers in terms of
energy efficiency in the axon comes at a price, in respect of oligodendrocyte
vulnerability (Hildebrand et al. 1993).
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The Pathology and Pathophysiology ofWhite Matter
Some of the reactive responses of glial cells were considered in Chapter 1 but
are considered in more detail here.
Astrocytes respond to local tissue damage in a variety of ways. They may
enlarge with increase in the number and length of their fibres (Norenberg
1994). This swelling occurs as an early response to traumatic injury, ischaemia,
status epilepticus and hypoglycaemia among other insults. The mechanism of
this swelling is complex, involving glutamate and an influx of sodium ions.
Astrocyte swelling may be a stimulus for proliferation (Reichenbach 1989).
which may be part of the later response of astrocytes to tissue injury. Early
swelling is followed by more distinctive changes including cytoplasmic
hypertrophy and nuclear enlargement with increased chromatin and more
prominent or numerous nucleoli. Glial fibrillary acidic protein (GFAP)
becomes a much more prominent constituent in astrocyte cytoplasm (Eng et al.
2000). Eccentric placement of the nucleus and increased expression of GFAP
characterises the swollen reactive astrocytes known as gemistocytes.
Occasional multinucleate forms are observed. The striking increase of long,
thick cytoplasmic processes is termed gliosis. In experimental animals, gliosis
follows the application of a minor stimulus within 24 hours, reaches a
maximum in 3-4 days and then gradually subsides over the next 2-3 weeks
(Amaducci et al. 1981). In humans the process is more protracted (Osterberg
and Wattenberg 1963). The apparent increase in astrocyte numbers in gliosis
may be more a factor of their size and increased expression of GFAP than of
actual proliferation (Eddleston and Mucke 1993).
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Reactive swelling may play a part in cerebral oedema. Astrogliosis, if
extensive, can interfere with remyelination and the regeneration of damaged
axons, as in multiple sclerosis. The appearance of some areas of tissue damage
might suggest that astrocytes migrate into such loci but there is no good
evidence that this can occur (Hatton et al. 1993).
Two particular features of astrocytic activation raised in the review by
(Norenberg 1994) may be relevant to this initial study. One is the finding that
diffuse reactive astrogliosis can occur in response to a focal injury (Eng and
Ghirnikar 1994), possibly due to intercellular gap junction signalling. The
other is that astrocytic responses may be out of all proportion to the extent of
local tissue disturbance, resurrecting an idea first raised by Charcot (Charcot
1868) namely that astrocytic hypertrophy may be primary rather than
secondary.
Oligodendrocytes have a rather restricted repertoire of reactions when
compared with astrocytes. Minor ischaemic and metabolic insults are
accompanied by cytoplasmic swelling but more serious disturbances are
followed by cell death, either by necrosis or apoptosis. Oligodendrocytes, like
neurons, and unlike astrocytes, do not contain glycogen and are especially
vulnerable to injury by hypoglycaemia. Astrocytes are able to convert glycogen
to lactate in this situation and thereby protect themselves and, to some extent,
the axons with which they are associated (Wender et al. 2000).
Oligodendrocytes are also highly susceptible to oxidative stress. They express
functional glutamate receptors (Gallo and Ghiani 2000) and death occurs
readily if these receptors are over-activated (McDonald et al. 1998). Cytokines,
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such tumour necrosis factor alpha (TNF-a), have been shown to mediate
oligodendrocyte death by apoptosis in mice (Akassoglou et al. 1998) but the
same molecule promotes proliferation of oligodendrocyte precursors (Arnett et
al. 2001).
Nutritional disorders affecting myelin, including excess food intake
(overnutrition) and under-nutrition, can impact on CNS structure and
functioning. High intake of animal fat, obesity and lack of exercise encourage
the development of atherosclerosis and its attendant problems of stroke and
hypoperfusion injury. Malnutrition, prevalent in the developing world, can
affect central nervous system (CNS) development in the foetus of a
malnourished woman, or myelination may be delayed in early childhood
(Martinez 1982) Specific deficiencies, such as thiamine deficiency, can lead to
microhaemorrhages in the mamillary bodies, astrogliosis and demyelination.
Vitamin B12 deficiency, occurring in the course of malabsorption or pernicious
anaemia, can result in subacute combined degeneration of the cord, in which
the posterior columns and corticospinal tracts show vacuolation of myelin and
demyelination.
Cerebral oedema is an important reaction occurring in response to many of
the factors mentioned above. A significant degree of oedema was noted in 45
of the 156 cases (29%) of the African paediatric cohort from which the current
study derives (Bell et al. 1997).
There are a number of classifications of cerebral oedema and a simple scheme
is as follows:
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• Vasogenic - in which the BBB is defective and extracellular
accumulation of water, sodium and protein occurs, especially in the
white matter. There is pallor of myelin with vacuolation and reactive
astrocytes, including gemistocytes, are seen. If oedema persists for
weeks, loss ofmyelin may occur especially in the periventricular white
matter.
• Cytotoxic - the commonest cause of this type is ischaemia and the
changes are mostly intracellular as a result of energy failure in neurons.
Other causes of this cytotoxic oedema are toxins such as triethyl tin and
hexachlorophane.
• Hydrostatic - in this type there is passage of protein poor fluid into the
extracellular space leading an increase in intravascular pressure and
dilating the capillary bed e.g. hypertensive encephalopathy.
• Interstitial oedema - as in obstructive hydrocephalus where fluid is
forced into the periventricular white matter.
• Hyperosmotic oedema - in which the swelling is due to a large
reduction in serum osmolality.
(Esiri 1996)
Some dietary items in susceptible individuals may cause disease of the CNS
or of the peripheral nervous system (PNS). Coeliac disease, in which there is
intolerance of the protein gluten found in wheat, is occasionally accompanied
by disorders of the CNS and PNS (Cooke and Smith 1966) (Wills 2000)
Examination of the brain in such cases may show a variety of histological
abnormalities, including cerebellar Purkinje cell loss and spongiform
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demyelination in the posterior and lateral columns of the spinal cord, with
lymphocytic infiltration in the hypothalamus, brain stem, cerebellum and spinal
cord in some cases (Cooke and Smith 1966).
Cell Growth and Proliferation
These activities are considered in some detail to provide a background for the
intriguing phenomenon of non-neoplastic cellular proliferation in tissues and
organs.
The natural processes of cellular growth, proliferation, migration and
differentiation, which characterise early embryonic life, soon become stable as
development proceed. Cells such as neurons are considered to be terminally
differentiated, unable to divide and not replaceable in the event of their death
by natural ageing, trauma or disease. In the last 25 years or so there has been
progressive modification of the concept of cellular differentiation because of
the advances in the fields of molecular biology and genetics and, in particular,
in stem cell research (Rosenthal 2003).
The dynamics of cell growth and proliferation have always been a subject of
scientific interest because of their relevance in cancer research. In addition,
proliferation of immune cells, and of the parenchymal cells of the target
tissue(s), is often an integral part of disease processes, especially in
inflammatory disorders such as rheumatoid arthritis. Cell loss by necrosis or
apoptosis is no less interesting but is considered outwith the scope of this
study.
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The cell cycle, which provides the basis for the understanding of cell division,
is now seen as a very complex process (Kumar 2004) and subject to numerous
stimulatory and inhibitory influences. Although cellular growth and
proliferation are sometimes discussed as though they were the same process,
they are separate events: the former signifying an increase in cell size and the
latter, an increase in cell numbers. The corresponding terms used in pathology
are hypertrophy and hyperplasia. Though they are intimately related and
growth usually precedes proliferation or mitosis, they can be independently
controlled and one process can occur without the other (Su and O'Farrell
1998).
The influences which have a positive or stimulatory effect on the cell cycle
are known as growth factors and a large number are known to be involved in
normal physiology and pathophysiology. Also, a large number of naturally
occurring compounds, for example the glycoproteins found in many plants and
known as lectins, e.g wheatgerm agglutinin, have been shown to have a potent
proliferative effect on cells in tissue culture and are perhaps better referred as
mitogens. Growth factors are generally polypeptides and often have a
spectrum of activity, which, in addition to influencing proliferation, may
promote cell motility and regulation of differentiation. Many are involved in
repair processes following trauma or inflammation. Some of the more
important growth factors are:
• Epidermal growth factor (EGF) - is secreted by platelets and
macrophages and is mitogenic for fibroblasts and keratinocytes.
134
• Insulin-like growth factor-1 (IGF-1) - is produced by fibroblasts and
macrophages and stimulates fibroblast migration and proliferation.
• Platelet derived growth factor (PDGF) - is produced by endothelial
cells, keratinocytes, macrophages and platelets. The isoforms of this
molecule have a wide variety of actions - they are potent stimulators of
mitosis for endothelial cells, fibroblasts, glial cells and smooth muscle
cells and have marked chemotactic properties. They are closely
involved in wound healing.
• Transforming growth factors a (TGF-a) - is produced by
endothelial cells, T lymphocytes, macrophages and platelets. These are
chemotactic for a number of cells and have proliferative influence on
hepatocytes and epithelial cells. In contrast TGF-P is a growth inhibitor
for epithelial cells and has a potent anti-inflammatory action.
• Vascular endothelial cell growth factor (VEGF) - is derived from
epithelial cells, smooth muscle cells and macrophages. It is important in
angiogenesis and induces endothelial cell proliferation and vascular
permeability.
• Tumour necrosis factor (TNF) - is produced by mast cells,
macrophages and T lymphocytes. It has a profusion of actions including
immune system activation. High circulating levels are present in HIV
infection (Odeh 1990) and it is thought to play a key role in the
pathogenesis ofHIVE (Wilt et al. 1995).
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• Interleukins (IL family) - are produced by many tissues,
macrophages, mast cells and lymphocytes. These cytokines have
multiple functions including chemotaxis and angiogenesis.
The Cell Cycle
In health, in those tissues having a slow rate of turnover of parenchymal cells,
the majority of the cells would be in a resting GO state. Conventionally the
proliferative cell cycle is divided into 4 stages - Gl, S, G2 and M. GO signifies
the quiescent or pre-cycle entry stage. Cells would enter the cell cycle only if
exposed to microenvironmental or systemic stimuli, many of which are now
understood. In some tissues, such as the human endometrium during
reproductive life, a cyclical pattern of proliferation is under hormonal control.
In other tissues the dynamics of normal cell renewal are less well known but in
most tissues there a regular replacement of cells that have died naturally,
although the precise determinants ensuring constancy of organ or tissue mass
in health are not yet defined. The experimental model of replacement of liver
tissue after partial resection is often quoted (Fausto 2000) . In disease states the
details of the repair process have been much studied by simple histology and
are now the subject of scrutiny by molecular biological techniques. The
mechanisms of escape from control by neoplastic cells are increasingly linked
to cancer associated genes that now number several hundreds. The potential for
cells to proliferate in the absence of external stimuli is the major hallmark of
malignancy.
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In normal physiology the essential steps in the process of cell proliferation
are:
■ One or more growth factors binds to its specific receptor(s), usually on
the cell membrane. These growth factors, signalling molecules (or
ligands), may have several sources as detailed below.
■ Activation of the receptor, usually transient and limited, is followed by
activation of several signal transducing proteins on the inner aspect of
the plasma membrane.
■ The signal is transmitted to the nucleus by messenger proteins.
■ Induction and activation of nuclear factors occurs, leading to DNA
transcription
■ The cell enters the cell cycle and proceeds to division.
(Kumar 2004)
The cell cycle itself is a sequence of elaborate and tightly regulated stages each
of which is subject to stimulators and inhibitors (Ekholm and Reed 2000). The
principal molecules involved belong to a family of proteins called the cyclin
dependent kinases (CDKs) and these are activated by compounds synthesised
de novo, known as cyclins. In the G1 phase there is a molecular on/off switch
triggered by the action of a cyclin dependent kinase, CDK4, which causes
phosphorylation of a molecule - retinoblastoma susceptibility protein (RB).
This critical reaction is seen as overcoming the principal barrier to cell division
(Sherr and McCormick 2002).
Ligands (ligand has several meanings and here signifies a molecule, or class
of molecules, that has become covalently linked to another molecule to form a
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conjugate) having the potential to activate growth receptors may either be
growth factors, examples of which are listed above, or molecules arising in the
extra-cellular matrix (ECM). Three general modes of signalling are recognised
according to the source of the ligand and the location of its target receptors:
1. Autocrine - in this mode of signalling cells respond to molecules that
they themselves secrete, a process that is referred as an autocrine loop.
This type of proliferation occurs in antigen stimulated lymphocytes.
2. Paracrine - this mode of signalling typically occurs between adjacent, or
very nearly adjacent cells, which are commonly of a different type. An
example of this is in wound repair where macrophages stimulate the
proliferation of fibroblasts, by means of their secretion of growth factors.
3. Endocrine - in this mode, long recognized, growth or proliferative
effects are produced in a tissue or organ by a molecule secreted at a
distance from an endocrine source - for example follicle stimulating
hormone (FSH), acting on the ovarian follicle, is produced in the anterior
pituitary. Endocrine growth factors are carried from the source to the
target tissue in the bloodstream. Of particular relevance to the present
study is the known action of cytokines produced in systemic
inflammation and acting, in effect, as endocrine agents.
TNF-a was noted above as a growth factor and reference was made to the
levels of this cytokine in HIV infection. A study of particular relevance was
published in 1996, in which the serum levels of several cytokines were
recorded in a population of HIV positive African women (Thea et al. 1996).
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Elevated levels of cytokines - IL-1, IL-6 and TNF-a- were detected in
asymptomatic HIV positive women. These were significantly greater than
those in women with AIDS, of whom only a small percentage showed any
circulating cytokines in the circulation. None of these cytokines was detected
in the HIV negative controls.
These cytokines are known to enter the CNS by passage across the BBB
(Banks et al. 1995) and are expressed at low levels in the normal CNS, by
perivascular macrophages, microglia and some endothelial cells (Morris and
Esiri 1998) The levels are considerably increased in HIV infection, both in
adults (Stanley et al. 1994) and in children (Mintz et al. 1989)
Responses of Intrinsic White Matter Cells to HIV Infection of the
Brain
The main neuropathology findings in HIV/AIDS were documented in Chapter
1. Here the evidence is considered for continued HIV presence in the brain
during both the asymptomatic and symptomatic phases of infection and the
ways in which this might impact on the cellular population of the CNS.
The presence ofHIV in the brain has been difficult in those subjects dying of
unrelated causes in the pre-symptomatic stage of infection (Bell 1998).
However, its presence in the brain is often inferred from the finding in the
cerebrospinal fluid (CSF) of HIV antigens and antibody in asymptomatic
patients (Shaunak et al. 1990) (Goswami et al. 1991). Indirect evidence of a
quiescent presence in the brain before the onset of AIDS was obtained from
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studies of animals infected with the closely similar simian immunodeficiency
virus (SIV) (Williams et al. 2001) (Sinclair et al. 1994).
In the early 1990's, two studies detected HIV-1 DNA by PCR in the brains of
HIV positive asymptomatic individuals - in 1992 in one case (Sinclair et al.
1992), and in 1996 in 17 out of 36 (An et al. 1999). HIV-1 is easily detected in
the brains of many AIDS patients, and in HIVE by definition. The associated
neuropathological findings, including myelin pallor, astrogliosis, microgliosis
microglial nodules and multinucleate giant cells, have been described in
Chapter 1. Changes occurring in presymptomatic individuals include -
astrogliosis, microgliosis and low grade lymphocytic infiltrates (An et al.
1996), despite the absence of productive HIV infection. The dynamics of viral/
glial interaction are of considerable interest in attempting to explain the
neuropathogenesis of HIV infection where key anatomical changes such as
neuronal and axonal loss occur in the late stages of infection.
Astrocytes and HIV/AIDS
In HIVE there is an extremely abnormal molecular milieu and the origins of
this are likely to be present in asymptomatic pre-AIDS cases, as noted above
(An et al. 1996). The pathways to astrocyte activation in asymptomatic cases
are likely to be multiple and these could be either direct, in response to
circulating cytokines or HIV products including gpl20, alerted through their
contacts with capillaries or their cell surface pattern recognition receptors
(PRR) (Farina et al. 2007), or indirect via the intervention of activated or
infected microglial (An et al. 1999) or neuronal signalling (Schipke and
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Kettenmann 2004) As noted earlier, astrocyte activation is characterised by an
increase in cell size and GFAP content (Eng and Ghirnikar 1994). At molecular
level, profound changes occur. Resting astrocytes possess a host of cell surface
receptors and produce a variety of cytokines and chemokines (Ridet et al.
1997). They also produce growth factors (including neurotrophic factors that
are important in neuronal and oligodendrocyte survival), for example NGF
(Farina et al. 2007). In activation the expression of these receptors is increased,
as is the production of most growth factors and cytokines, especially TNFa
(Merrill and Benveniste 1996) and IL-6 (Morganti-Kossmann et al. 1992).
Neurons and HIV/AIDS
Neurons are not known to be infected with HIV but suffer damage and loss in
HIV infection of the brain. Neuronal loss is demonstrable in HIVE and its
clinical correlate is HAD or lesser degrees of cognitive disorder, which can be
detected by psychometric testing (Heaton et al. 1995). Although the cause of
this neuronal loss is likely to be multifactorial, activated astrocytes may
contribute in a number of ways. Though astrocytes are infrequently infected,
such infected cells are likely to be important numerically (by virtue of the
absolute size of the astrocyte population), and are a significant factor in
maintaining a reservoir of virus (Brack-Werner 1999), another cause of
astrocyte activation. Neuronal integrity could be prejudiced by failure of
astrocytic metabolism of glutamate and its seepage from the cell to cause
neuronal cytoxicity (Ye et al. 2003). Furthermore, astrocytes exposed to HIV
envelope protein gpl20 produce toxic nitric oxide synthase (NOS) which could
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interfere with their neuronal support function (Nath 1999). TNF-a causes
proliferation of astrocytes in vitro (Selmaj et al. 1990) and is associated with
astrogliosis in early asymptomatic HIV infection (Gray et al. 1992) and in
AIDS in cases with a history of HIV associated dementia (HAD) (Seilhean et
al. 1997). Astrocyte apoptosis may occur in parallel with astrogliosis (Sabri et
al. 2003).
Oligodendrocytes and HIV/AIDS
Oligodendrocytes are thought not to be infected by HIV and only a few
studies have attempted to document their numbers in this condition, perhaps
because there is no good immunohistochemical marker for them. Esiri, (Esiri et
al. 1991) compared the changes in the oligodendrocyte populations in 22 HIV-
1 infected cases with 11 uninfected controls. 14 of the 22 HIV+ve cases had
AIDS or AIDS-related complex (ARC).Oligodendrocytes were detected by
immunocytochemistry using antibodies to two enzymes found in
oligidendrocytes - carbonic anhydrase isoenzyme II (CAII) and 2'3' -cyclic
nucleotide 3' -phosphodiesterase (CNPase). The findings of interest were that
in the normal control brains the mean oligodendrocyte density in the white
matter was 667/sq.mm ( in the discussion it was acknowledged that not all
oligodendrocytes were labelled). Higher numbers of oligodendrocytes were
found in the white matter of HIV-1 positive cases, particularly those showing
only mild myelin pallor and no giant cells, suggesting that there is slight
hyperplasia of oligodendrocytes in HIV-1 infection particularly before the
onset of HIVE and in the absence severe myelin pallor. Conversely,
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circumstantial evidence would dictate that in HIVE , where there is myelin
loss, there must almost certainly be oligodendrocyte loss (Budka et al. 1987).
In respect of the response to cytokines, there is evidence from an in vitro
study that TNFa is toxic for oligodendrocytes (Tyor et al. 1992) but more
recently the same cytokine was found to promote proliferation of
oligodendrocyte precursors (Arnett et al. 2001). IL-2 was found to cause
proliferation of oligodendrocytes in glial cell cultures (Benveniste and Merrill
1986). HIV derived molecules, particularly HIV-gpl20, were found to be
toxic in vitro for oligodendrocytes (Bernardo et al. 1997)
Microglia and HIV/AIDS
Microglia, through their possession of CD4 and CCR5 surface receptors, are a
primary target for HIV in the CNS and are the only CNS cells capable of
supporting productive infection (Gartner 2000). In the late stages of infection
they are the largest group of CNS infected cells (Cosenza et al. 2002).
Microglial activation can be detected in the very early stages of SIV infection
(Chakrabarti et al. 1991) When activated, whether by direct infection with
HIV, or indirectly by mechanisms similar to those operating in the activation of
astrocytes, microglia produce a wide range of cytokines and allied molecules.
In particular, some of these cytokines such as interleukin-1 (IL-1), interferon
(IFN)y and TNF-a (Nath 1999) and other molecules, such as nitric oxide
(NO), superoxide anions and glutamate receptor agonist, have neurotoxic
potential ((Budka et al. 1987)). In addition, microglia infected by HIV produce
increasing amounts of virus and viral proteins which are neurotoxic in HIV
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encephalitis (HIVE) (Smith et al. 2001). Astrocytes also modulate microglial
activity (Eder and Fischer 1997). Furthermore, activated T-cells promote
inflammatory responses in microglia(Benveniste et al. 2004). Priming of
microglia has recently been detected as a manifestation of even minor
peripheral infections (Rivest 2003)
Endothelial Cells of the CNS and HIV/AIDS
Endothelial cells, which are derived from mesoderm, have a very slow turnover
in health, and replacement of individual cells may not occur more often than
every ten years. TNF-a was discovered to be a powerful promoter of new
blood vessel formation (Leibovich et al. 1987). and in 1990 endothelial
changes were noted in the blood vessels of the white matter of patients with
AIDS (Smith et al. 1990). These changes included endothelial cell
hypertrophy, hypercellularity and pleomorphism. This effect of TNF-a appears
to be mediated at least in part through the agency of vascular endothelial
growth factor (VEGF) (Ryuto et al. 1996) and IL-1 (Li et al. 1995). VEGF is
the most important factor in adult angiogenesis, promoting endothelial cell
proliferation in physiological and pathological settings (Ferrara et al. 2003).
The modulation of this molecule by TNF-a is considered to operate in both
autocrine and paracrine pathways (Yoshida et al. 1997) Another factor
implicated in cerebral endothelial pathology in HIV infection is the envelope
glycoprotein gpl20 which, as a circulating HIV soluble product, activates
endothelial cells to express cell adhesion molecules (ICAM-1 and VCAM-
l)(Stins et al. 2001). As discussed in Chapter 1, the integrity of the
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endothelium as the major component of the BBB plays a pivotal part in the
dynamics of CNS involvement in HIV infection (Nottet 1999). (Banks et al.
2006)
Neuropathology of the Late Stage of HIV Infection
Before the introduction of HAART, some 20-30% of HIV sufferers (without
opportunistic or neoplastic complications) developed HAD (McArthur, JC
1993), characterised by variable, and often profound, memory loss, motor
weakness and behavioural problems. Examination of the brain in such cases
showed a constellation of findings, the major features being neuronal/axonal
and glial loss, extensive demyelination, inflammation with microglial and
macrophage proliferation, oedema and lymphocytic infiltration and sometimes
but not always, the signs of HIVE - namely the presence of HIV containing
multinucleate giant cells, macrophages and microglia(Budka 1991). The
problem of correlation of the clinical features with the underlying
neuropathology has been the subject of extensive enquiry - neither CNS viral
load nor HIVE appeared to relate directly to HAD and the best correlate for
HAD appears to be the degree of microglial and macrophage activation (Glass
et al. 1995).
There has been no convincing evidence for direct neuronal infection (Trillo-
Pazos et al. 2003) and the neuronal damage and loss appears to be secondary,
due to the influence of toxic molecules from various sources and/or disturbed
signalling from normally supportive astrocytes and microglia. The toxic
molecules may arise from astrocytes (Patton et al. 2000), microglia (Mattson et
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al. 2005) and macrophages (Nath 1999) as described above. Viral proteins,
such as gpl20 and Tat, secreted by infected cells are neurotoxic (Lannuzel et
al. 1995). Neuronal apoptosis has been demonstrated in HAD (Masliah et al.
1992)(a). Lesser degrees of neuronal damage, but which nevertheless
contribute to the clinical burden of cognitive impairment, are dendritic pruning
(Masliah et al. 1992)(b) and synaptic loss (Everall et al. 1999).
Axonal damage in the CNS of pre-AIDS and AIDS cases became readily
identifiable with the application of P-amyloid precursor protein ((3APP)
immunohistochemistry and a number of studies have confirmed the degree and
extent of this change (An et al. 1997) (Raja et al. 1997). The principle sites of
damage were found to be in the sub-cortical white matter, the basal ganglia and
the brain stem (Gray 1998 ). The pathogenesis of axonal damage is probably
multifactorial. Although axonal damage can relate to areas of myelin pallor,
(3APP positivity can exist in the absence of pallor (Raja et al. 1997) . In some
studies of axonal damage in HIV infection, perivascular localisation has been
described (Raja et al. 1997), but this was not confirmed by other investigators
in a study of pre-AIDS cases (Giometto et al. 1997)
The presence of extensive white matter damage in AIDS has been both in
adults (Price et al. 1988) and in children (Sharer et al. 1986) , affecting the
central white matter principally, and characterised by myelin pallor and
astrocytosis. In the absence of multinucleate giant cells inflammatory changes
tended to be minimal. Focal rarefaction ofmyelin was described and in severe
cases, diffuse and focal spongy vacuolation of the myelin was present together
with oedema and, uncommonly, demyelination.
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The causes of these changes, like those affecting neurons, remain a subject of
debate (Bell 1998) and perhaps in time new circulating molecules other than
cytokines and viral products will be discovered. In the years since the
introduction of highly effective anti-retroviral therapy (HAART) there has
been a reduction in the incidence of HAD but conversely, the prevalence is
rising because of longer survival of treated subjects. The incidence of minor
cognitive defects is also rising (Bouwman et al. 1998). In terms of
neuropathology in the HAART era, novel findings include an increase in
inflammation and in neurodegenerative changes in the hippocampus (Anthony
et al. 2005).
Background to the Present Study
Given the known effects of HIV in the nervous system of both adults and
children, some of the changes in the white matter of infected individuals are
entirely predictable. A preliminary simple microscopical screening of the
archival haematoxylin and eosin (HE) stained sections of all cases aged two
and over in the African cohort confirmed that there appeared to be differences
in white matter, particularly in nuclear densities, between HIV positive and
negative cases. This screening process established a rough notion of a range of
"normality" in terms of nuclear numbers but the challenge was to attempt to
convert these subjective impressions into more reliable data in the form of a
reproducible range of total white matter cell numbers for HIV negative cases,
as a basis for evaluating HIV associated pathological changes.
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The hypotheses forming the basis of this initial study were that:
1. There would be significant differences in glial cell numbers when HIV
positive and HIV negative children were compared.
2. It was likely there would be increases in cell numbers rather than decreases,
affecting particularly microglia and astrocytes.
Accordingly, the aim of the Initial Study was to compare white matter
changes in HIV positive and negative children, in particular to attempt the
quantification of glial cell numbers. A small subset of the original African
cohort was selected, comprising age matched HIV positive and negative
children aged four years or more, in order to minimize the confounding factor
ofmaturing myelination in younger children.
3.2 - Materials and Methods
Ten cases were selected from the original cohort of 155 cases, including four
HIV positive and four negative cases of ascending age, together with an HIV
negative case at the lower and upper ends of the age range (Table 3.2.1). All
selected cases were aged four years or more and only 25 of the original cohort
were in this age group. Of these 25, 1 was HIV-2 positive and 10 were HIV-1
positive, of which only 3 lacked significant neuropathological changes. The
constraints of age and gender matching dictated that the final selection of HIV
positive cases included 1 without recorded pathology, 2 with a degree of
lymphocytic infiltration and 1 with HIVE. HIV negative cases were selected on
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the basis of age and gender matching as well as displaying no, or minimal,
CNS pathology. The causes of death found at autopsy in the selected cases are
listed in Table 3.3.2











C85 4 F - 1290 none on routine examination
C61 5 F - 1285 none on routine examination
C16 5.3 F + 1305 none on routine examination
C48 5.8 M - 1480 none on routine examination
C31 5.5 M + 1180 HIV Encephalitis
C79 7 M - 1455 microhaemorrhages
C80 7 M + 1555 lymphocytic infiltrate only
C40 8 M - 1310 microhaemorrhages
C146 8 M + 1375 lymphocytic infiltrate only
C84 9 M - 1670 microhaemorrhages
Key to Table 3.2.1: Where the age is not a whole number, the number after
the decimal point signifies an approximate fraction of a year as determined in
the original study, based on somatic length measurement (Lucas et al. 1996).
This derivation is acknowledged to be a rather imprecise estimate of age
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because of the possible influences of malnutrition and disease on growth, both
in fetal and post-natal growth.
Table 3.2.2 - Causes of death, based on autopsy findings, in the
Initial Study cases
Case Cause of death Associated conditions
C85 enteritis past malaria
C61 enteritis
C16 interstitial pneumonia CMV enteritis
C48 anaemia, profound haemo lytic uraemic syndrome
C31 pneumonia, bilateral
C79 leukaemia pancreatitis
C80 sickle cell anaemia colitis
C40 TB - generalised
CI 46 pneumonia measles enteritis
C84 lymphoma B-cell
Four different brain areas were chosen in the selected cases, including the
cerebral convexity, the hippocampus, the basal ganglia and the cerebellum.
Sections were cut from the appropriate blocks and stained with haematoxylin
and eosin (HE), Luxol fast blue (LFB) and immunostained for glial fibrillary
acidic protein (GFAP), myelin basic protein (MBP), Beta amyloid precursor
protein (|3APP) and von Willebrand factor. Stained sections were used to
assess the presence of white matter changes in myelin, axons and vascular
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endothelium. Sections stained with HE and immunostained for GFAP were
used in the counting process and the results recorded using a manual tagging
system. A systematic, i.e. non random, approach was adopted with respect to
the areas of white matter sampled, as it is known that different white matter
tracts differ in their numbers of associated oligodendroglial cells (Suzuki et al.
1988). Sections were examined blinded to age, sex and HIV status.
The plan was to sample white matter within the chosen section where the
preferred orientation of fibres was in longitudinal, i.e. linear or curvilinear,
array. However despite careful examination of previously stained sections from
the original study, and the blocks themselves, it was apparent that this was not
possible for all cases because of the variation of original sampling at post¬
mortem or that the requisite blocks were not available. Within the internal
capsule the oblique cut of fibres dictated a departure from this plan but
contrary to expectations satisfactory results were obtained. In the case of the
cortical sections, because of varying availability, fronta 1 or parietal cortex was
used.
In the cortical sections, areas of white matter were selected in the short
arcuate fibres (CNS region 1), in the core of one or more gyri (CNS region la),
and in the core of the parahippocampal gyrus (CNS region 2), as well as in the
fasciculi of the internal capsule (CNS region 3) and at the bases of the folia in
the cerebellum (CNS region 4). The cells of the white matter were
provisionally identified by nuclear morphology in the case of
oligodendrocytes, microglia and endothelial cells and GFAP staining for
astrocytes. Total nuclear numbers, and subsequently the subsets of glial cells
151
according to their GFAP positivity or nuclear morphology, were counted.
Early attempts to also count inflammatory cells, particularly lymphocytes, were
abandoned because of variability in the quality of immunostaining for
lymphoid and macrophage markers. The reasons for this failure were at first
obscure despite attempts to optimize methods. However in the Main Study,
success was achieved using new antibodies and new coverplates for each new
staining run. Hence the initial failure was attributed to less than optimal
reagents.
Using sections stained with HE and for GFAP, two separate and complete cell
counts were made. The first count, an exploratory exercise, was based on a
total field sampling area for each section of 1 sq. mm, accomplished by taking
12.33 fields, amounting to a total area of 1 sq.mm. This proved time-
consuming and inefficient and, after an informal discussion with a stereologist,
a further count was made, based on a smaller sample of fewer fields, total area
of 20243.8. sq.pm. When multiplied by 4.94, the second set of totals achieved
total areas of 1 sq.mm, matching the first set of data. These two counting
assessments are set out in Appendix 7. The means of the two counts were
determined and the values so obtained were the ones used in subsequent
calculations.
Sampling was generally spaced as widely within each zone as possible. In
the case of the cerebellum, for example, fields were sampled from the bases of
separate folia, and in the internal capsule, one from each fascicule, if there
were sufficient. The cell counting rules were fairly simple - all nuclei in focus,
other than those having an overtly neuronal morphology, were counted in
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sections stained with glial fibrillary acidic protein (GFAP) antibody and
counterstained with haematoxylin.
Subsets of this total population were counted on the following basis:
1. All cells which had GFAP positive cytoplasm.
2. All cells, which by position or association, were clearly endothelial cells.
3. All cells having round or oval nuclei, irrespective of nuclear size or
density.
4. All cells having elongated nuclei, equivalent to rod-like cells - where the
major axis appeared twice as long or more, than the minor axis, or where
the nucleus was of aberrant, for example triangular, shape.
It should be added that several short trials were made to see if the counting
could be semi-automated by labelling nuclei, using the soft-ware, according
their area, diameter, density or degree of roundness. Though it was possible to
obtain results, these almost always required adjustment by virtue of differing
staining intensity between sections, inter-cell contact and out-of-focus profiles.
This possible approach was therefore discarded.
The population of GFAP positive cells was considered to contain most of the
fibrous astrocytes. These cells generally were characterised by having larger,
lighter and polygonally shaped nuclei (see Fig. 3.2.1). The pattern of GFAP
positivity varied from case to case: in some it was lightly and regularly
distributed throughout the cell, and in others it appeared as a coarse particulate
deposit in the processes, giving a tracer-like appearance. The presence of
oedema seemed to favour this latter display.
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Endothelial cells were counted if the nuclei were clearly part of a capillary,
either in transverse or longitudinal section. There was little variation in their
morphology, except in degree of compactness.
The population of rectangular nuclei was thought to capture a consistent
proportion of the resting or ramified microglia. By adopting the practice of
sampling in linear or curvilinear fibre arrays, in which the microglia lie
preferentially along the axis of the fibres, their identification was more certain.
Generally their nuclei were dark, but the morphology varied from rectangular
to comma-like or triangular, and all these were counted together.
Fig. 3.2.1 Cerebellar White Matter stained for GFAP - subsets of
nuclei for quantitation:
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White matter from Case C85 (HIV negative) showing glial cells. Black
arrowhead - GFAP stained astrocyte; green - endothelial cell; brown - round
nucleus - possible oligodendrocyte; red - rectangular nucleus thought to be a
microglial cell; and yellow - a perivascular macrophage. Original mag. x 400
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Image analysis software, Image-Pro 4.5 supplied by MediaCybernetics and
coupled to an Olympus BX40 microscope, was used to capture images, using
the x40 objective lens. At this magnification the single frame dimensions
were: width = 164.18pm, height = 123.29pm and area = 20,243.8 sq.pm. Four
categories of nuclei, as shown in Figure 3.2.1, were counted using the software
manual tagging "class" system. It was found easier to count starting with the
most numerous nuclear populations, and the first class number assigned by the
software was "0". Accordingly, in some tables there is reference to these
classes and the key is:
Class 0 refers to round or oval nuclei
Class 1 refers to GFAP positive cells
Class 2 refers to rectangular nuclei
Class 3 refers to endothelial cells.
The rules were that nuclei had to be in focus, or very nearly so, to be counted.
Neurons, or cells suspected of being neurons, were excluded if encountered in
white matter. Nuclei in contact with the left or bottom sides of the frame were
counted, those in contact with the right or top sides were not. The nuclei of
cells in a perivascular location were sorted according to the above criteria and
counted with the parenchymal cells.
The results were tabulated in Excel for the different regions, and compared
for HIV negative and positive cases using the statistical software Minitab. The




Assessment of the white matter status in routine and immunostained
sections, using a light box initially, showed only one case (c31) was
considered to show diffuse pallor in the cerebrum with respect to the others,
and only one (c84) to show focal pallor in an area of several sq. mm. (Fig.
3.3.1). At microscopical examination, all cases were considered to show at
least focal hypoxia in some if not all areas (Fig. 3.3.2). Oedema, focal or
diffuse, cortical or in white matter, was a very common finding, especially
in the cerebellum. In some oedematous areas pairs of astrocyte nuclei were
present, suggesting a possible proliferative response (Fig. 3.3.3).
Fig. 3.3.1 Cortex Parasaggital Section
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An HIV negative case (c84) showing focal pallor of the white matter with
myelin bulb formation in the centre of the field. LFB x 40
Fig. 3.3.2 Cerebellum
An HIV negative case (c79) showing hypoxic neurons of the dentate nucleus.
HExlOO




















HIV negative case (c61) showing astrocyte nuclei in pairs in oedematous
white matter. HE x 400
Focal abnormalities included microhaemorrhages (c40 and cl46) and an
occasional gliotic area, for example in case c79. Two cases showed attenuation
of the white matter in the lateral angle of the lateral ventricle (cl46 and c84).
Perivascular macrophages and lymphocytes were more common in the HIV
positive cases.
LFB stained sections were quite variable in the intensity of overall staining.
When viewed on the light box there was both intra- and inter-case variation
and the simple scoring system - where 1 = "normal intensity" and 2 = "slight
or definite pallor" - suggested that HIV negative cases were as likely to show
pallor as HIV positive cases, if not more so. The pallor noted in haematoxylin-
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stained section c31, cortex, was confirmed in its LFB counterpart. In the same
way, the pallor in the lateral angle of the ventricle in case cl46, parasagittal
section, showed staining deficiency in the LFB section.
Sections stained with GFAP showed a variety of appearances and astrogliosis
was apparent in some cases, for example in the case with HIVE (c31) (Fig.
3.3.4).
Fig. 3.3.4 Cerebral Convexity White Matter
Case ofHIVE (c31) showing astrogliosis. GFAP xlOO
Immunostaining for HIV nucleocapsid protein p24 gave positive results for
three out of the four HIV positive cases. In case cl6, rare positive cells were
seen. In the case with HIVE (c31), displaying giant cells (Fig 3.3.5), numerous
HIV p24 positive foci were seen in the white matter (Fig 3.3.6). A single tiny
focus was seen in the basal ganglia section of case c80.
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Case ofHIVE (c31) showing a microglial nodule. HE x200
Fig. 3.3.6 Basal Ganglia
Case ofHIVE (c31) showing a microglial nodule with a giant cell and
abundant HIV p24 positivity. HIV p24 x 400
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The anti-MBP stained sections were similar in display to LFB stained
sections, and no additional information was obtained. Similarly no additional
information was derived from the transferrin stained sections. In these sections
only about one third of cells having a nuclear morphology suggestive of
oligodendrocyte type were transferrin positive and, furthermore, cells with
small amounts of cytoplasm and nuclei resembling those of astrocytes were
also positive.
PAPP immunopositivity was infrequent and meagre. Two cases, both HIV
negative (c48 and c79) showed no staining at all. In most cases, affected areas
were faint and only present in one or two regions. In others, restricted
neuronal positivity was present, especially in the dentate neurons that had
shown hypoxic change in the HE stained sections. The case (c80) showing
most marked positivity, in all regions, was HIV positive and displayed
lymphocytic infiltrates. The changes seen in the HIVE case (c31) were slightly
less pronounced.
Immunostaining for von Willebrand factor gave generally satisfactory results.
The endothelial cells varied slightly in their morphology - there was a
tendency towards minor degrees of swelling in the HIV positive cases. No
positive cells were seen with Ki67 immunostaining.
Cell Counting Studies
The basis for distinguishing nuclear appearances has been described. On
counting the round nuclei, the presence of different nuclear sizes and densities
was confirmed, as described by (Mori and Leblond 1970). They ranged from
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3.5 to 8pm in diameter but no attempt was made to estimate the proportion of
the different sizes.
First and second nuclear counts for each of the five white matter areas in each
of the 10 cases, comprising total numbers of nuclei, nuclei of GFAP positive
cells, endothelial nuclei, round and rectangular nuclei, are shown in the Table
at Appendix 8, tabulated in Excel. Neither set of counts was uniformly greater
or smaller with respect to the other. Appendix 8 also displays the means and
standard deviations for the consecutive counts. In the Table, the 10 Initial
Study cases are listed across the top in ascending age order, irrespective of
HIV status.
The mean values of the first and second counts for each of the different brain
areas, and for each of the nuclear count subsets, are set out in a two part Table
(Appendices 9a & 9b). Appendices 9a and 9b also include an overall brain
mean value, with standard deviation and paired t-test for each nuclear subset.
In Appendix 9a, the results for total counts, totals minus endothelial cells and
GFAP positive cells are shown. Appendix 9b shows the mean counts for
endothelial cells, round nuclei and rectangular nuclei. The results shown in this
two part table were used as the basis for all further analyses.
Tables 3.3.1 to 3.3.6 show summary statistics for the cell counts for cell
subsets.
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Table 3.3.1: Paired T-Test and CI: HIV-ve and HIV+ve mean values for
total cell counts
N Mean SD SEM
HIV-ve 20 874.60 127.37 28.48
HIV+ve 20 1159.60 223.58 49.99
Difference -285.00 202.991 45.39
P-Value = 0,000
Table 3.3.1 shows the values for the total nuclear counts
(glial plus endothelial) in all areas, for HIV positive
cases and HIV negative cases separately.
Table 3.3.2: Paired T-Test and CI: HIV-ve and HIV+ve mean values for
totals minus endothelial cells
N Mean SD SEM
HIV-ve 20 843.95 124.79 27.90
HIV+ve 20 1125.05 224.13 50.12
Difference -281.10 209.111 46.759
P-Value = 0.000
Table 3.3.2 shows the values for the total glial cell
counts in all areas for HIV positive cases compared with
those of HIV negative cases.
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Table 3.3.3: Paired T-Test and CI: HIV-ve and HIV+VE mean values for
GFAP positive cells





20 57.60 14.7841 3.3058
20 82.20 24.4295 5.4626
-24.60 24.2105 5.4136
Table 3.3.3 shows the values for GFAP positive cell
counts in all areas for HIV positive cases compared with
those of HIV negative cases.
Table 3.3.4: Paired T-Test and CI: HIV-ve and HIV+ve mean values for
endothelial cells
N Mean SD SEM
HIV-ve 20 30.5500 8.0686 1.8042
HIV+ve 20 38.1500 9.2411 2.0664
Difference -7.6000 3.72743 1.66696
P-Value = 0.007
Table 3.3.4 shows the values for the endothelial cell
counts in all areas for HIV positive cases compared with
those of HIV negative cases.
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Table 3.3.5: Paired T-Test and CI: HIV-ve and HIV+ve mean values for
round nuclei
N Mean SD SEM
HIV-ve 20 754.05 115.151 25.749
HIV+ve 20 971.05 200.173 44.760
Difference -217.00 187.660 41.962
P-Value = 0.000
Table 3.3.5 shows the values for the round nuclei cell
counts in all areas for HIV positive cases compared with
those of HIV negative cases.
Table 3.3.6: Paired T-Test and CI: HIV-ve and HIV+ve mean values for
rectangular nuclei
N Mean SD SEM
Rect nuclei HIV- 20 33.10 19.1419 4.2802
Rect nuclei HIV+ 20 71.95 36.5592 8.1749
Difference -38.85 40.7861 9.1200
P-Value = 0.000
Table 3.3.6 shows the values for the rectangular nuclei
cell counts in all areas for HIV positive cases compared
with those of HIV negative cases.
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Table 3.3.7: Percentage increases in mean cell counts (total number and
individual subsets) in HIV+ve compared with HIV-ve brains
For total cell counts - means of 20 values + 33%
For total counts minus endothelial cells - means of 20 values + 33%
For GFAP positive cells - means of 20 values + 43%
For endothelial cells - means of 20 values + 25%
For round nuclei - means of 20 values + 29%
For rectangular nuclei - means of 20 values + 117%
Table 3.3.7 shows the percentage increases in all cell
classes in HIV positive compared with HIV negative cases.
In the next analyses, the youngest (c85) and oldest (c84 )HIV negative cases
were first excluded from the mean cell counts of the remaining 4 HIV negative
cases and then separately compared with those means (Tables 3.3.8 to 3.3.13).
In summary, in c85 all cell types except those with round nuclei are
significantly increased with respect to the corresponding HIV negative means.
In contrast, when c84 was compared with the HIV negative means in the same
way no significant difference was detected for any of the cell count categories.
Further detail of the means of the HIV negative cases is shown in Appendix 10
which includes a graphical display of the degree of variation across the
different brain areas for the different cell subsets (endothelial counts excluded).
The percentages of each cell category are given. There seems to be reasonable
accord between the populations within different brain locations, average
percentages of 90%, 6%, and 4 % for the round nuclei, GFAP positive and
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rectangular nuclei respectively. Although there is an impression that cell
densities might be greater at convexity level than lower in the neuraxis, there is
insufficient data to substantiate this possibility. An HIV negative case, c40,
showed the least variation between cell counts in different locations.
Table 3.3.8: Paired T-Test and CI: 4 HIV-ve compared with c85 for total
nuclear counts
Mean SD SEM
4 HIV-ve 874.60 74.30 33.23
c8 5 1071.80 126.14 56.41
Difference -197.20 151.463 67.736
P-Value = 0.044
Table 3.3.8 shows the values for case c85 of total cell
counts in all areas compared with those of HIV negative
means.
Table 3.3.9: Paired T-Test and CI: 4 HIV-ve compared with c85 for total
minus endothelial cells
Mean SD SEM
4 HIV-ve 844.20 74.73 33.42
c8 5 1033.60 134.35 60.08
Difference -189.400 152.671 68.276
P-Value = 0.050
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Table 3.3.9 shows the values for case c85 of total
glial cell counts minus endothelial nuclei in all
areas compared with those of HIV negative means.


















Table 3.3.10 shows the values for case c85 of GFAP
positive cell counts in all areas compared with those of
HIV negative means.



















Table 3.3.11 shows the values for case c85 of endothelial
cell counts in all areas compared with those of HIV
negative means.
Table 3.3.12: Paired T-Test and CI: 4 HIV+ve compared with c85 for
round nuclei
Mean SD SEM
4 HIV+VE 754.0 74.790 33.447
c8 5 851.2 149.279 66.760
Difference -97.2 157.4554 70.4162
P-Value = 0.240
Table 3.3.12 shows the values for case c85 of round
nuclei counts in all areas compared with those of HIV
negative means.
Table 3.3.13: Paired T-Test and CI: 4 HIV-ve compared with c85 for
rectangular nuclei
Mean SD SEM
4 HIV-ve 33.20 8.5264 3.8131
c85 86.80 15.8019 7.0668
Difference -53.60 8.1731 3.6551
P-Value = 0.000
Table 3.3.13 shows the values for case c85 of rectangular
nuclei counts in all areas compared with those of HIV
negative means.
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The cell counts are also illustrated graphically as boxplots which include all ten
cases, including 4 age matched HIV negative and 4 positive cases, and the 2
"bookend" HIV negative cases (Figures 3.3.7 to 3.3.12). In these Figures the
interquartile range boxes are arranged from left to right with case numbers
corresponding to the order shown in Tables 3.2.1 and 3.2.2. The cases at either
side, c85 and c84, are the youngest and oldest cases, both HIV negative, and
the data for these two cases are not used in the formal statistical analyses (apart
from the comparison of each with the mean results of the HIV negative cases,
as described in the text and, for c85, shown in Tables 3.3.8 to 3.3.13). The
main statistical analyses are restricted to the 4 remaining HIV negative cases
(c61, c48. c79 and c40) and the 4 HIV positive cases (cl6, c31, c80 and cl46).
The HIV positive cases are clearly identified and a mean connect line is drawn.





























HIV +ve HIV +we HIV +ve HIV +we
85 61 16 48 31 79
Case numbers
80 40 146 84
Boxplot showing nuclear totals (glial and endothelial cells) in each CNS area
sampled. The HIV negative cases c85 (age 4) and c84 (age 9) serve to bracket
the other HIV negative cases and all of the positive cases.
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Fig. 3.3.8




















HIV +ve HIV + ve HIV + ve HIV +ve
85 61 16 48 31 79
Case numbers
80 40 146 84
Boxplot of 10 cases - nuclear totals minus endothelial cells. These totals are
for glial cell nuclei only.
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Fig. 3.3.9




















HIV + ve HIV + ve HIV +ve HIV +ve
85 61 16 48 31 79
Case numbers
80 40 146 84
Boxplot of 10 cases - GFAP positive cells. The counts for the HIV positive
cases are clearly greater than their HIV negative counterparts. HIV negative
case c85 has counts in the higher HIV positive range.
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Fig. 3.3.10


















HIV +vc HIV +we HIV +ve HIV +ve
85 61 16 48 31 79 80
Case numbers
40 146 84
Boxplot of 10 cases - endothelial cells. The counts for HIV positive cases are
generally higher than HIV negative case, c85, which has a higher mean and
median values than the other HIV negative cases.
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Fig.3.1.11
Boxplot of 10 cases - round nuclei - mean connect line
85 61 16 48 31 79 80 40 146 84
Case numbers
Boxplot of 10 cases - round nuclei. The counts for the HIV positive cases are
higher than their HIV negative counterparts. Case c40 shows minimal variation
in count totals for the different CNS areas (mean 673 SD ±14.36)
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Fig. 3.3.12





























HIV + ve HIV +ve HIV +ve HIV + ve
85 61 16 48 31 79 80
Case numbers
40 146 84
Boxplot of 10 cases - rectangular nuclei. The differences between cases c79
(HIV negative) and c80 (HIV positive) are minimal. Case c85 shows the
second highest count overall.
The second set of boxplots (Figures 3.3.13 to 3.3.18) illustrates the
significant differences between the collected data from 5 brain areas in the 4
HIV negative (excluding the youngest and oldest HIV negative cases) and
4HIV positive cases, for each of the different cell groups. Each interquartile
range box represents the collected data for 20 counts in HIV negative and HIV
positive cases. The mean symbols are included in each boxplot.
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Fig. 3.3.13
















HIV-ve: 4 cases, 20 values HIV+ve: 4 cases, 20 values
Boxplot ofHIV positive and negative cases compared for total nuclear counts
- glial and endothelial cells. The difference is significant, p=0.000
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Fig. 3.3.14














HIV-ve: 4 cases, 20 values HIV+ve: 4 cases, 20 values
Boxplot of HIV positive and negative cases compared - for glial cell totals
only. The difference is significant, p=0.000
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Fig. 3.3.15






















HIV-ve: 4 cases, 20 values HIV+ve: 4 cases, 20 values
Boxplot of HIV positive and negative cases compared - GFAP positive cells.
The difference is significant, p=0.000
179
Fig. 3.3.16













HIV-ve: 4 cases, 20 values HIV+ve: 4 cases, 20 values
Boxplot of HIV positive and negative cases compared
difference is significant, p=0.007
- endothelial cells. The
Fig. 3.3.17
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HIV-ve: 4 cases, 20 values HIV+ve: 4 cases, 20 values
Boxplot of HIV positive and negative cases compared - round nuclei. The
difference is significant, p=0.000
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Fig. 3.3.18















HIV-ve: 4 cases, 20 values HIV+ve: 4 cases, 20 values
Boxplot of HIV positive and negative cases compared - rectangular nuclei.
The difference is significant, p= 0.000
The data for the separate groups or categories of counts were analysed by
paired t-testing, excluding the youngest and oldest case as explained
previously. In each group, and for the HIV negative and HIV positive cases
separately, the values of the counts for all areas and for all cases were collected
together and compared. As the endothelial cells are clearly not part of the glial
cell population there is a case to be made for excluding them from a total
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count. On the other hand, they are certainly part of the total nuclear population
and so the total counts, including endothelial cells, are also of interest.
Inspection of Tables 3.3.1 to 3.3.6 confirms the highly significant increases in
the counts for each of the nuclear subsets in HIV positive compared with HIV
negative cases.
In general, c80 seems to be the least reactive, and cl6 the most reactive, of the
HIV positive cases. These increased counts were found in almost all regions in
the HIV positive brains (Appendix 8). The counts for the cerebellum are
generally lower than at other levels. In part this may be due to the appearance
of marked oedema in the cerebellum. The increase in GFAP positive cells is
least marked in cl46. Case c80 at cortical level shows least increase in
rectangular nuclei. It is of interest that c31 did not show the maximum increase
in any class of cell, despite being the one case with HIVE.
Correlation of Cell Counting with Routine Histology
The apparently increased cellularity of the white matter, on simple
inspection, was usually confirmed on counting. For example, in an HIV
positive case (cl6), the nuclear numbers appeared increased on inspection of
sections of the cerebral convexity (Fig. 3.3.) and this was confirmed with a
mean count of 1608 per sq.mm. For comparison, in sections of the cerebral
convexity in HIV negative case (c61), the white matter nuclear density
appeared less (Fig. 3.3.) and the corresponding mean nuclear count was 1063
persq.mm.
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Fig. 3.1.19 Cerebral Cortex
Section of the gyral white matter from an HIV positive case (cl6) showing
hypercellularity of the white matter. The total nuclear count was 1,608 per
sq.mm. HE x 100
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Fig. 3.3.20 Cerebral Cortex
Section of the gyral white matter from an HIV negative
case (c61) for comparison of cellularity with the HIV
positive case shown in Fig. 3.1.19. The total nuclear count
was 1,063 per sq.mm. HE x 100.
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3.4 - Discussion and Conclusions
The aim of this Initial Study was to attempt to define the glial populations in
their totality and, if possible, the contribution of their separate types to the total
value in each of various regions of the CNS in this paediatric African cohort. In
this size-limited survey there are several findings of interest and which merit
further investigation.
1. The study suggests that it is possible to obtain reproducible figures for each
glial cell type (defined in the ways indicated above) in specific areas of
disease-free brains ofHIV negative African children. The question arises as
to whether similar values would be found using the same approach if the
white matter of Caucasian children, or of adults of differing ethnic origin,
were to be investigated.
2. This study also suggests that HIV infection is associated with hyperplasia,
i.e. increased numbers, of each of the cell types as defined above. This
response appears both diffuse and widespread, occurring as it does in
widely different regions of the brain and throughout the neuraxis. In the
case of the round nuclei, the objection arises that an influx of lymphocytes
may contribute to the total, or that they are rectangular nuclei cut in
transverse section, but if so, the pattern of distribution of nuclei appears
little different from that of the normal white matter parenchyma. This
problem could be explored using immunostaining with lymphocyte
markers. The microglial and macrophage populations, with their labile
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morphology in pathological conditions, further serve to cloud the issue. It is
unclear whether this hyperplasia, which appears to affect all glial
populations, is the result of occult HIV infection in the brain, or the result
of a common and "remote" stimulus, for example a circulating cytokine.
3. This study suggests that there is also endothelial cell hyperplasia in
association with HIV infection. The difference between the means of HIV
negative and HIV positive cases is statistically significant. This result was
unexpected and the reason for it is not clear. Does it represent a response to
a circulating mitotic stimulus? There are possible implications for the
integrity of the Blood Brain Barrier and it would be worthwhile exploring
this further with specific immunostains, for example, ZOl.
At cellular level, there may be limitations to the usefulness of counts in any
particular region. It is known that the density of microglia varies from region to
region (Lawson et al. 1990) and also that the numbers of oligodendrocytes vary
between different fibre tracts (Friede 1961). The orientation of the fibres
probably affects the counts. A cursory check, using an eyepiece graticule,
certainly suggests that this is so, the numbers in the obliquely cut internal
capsule appearing less than in the curvilinear fibres of the external capsule.
Any enquiry of this sort is beset with difficulties and liable to criticism on
several grounds, especially in respect of the identity of the glia, which, even in
the experimental animal, can remain elusive. The illuminating results obtained
by gold and silver staining in the early days of neurohistology served to
intensify the debate, already active throughout Europe, on morphology and
function of the neuroglia. The introduction of electron microscopy likewise
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provided a further opportunity to examine the glia and their relationships.
Immunocytological stains used today vary in their specificity - only a
proportion of fibrous astrocytes are stained with the GFAP antibody - and that
proportion is affected by physiological and pathological conditions. The other
glia, likewise, cannot be visualised exclusively or in their entirety.
Whereas a few decades ago there was a tendency for clinicians and
pathologists to confidently assign this sign, or those appearances, to a specific
condition, now there is a greater acknowledgment of uncertainty. Current
histological texts, when illustrating the neuroglia, tend to suggest that "this cell
may be presumed to be an oligodendrocyte" or "that cell is probably an
astrocyte".
It is hoped that the pragmatic approach adopted in this study has produced
results that stand comparison with any others which refer to glial numbers in
human subjects (Esiri et al. 1991; Sjobeck and Englund 2003) It is noteworthy
that the proportions of different glial types found in this study are not dissimilar
to these previous studies. The limitations of small case number are
acknowledged but investigations of this type are very labour intensive and time
consuming.
The findings relating to c85, a young HIV negative case, are of note in
deviating from the general pattern of lower values for nuclear counts in HIV
negative cases. Though no specific abnormal findings were detected at the
initial screening in 1997 (Bell et al. 1997), these results raise the possibility of
significant subtle brain pathology., possibly relating to the history of past
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malaria. An alternative explanation is that this case shows less oedema than the
others.
Several other limitations in technique and method should be mentioned. At
the cutting stage, difficulties were sometimes experienced in obtaining
consistent section quality, despite consideration of the usual causes and seeking
advice. In view of the unique value of the material, in terms of how it was
acquired, as few sections as possible were discarded. Their quality, therefore,
may in places appear suboptimal. Another problem arose at the mounting stage
- just above the mounting hood the ceiling tiles were starting to crumble,
following a leak in a drainage pipe; dust was unavoidably encountered and
deposits on some the sections occurred. The difficulty with the immunostaining
for lymphocyte and macrophage markers was referred to in the Material and
Methods (later overcome in the Main Study).
As mentioned in the results section, many of the cases showed oedema in at
least one of the regions examined, especially in the cerebellum, where in
addition spaces were sometimes seen, suggestive of nuclear loss, presumably in
processing. The impression was that this was more likely to affect the round
nuclear population and that it could amount to 10% or more - cerebellar counts
may be underestimates of the true number.
As regards the general white matter assessment, the selection of cases aged
over the age of 4 years ruled out the potential confounding influences of early
stages ofmyelination. The finding of varying degrees of myelin pallor seemed
to be inseparable from the equally frequent finding of early hypoxic neuronal
change and oedema. These, in their turn, are a reflection of agonal changes in
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children beset with infections and presumed severe metabolic derangements. It
seems unwise to draw any firm conclusions about white matter pathology
where pallor alone is present. Moreover, assessment of pallor is a very
subjective matter and intra-case variability alone precludes useful case
comparison. However, the case that showed the most definite pallor, c31, also
showed conspicuous astrogliosis, especially in the cerebellum, suggesting a
morphological basis for the pallor.
Also, in any morphological study, the question of shrinkage of tissue arises
and, of course, it is impossible to discount this factor in the cases under study
here. However, the post mortem examinations were performed soon after
death, at the same locus, and the tissue was processed in a standardised way;
and the quality of the histology is consistently high. Any variations in tissue
shrinkage are likely to reflect antemortem factors outwith the control of this
study.
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Chapter 4: The Main Study
4.1 - Introduction
Since microglia are the principal central nervous system (CNS) cell type to be
infected with HIV, and viral infections of the brain elicit a lymphocytic response, it
is not surprising that most neuropathology studies in AIDS have focussed on
inflammatory reactions.
The concept of immune privilege of the CNS - once held to be absolute - is now
seen as one in which there is both temporal and spatial latitude (Engelhardt 2006)
and the principles involved are essential to the understanding of the
neuroinflammatory responses illustrated in this study. Lymphocyte transit into the
brain appears to occur at post-capillary venule level rather than in the capillary bed
(Raine et al. 1990) and cell passage occurs through the endothelial cell (transcellular
route), rather than around it (paracellular route) (Wolburg et al. 2005).
The microvasculature of the grey and white matter, and of the spinal cord, appears
uniform at microscopical and ultrastructural level but there are significant differences
when compared with the meningeal micro vessels (Allt and Lawrenson 1997). The
meningeal, or pial, microvessels have no astrocytic association or envelopment and
the endothelia of the cerebrospinal microvessels lack one of the molecular pathways
- p-selectin - necessary for neutrophil adhesion (Barkalow et al. 1996). These
features help to explain the marked difference in response to inflammation in two
intimately associated tissues - the relative impermeability of the CNS parenchyma to
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neutrophil access is in strong contrast to the exuberant meningeal response in
meningitis.
There is also evidence to suggest that at molecular level there may be subtle
differences in pathways involved in inflammatory cell access between the cerebral
and spinal microvasculature. A technique known as intravital microscopy (Piccio et
al. 2002) has revealed in mice that activated lymphocytes may roll on endothelium
prior to transit across walls of microvessels in the brain, but are captured
immediately in spinal cord microvessels. This suggests a regional specialization
which might help to explain differing localization and intensity of the inflammatory
process within the CNS. Furthermore, it was shown that priming of the endothelium
of microvessels by an injection of lipopolysacharride or TNFa could enhance the
subsequent sequestration of activated lymphocytes (Piccio et al. 2002) and thereby
raises the possibility of CNS involvement by systemic stimuli(Engelhardt 2006).
In health there is limited immune surveillance in the the subarachnoid and
perivascular spaces . The lymphocyte population of the cerebrospinal (CSF) is
replenished twice daily by interchange with the bloodstream through the choroid
plexus. As noted in Chapter 1, T and B lymphocytes enter the normal CNS in small
numbers (flickey 1999; Anthony et al. 2005). In disease states lymphocyte
interactions with the CNS are much enhanced.
Much of what is known of the cellular and molecular biology of inflammatory cell
dynamics in CNS inflammation is derived from the study of an animal model of
demyelination known as experimental allergic encephalitis (EAE), first described in
1935(Rivers 1935). In EAE, rodents are sensitized against a component of myelin
and the effects are studied under varying conditions. Much of the experimental work
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has focused on the dynamics of CD4 T-cells (Ben-Nun et al. 1981; Beraud et al.
1993) but more recently the pathogenic role of CD8 T-cells has been explored
(Huseby et al. 2001) (Ji and Goverman 2007).
Infiltrates of lymphocytes and macrophages are a characteristic feature of acute and
chronic inflammatory diseases of the CNS - e.g. viral infections and multiple
sclerosis, and in CNS ischaemia and trauma. The degree and location of the
infiltrates vary according to the nature of the insult; there may be no more than a few
cells along the course of small vessels or there may be multilayered vascular cuffing
with focal and diffuse parenchymal cellular collections. The recruitment of such cells
is complex and there are subtle interdependencies between the cells of the innate and
adaptive immune system. However the initial part of the process - that of leucocyte
adhesion and passage through the endothelium, known as transmigration - is well
defined in molecular biological terms (Muller 2002). It is governed by the
interaction, by means of chemical mediators, of adhesion molecules on the surfaces
of leucocytes and endothelial cells. The most important receptors belong to three
main groups, each having a slightly different profile of activity:-
The selectins are named because of their affinity with sugar binding mammalian
lectins. The three main selectins are E- selectin found in endothelium, P-selectin in
endothelium and platelets and L-selectin, present on most leucocytes. The selectins
are mostly involved in rolling and adhesion of leucocytes on the endothelial surface.
The immunoglobulin family contains two well recognised adhesion molecules;
intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule-1
(VCAM-1) These are present on endothelial cells. ICAM-1 is involved in
transmigration.
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The integrins are a large family of transmembrane proteins present on many cell
types and which bind to endothelial cells or to other cell types through ICAM-1 or
VCAM-1. Induction, or up-regulation, of adhesion molecules on endothelia occurs in
response to a variety of stimuli ranging from local trauma to circulating cytokines. In
the particular case of CNS endothelia, circulating cytokines such as TNF-a, locally
produced cytokines (by perivascular cells) including TNF-a and IL-1, and cell to cell
signalling originating in the end feet of activated microglia and astrocytes, probably
all play a part (Dorries 2001). Furthermore, in HIV infection, endothelial cells
secrete immuno-active molecules in response to certain HIV products, such as gpl20
and Tat (Banks et al. 2006).
The behaviour of lymphocytes which have traversed the blood brain barrier (BBB)
is subject to a number of chemotactic stimuli, at least one of which is determined by
activated macrophages. A study on EAE in mice showed that whilst macrophage
depletion allowed transvascular passage of autoreactive T-cells, parenchymal
infiltration did not follow and demyelination did not occur (Tran et al. 1998). The
influx of CD8 T-cells into the CNS in viral infection is partly determined by
signalling from natural killer cells which precede them as an innate immune
response. Natural killer cells secrete IFN-y, which is a major activator of CD8 T-cells
(Dorries 2001). Activated microglia acquire antigen presenting properties and in
their interaction with CD8 T-cells confer cytopathic ability. Another pathway is for
antigen specific CD8 T-cells to gain independent access through interaction with
MHC class 1 expressing endothelial cells (Galea et al. 2007).
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T-cells and HIV infection
One of the features of early HIV infection is the presence of perivascular and
leptomeningeal lymphocytic infiltration, which has been interpreted as evidence of
an immune response to the presence of HIV (Bell et al. 1993) (Gray et al. 1992). A
few early studies on the brain lymphocytic population in AIDS failed to detect
significant numbers in the perivascular position and could not find a difference
between AIDS brains and controls (Tyor et al. 1992) (Wesselingh et al. 1993).
However later studies did show perivascular lymphocytic aggregations both in adults
(Weidenheim et al. 1993) and in children in AIDS (Katsetos et al. 1999). A more
recent study (Petito et al. 2003) investigated the dynamics of lymphocytic infiltration
in the hippocampus of AIDS subjects and showed that perivascular T-lymphocytes
were increased in the peri-hippocampal white matter in the presence of HIV
encephalitis (HIVE) but were rare or absent in controls and AIDS cases without
HIVE. These T-lymphocytes included CD45RO+ (activated/memory cells) and
CD3+, CD4+ and CD8 cells. Parenchymal CD45RO+ and CD3+ lymphocytes were
numerous in areas adjacent to HIVE foci. Minimal evidence of infection of
lymphocytes was detected by HIV p24 antigen testing. In addition, all lymphocyte
subsets were seen to participate in the formation of microglial nodules along with
microglia, macrophages and multinucleate giant cells. Several reasons for the
accumulation of lymphocytes were considered in this study, including factors
favouring transmigration and cytokine induced chemotaxis. Another possible
mechanism involving reduced apoptosis of infiltrating cells, due to astrocyte
malfunction, has also been proposed (Gold et al. 1996). The proximity of
lymphocytes to neurons in HIVE cases may suggest a neurotoxic relationship (Petito
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et al. 2006). Another possible adverse effect was enhanced productive HIV infection
through the agency of secreted T-cell factors (Tornatore et al. 1991).
A further study by the same group (Petito et al. 2006) explored the CD8 and
cytotoxic lymphocyte populations in HIVE. In this study, the CD8 sub-population
of activated or cytotoxic T-lymphocytes was identified by the possession of
granzyme or perforin granules, detected by immunocytochemistry. The areas studied
were the hippocampus and basal ganglia and the subjects were a small group AIDS
patients - some with HIVE and some without. Perivascular CD8 cells were more
numerous in HIVE and in AIDS cases without HIVE than in controls. CD8
parenchymal cells were frequent in the HIVE cases and were largely absent from the
AIDS cases lacking HIVE, and from controls. These findings were paralleled by
those for those CD8 granule positive cells, except that the numbers were smaller. As
in the previous study, lymphocytes were found in close contact with neurons in
HIVE cases and the authors proposed that their presence in such a situation could
serve as a marker for productive infection, if lymphoma and opportunistic infection
were excluded. Another inference was that glial cells were also susceptible to the
attention of cytotoxic T-lymphocytes, though this activity was not specifically
detected.
McCrossan et al (McCrossan et al. 2006) examined lymphocytic infiltrates and
inflammatory change in 15 presvmptomatic HIV cases, in addition to CNS viral
genetic analysis. The subjects had died of causes unrelated to HIV and no evidence
of HIVE or HIV associated neuropathology was found at post mortem; none had
received anti-retroviral therapy. Perivascular CD8 lymphocytes were found in small
numbers in all HIV cases and 3 cases showed large numbers of perivascular cells,
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extending to the parenchyma in one of these cases. A correlation was shown between
the degree of CD8 infiltration and both viral load and markers of immune cellular
activation - CD 14, CD 16 and CD68.
HIV-1 specific cytotoxic T-cells are found in the blood ofHIV positive patients and
are thought to be responsible for viral control until the late stages of the disease
(Brander and Riviere 2002). In children, a falling blood CD8 T-lymphocyte count
and a rising monocyte count were found to be predictors of HIV-1 progressive
encephalopathy (Sanchez-Ramon et al. 2003).
Another aspect of CD8 immunopathology, mentioned briefly in Chapter 1, is the
immune reconstitution syndrome (IRIS), in which HIV infected patients on HAART
suffer severe relapse of their disease. The most significant CNS post mortem finding
in this condition is perivascular and parenchymal accumulation of large numbers of
CD8 T-lymphocytes (Miller et al. 2004). This is thought to be due to the abrupt
recovery of a severely depleted peripheral CD8 lymphocyte population and its
subsequent influx into a relatively unprotected CNS (Berkeley et al. 2008).
B lymphocytes and HIV infection
Very little was known about CD20 lymphocytes (B-lymphocytes) in the brain until
2003, when a seminal paper was published, documenting not only the discovery of
B-lymphocytes in normal brain but also their presence in several groups of HIV
positive subjects (Anthony et al. 2003). In the normal adult brain, B-lymphocytes
were found in very low numbers in all regions of the brain and were truly
parenchymal in location. These cells possessed an activated phenotype, expressing
CD79a. In asymptomatic HIV subjects compared with controls, they were found in
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increased numbers in both the perivascular and parenchymal compartments.
Increased numbers of perivascular T-cells in a similar group of subjects had been
noted in previous studies (Bell et al. 1993) (Tomlinson et al. 1999). In some AIDS
subjects in whom blood CD4 and CD8 lymphocyte counts had fallen to low levels, a
decline in perivascular and parenchymal B lymphocytes to negligible proportions
was noted. This finding was in accordance with a similar scarcity of T lymphocytes
noted in AIDS cases (Bell et al. 1993) (Bell et al. 1996). In contrast, a subset of
AIDS subjects was found to have marked pleomorphic lymphocytic collections in the
perivascular compartment. In these loci B cell numbers were increased. The
significance of these aggregations was uncertain - it was not thought to be a pre-
lymphomatous condition since the distribution was diffuse rather than focal, and in
primary CNS lymphoma (PCNSL) such collections are uncommon away from
lymphomatous foci. Furthermore, the B cells in such collections were Epstein-Barr
virus (EBV) negative. The authors also felt that these pleomorphic collections were
unlikely to be an extension of the perivascular cells seen in asymptomatic cases, but
rather represented a separate process.
Microglia/macrophages and HIV infection
The general principles of entry for immune cells into the CNS are considered in
Chapter 1, and additional factors probably operate in respect of monocytes. In late
HIV infection, the increased numbers of monocytes in the circulation (cf. decreased
numbers of lymphocytes at this stage) favours increased migration of monocytes to
the brain (Pulliam et al. 1997).
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The essential features ofmicroglial micro-anatomy and physiology and their role in
the pathogenesis of HIV infection were considered in Chapter 1. As regards their
proportion in the human brain, various figures are quoted, such as 12% of the total,
(Sedgwick et al. 1991), 15% in some parts of the CNS (Hauwel et al. 2005) and 5-
10% in HIVE (Fischer-Smith et al. 2004). Microglia are the resident immune cells
of the brain and have a very low turnover in health. They exist in a resting state as
cells with a ramified morphology and there is no overlap of individual microglial
territories. In the absence of stimulation of any kind, their resting state is regulated
by astrocytic secretion of a molecule known as macrophage stimulating factor (M-
CSF) (Eder and Fischer 1997). Neurons also suppress activation of microglia through
the action of neurotrophins. Interaction with T-cells may result in marked reciprocal
activation, depending on the circumstances (Benveniste et al. 2004). Quiescent
microglia express immune receptors and ligands at very low levels. A variety of
stimuli can cause activation and these include trauma, bacterial lipopolysaccharide
(LPS), DNA and viruses (Lokensgard et al. 2000). A change occurs to a more
rounded phenotype, with reduced processes, and surface receptors, including Toll¬
like receptors (TLRs) are upregulated. TLRs are a family of receptors akin to the
Toll receptors of the much studied fruit fly Drosophila, which recognize molecules
associated with bacterial pathogens. These in turn trigger the secretion of cytokines
such as TNFa, and interleukins 6 and 10 (Bsibsi et al. 2002)
Other important secretory products of microglia include the matrix
metalloproteinases (MMPs). These are a family of proteolytic enzymes associated
with the extracellular matrix. Activation results in damage both directly, and also
199
following the conversion of TNF precursor into active TNF. The MMPs are
implicated in BBB breakdown and tissue destruction in HIV (Ghorpade et al. 2001).
In addition to the deleterious effects ofmicroglial activation, it should be noted that
there is also a protective role for microglia (Gras et al. 2006) through the glutamate
cycle though the dynamics of this process are not yet fully understood.
In activation, a complex and dynamic situation exists in which the whole spectrum
of microglial function may be displayed including antigen presentation, pro- and
anti- inflammatory activity, migration and proliferation (Benveniste 1998). In vitro
studies have shown that microglia can, through auto-secretion of molecules such as
IL-1 (3 and IL-4, stimulate self proliferation. In HIV infection, whether or not a
microglial cell is infected, activation may occur. Early infection of microglia is
believed to occur and since microglia are long lived, the virus can remain in a latent
state for many years, suppressed by both systemic (Sadagopal et al. 2008) and local
innate immune control (Sopper et al. 1998). These controls eventually fail, probably
because of falling CD8 counts and rising monocyte levels in the blood, and local
factors, which may include positive feed-back loops (Wilt et al. 1995). In the
increasingly rich cytokine CNS microenvironment, latent virus is awakened. TGFp
has been shown to change the viral long terminal repeats (LTR) in astrocytes (Coyle-
Rink et al. 2002) and IL-4 and IL-10 can cause increased viral replication in
microglia (Wang et al. 2002).
The formation in HIVE of the pathognomic multinucleate giant cells is believed to
arise from the fusion of infected microglia (Michaels et al. 1988). Microglial
nodules, also a feature of HIVE, should perhaps be termed inflammatory nodules
(Vintners 2008) as they contain other cell types, including CD8 lymphocytes.
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The biology of the monocyte/macrophage/microglial populations has been of
crucial importance in the understanding of neuroAIDS from the outset of the
epidemic. Interest was focussed initially on the function of the infected
monocyte/macrophage as a vehicle for transport, and then as a reservoir of infection,
sequestered from the normal surveillance of the immune system. In recent years the
emphasis has been on the relationship between activated and infected CNS
macrophages and microglia, their production of toxic cytokines and viral products,
and parenchymal damage. As HIV positive subjects survive longer on HAART, and
neurodegenerative conditions such as Alzheimer's disease become superimposed,
there is a need to explore the relationship on economic grounds as well as those of
science.
Confusion exists regarding the terminology of macrophage populations and
disagreement as to which marker detects which cell type, and whether or not
activation is present (Williams et al. 2001; Williams et al. 2001; Fischer-Smith et al.
2004). There seems to be a consensus that CD68 detects all activated cells of
monocyte/macrophage lineage, including microglia (a fine point being when does an
activated microglial cell become a macrophage?). CD68 may not detect resting
microglia, since the markers CD 16 and MHC class II may occasionally detect higher
levels in AIDS subjects lacking HIVE (Anthony et al. 2005).
CD 14 is generally accepted as a marker for perivascular macrophages. The term
perivascular cell could apply equally to macrophages and microglia as both occur in
a perivascular position. The microglia in such a locus share with astrocytes a small
percentage (5-13%) of the surface area of the BBB, by means of end feet (Lassmann
and Hickey 1993). These cells should be termed parenchymal microglia according to
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one author (Williams et al. 2001). However parenchymal microglia can also express
low levels of CD 14, both under in-vitro and in-vivo conditions (Becher and Antel
1996).
The situation regarding CD 16 expression is no less complex. Perivascular and
parenchymal cells that are CD 16 positive are probably a heterogenous populaton
derived from monocytes recently recruited from the blood, activated and sometimes
infected perivascular macrophages, and activated parenchymal microglia (Fischer-
Smith et al. 2004).
As regards the microglial cell type which is principally infected, both at initial
infection and in the late stages of AIDS, opinion differs. In a very carefully
controlled study of simian immunodeficiency virus (SIV) there seemed little doubt
that the perivascular macrophage population, rather than the parenchymal microglia,
was the major repository of HIV infection (Williams et al. 2001). This finding was
supported by a study of HIVE cases in which HIV p24 immunostaining was located
in CD 14 positive cells in both perivascular and parenchymal sites (Fischer-Smith et
al. 2001). However Cosenza (Cosenza et al. 2002) considered that the majority of
productively infected cells were parenchymal microglia.
The CNS parenchymal changes in HIV/AIDS in children
Naturally the opportunities to study the pathological changes in the CNS of pre-
symptomatic individuals are limited and the few published studies are of small
numbers of subjects, usually drug dependent individuals (Gray 1997), and occasional
single case studies (Lenhardt et al. 1988). In 4 drug dependent pre-symptomatic
cases (Budka 1991), compared with a similar group of HIV negative controls,
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conspicuous differences included the much greater degree and extent of vascular
inflammation, myelin pallor and astrocytic gliosis in the HIV positive group.
Perivascular cuffing was a consistent finding, associated with small parenchymal or
leptomeningeal vessels, especially veins. Nothing is known regarding the
neuropathology of the early stages ofHIV infection in children.
Regarding the symptomatic stages of AIDS, much of our knowledge of the changes
in late HIV infection stems from post-mortem studies conducted in the USA before
the availability of highly active anti-retroviral therapy (HAART). The first study to
document the CNS appearances in children with AIDS (Epstein et al. 1985)
provided the clinical details of four children aged from 9 months to 11 years, who
had developed neurological illnesses, associated with immunodeficiency. Three of
these children died and cerebral atrophy was found in all. Microscopical examination
showed the presence ofmultiple foci of microglial cells, present throughout the brain
and particularly in the basal ganglia, thalamus and brain stem. In one case these
nodules had necrotic centres. Gliosis was prominent in one case, which also showed
marked neuronal loss. Cytomegalovirus (CMV) was present in another.
A large post-mortem study of 268 AIDS patients in 1991(Kure et al. 1991)
included 31 infants and children. Sub-acute AIDS encephalitis was found in 26% of
adults and in 48% of paediatric brains. HIV antigen gp41 testing in a sample of 100
adults and 20 paediatric brains was positive for 78% of the former and 40% of the
latter. Opportunistic infections were uncommon in paediatric brains compared with
adults and were restricted to 2 cases of CMV encephalitis. Brain weight was
generally reduced and in some cases this reduction was marked, and associated with
extensive gliosis in the white matter. Microcalcification in the basal ganglia was the
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most frequent finding and in about a third of the children, microglial nodules and
multinucleated cells were present. Myelination was frequently defective due either to
delay, or to myelin loss, which appeared multifocal. In those spinal cords that were
examined, myelin was reduced in the corticospinal tracts. Six of the 31 paediatric
brains showed the presence of lymphomas and all were B-cell tumours.
A difference was noticed between younger and older children in respect of HIV
antigen detection and inflammation, both ofwhich were commoner in older children.
The authors surmised that this might be related to factors such as lower TNF levels
and relative immaturity of the microglial population in younger children.
A further large study of paediatric HIV neuropathology, in the period before
HAART, was published in 1993 (Dickson et al. 1993). The findings of 45 autopsies
were recorded, for brain and spinal cord in 18 cases, for the brain only in 24 cases
and the spinal cord only in 3 cases. All cases were symptomatic. Reduced brain
weight with atrophy was a common finding. Gliosis with basal ganglia
microcalcification was also common. HIVE, diagnosed on the basis of microglial
nodules and multinucleate cells, was judged to be present in just over 60% of brains.
As noted in the previous study, a trend towards greater levels of inflammation in
older children was detected. Cerebrovascular pathology was found in 22 (52%) of
I
cases, chiefly in the form of anoxic-ischaemic encephalopathy. Lymphomatous
deposits were found in 8 brains - the youngest being only six months of age.
Opportunistic infection was uncommon and only CMV was found.
The next large study to be published was on HIV/AIDS in children in Africa,
namely the 1997 study of Bell et al (Bell et al. 1997), from which the present study
derives. Following the publication of the general pathology and baseline
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neuropathology findings, it was clear that this cohort warranted further investigation
with a wider immunohistochemical panel, to determine both the CNS inflammatory
infiltrates associated with HIV infection and the associated white matter reactions.
The following hypothesis was formulated:
The HIV positive children would show a higher level of activated microglia and
infiltrating lymphocytes than that shown by the HIV negative children, despite the
high level of background brain pathology in the latter group.
Accordingly, in this Main Study, the aim was to quantify and compare
microglia/macrophages (innate neuroimmune system) and lymphocytes (adaptive
neuroimmune response) in selected HIV positive and negative children and to review
the associated changes in axons and astrocytes.
4.2 - Materials and Methods
In this study two different parts of the brain, the basal ganglia and the
hippocampus, were examined in an attempt to define the degree and extent of
inflammation in HIV negative and positive children; and both grey and white matter
were examined to try to detect any differential involvement of these parts in
neuroinflammation. Because of differing block availability for these two brain areas,
the cases used differ very slightly, (Group Al, basal ganglia blocks, n=40 and Group
A2, hippocampus, n=40), but the cases were age matched. Groups Al and A2 were
each made up of 20 HIV negative and 20 positive cases. A battery of immunostains
was applied, as described in Chapter 2. The sections were then assessed in several
ways. The haematoxylin and eosin sections, and those stained by Luxol fast blue,
were examined by simple microscopy with a view to identifying the main
pathological features and degree of myelin pallor, if present. The degree of
microglial and macrophage activation (area of staining-sq.pm/4 sq.mm of section)
was determined by image analysis for CD16 and CD68. The assessment of CD14
staining was by simple grading partly because of potential confounding CD14
positivity in intravascular cells (less of a problem with CD68 and not a problem with
CD 16) and partly, the diffuse pattern of CD14 staining precluded precise cell counts.
The presence and distribution of lymphocytes was assessed by simple counting of
CD8 and CD20 positive cells. In contrast to microglia, the defined cell outlines of
lymphocytes facilitated simple counting.
Astrocyte activation was assessed and graded simply according to the intensity and
pattern of distribution of glial fibrillary acidic protein (GFAP) positivity. Axonal
pathology was detected by p amyloid precursor protein (PAPP) immunostaining and
recorded as to its presence and extent.
The results for all stains were tabulated, displayed and analysed using the statistical
software, Minitab.
The 40 cases for the main study, chosen from the original cohort, did not include
the 10 initial study cases. Children aged 11 and 12 years were also excluded from the
main study because they were much older than the majority of cases in the original
cohort. Group Al, consisting of basal ganglia blocks, often referred to the Tables as
"BG", was selected in the following way: seven HIV negative and seven positive
cases, each set drawn from the youngest and middle age groups in the cohort, while
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six HIV negative and six HIV positive cases were chosen from the oldest age group
(n=40). These cases are listed in Table 4.2.1, in which the cases are sorted by age.
This table also contains the set of the hippocampal blocks (Group A2), which differs
in composition slightly because of block availability. Table 4.2.1 contains 48 cases
and there are 32 cases in common between Groups A1 and A2. The pathology
findings, available from the results of routine staining as described in the original
study, are also listed. Tables 4.2.2 and 4.2.3 show the basal ganglia set (Group Al)
and hippocampus set (Group A2) respectively, sorted on HIV status, together with
general neuropathology findings. In Tables 4.2.2 and 4.2.3, the cases are listed in
order of acquisition to the original study, and no longer by age. This is the order in
which cell quantitation results are provided in later Tables in the Results.
From both Groups Al and Group A2, a subset of 5 HIV negative and 5 HIV
positive cases was selected on the basis of having no significant neuropathological
findings. The case numbers for these subsets are shown in Tables 4.2.2 and 4.2.3.
This grouping allowed comparison between HIV negative and HIV positive cases
without the very diverse and major CNS pathology present in most of the other cases.
These subsets appear in Figures and Tables and are designated Groups BI and B2
(Tables 4.2.2 and 4.2.3). Sampling of grey matter for histological assessment and
quantitation was from the hippocampal and parahippocampal gyrus, and of white
matter from as widely-spaced areas as possible - the total area sampled being 4 sq.
mm. for each case.
r
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Table 4.2.1 Joint basal ganglia and hippocampus set sorted on age
Case
No Age* Sex HIV BG* Hippo*
CNS pathology findings on routine
staining
c82 0.2 F + Y Y cerebellar infarct & microhaemorrhages
C157 0.2 M + Y Y purulent meningitis
C77 0.3 F - Y Y possible septicaemia
C54 0.4 M - Y Y meningoencephalitis & infarcts
Clio 0.4 M + Y Y toxoplasmosis
CI 13 0.4 M - Y N no significant findings
C129 0.4 F + Y Y low grade lymphocytic infiltrate
C131 0.4 M + Y Y low grade encephalitis
C150 0.4 F + Y Y nothing significant
C52 0.5 M - N Y no significant findings
C89 0.5 F - Y Y purulent meningoencephalitis
C94 0.5 M - Y Y no significant findings
C100 0.5 F - Y Y no significant findings
C109 0.5 F - Y Y purulent meningitis
C23 1.5 M - N y no significant findings
C60 1.5 F - Y Y no significant findings
C74 1.5 F - Y N no significant findings
C93 1.5 F - Y Y no significant findings
C125 1.5 M + Y Y no significant findings
C126 1.5 F + Y Y no significant findings
C33 1.6 F - Y Y possible septicaemia
C50 1.6 F - Y Y no significant findings
C59 1.6 M - Y Y purulent meningitis
C76 1.6 M - Y N no significant findings
C91 1.6 M + Y Y low grade lymphocytic infiltrate
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C121 1.6 M + Y N cerebral oedema
C5 1.7 F + Y Y no significant findings
C55 1.7 M + Y Y low grade lymphocytic infiltrate
C51 1.8 F + N Y low grade lymphocytic infiltrate
C86 1.8 F - N Y no significant findings
C128 1.8 F + Y N low grade lymphocytic infiltrate
C70 2.1 F + N Y low grade lymphocytic infiltrate
C63 2.5 F - N Y no significant findings
CI 17 2.9 M - Y Y cerebral malaria
CI 22 3.3 F + Y Y low grade lymphocytic infiltrate
C8 3.5 F + Y Y subtle widespread wm damage
C62 4.0 F + Y Y low grade lymphocytic infiltrate
C67 4.0 F - Y N no significant findings
CI 01 4.0 M - Y Y possible septicaemia
CI 40 4.0 M + Y Y no significant findings
C24 5.0 M + Y Y measles encephalitis
C42 5.0 F - Y N no significant findings
C57 5.0 F - Y Y no significant findings
CI 24 5.0 M - N Y no significant findings
C9 5.1 F + Y Y medullitis
C16 5.3 F + N Y no significant findings
CI 04 6.0 M - Y Y cerebral malaria
C152 6.4 M + Y N FIIV encephalitis & toxoplasmosis
r
209
Notes for Table 4.2.1
1. The basal ganglia and hippocampus sets differ slightly in composition due
to varying block availability.
2. * The ages were originally recorded in this decimal format as estimates
derived from somatic length. The limitations of this approach are considered
in the text and the format is retained here to conserve data integrity.
3. BG* refers to blocks selected as Group Al. Hippo* refers to blocks
selected as Group A2.
Table 4.2.2 - Basal ganglia cases (Group A1) sorted on HIV status and
showing the pathology findings and causes of death. The Group B1
subset cases are entered below the main HIV sets
Code Age Sex HIV
CNS pathology findings on routine
Staining Causes of death
HIV negative cases
c33 1.6 F - possible septicaemia pulmonary infarction
c42 5.0 F - no significant findings pneumonia
c50 1.6 F - no significant findings pneumonia malaria
c54 0.4 M - meningoencephalitis and infarcts no significant findings
c57 5.0 F - no significant findings lymphoma - B-cell
c59 1.6 M - purulent meningitis malnutrition
c60 1.5 F - no significant findings malaria pulmonary infarction
c67 4.0 F - no significant findings pneumonia
c74 1.5 F - no significant findings pneumonia
c76 1.6 M - no significant findings colitis
c77 0.3 F - possible septicaemia sickle cell crisis
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c89 0.5 F - purulent meningoencephalitis pulmonary abscess
c93 1.5 F - no significant findings colitis
c94 0.5 M - no significant findings no significant findings
clOO 0.5 F - no significant findings pneumonia - measles
clOl 4.0 M - possible septicaemia septicaemia
cl04 6.0 M - cerebral malaria malaria
cl09 0.5 F - purulent meningitis pneumonia
cl 13 0.4 M - no significant findings pneumonia
cl 17 2.9 M - cerebral malaria malaria
HIV negative cases for Group B1 - c50,c67,c76,c93 and cl 13
HIV positive cases
c5 1.7 F + no significant findings CMV enteritis and pneumonia
c8 3.5 F + subtle widespread wm damage pyothorax post measles
c9 5.1 F + medullitis disseminated herpes
c24 5.0 M + measles encephalitis pneumonia CMV diseminated
c55 1.7 M + low grade lymphocytic infiltrate pneumonia strongyloidosis
c62 4.0 F + low grade lymphocytic infiltrate pneumonia
c82 0.2 F + cerebellar infarct & microhaemorrhages pneumonia
c91 1.6 M + low grade lymphocytic infiltrate pneumonia strongyloidosis
cl 10 0.4 M + toxoplasmosis pneumonia measles
c 121 1.6 M + cerebral oedema pneumonia
cl22 3.3 F + low grade lymphocytic infiltrate pneumonia
cl25 1.5 M + no significant findings pneumonia
cl26 1.5 F + no significant findings TB - miliary
cl28 1.8 F + low grade lymphocytic infiltrate pneumonia
cl29 0.4 F + low grade lymphocytic infiltrate pneumonia
cl 31 0.4 M + low grade encephalitis CMV enteritis
cl40 4.0 M + no significant findings pneumonia
f
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cl50 0.4 F + no significant findings pneumonia
cl52 6.4 M + HIV encephalitis & toxoplasmosis pneumonia, interstitial
cl57 0.2 M + purulent meningitis Pneumocystis pneumonia CMV
HIV positive cases for Group B1 - c5, cl25,cl26,c!40 and c!50
Table 4.2.3 - Hippocampus cases (Group A2) sorted on HIV status and
showing the pathology findings and causes of death. The Group B2
subset cases are entered below the main HIV sets
Code Age Sex HIV CNS pathology findings on routine staining Causes of death
c23 1.5 M - no significant findings enteritis pulmonary CMV
c33 1.6 F - possible septicaemia pulmonary infarction
c50 1.6 F - no significant findings pneumonia malaria
c52 0.5 M - no significant findings pneumonia
c54 0.4 M - meningoencephalitis & infarcts no significant findings
c57 5.0 F - no significant findings lymphoma - B-cell
c59 1.6 M - purulent meningitis malnutrition
c60 1.5 F - no significant findings malaria pulmonary infarction
c63 2.5 F - no significant findings pneumonia colitis
c77 0.3 F - possible septicaemia sickle cell crisis
c86 1.8 F - no significant findings pneumonia
c89 0.5 F - purulent meningoencephalitis pulmonary abscess
c93 1.5 F - no significant findings colitis
c94 0.5 M - no significant findings no significant findings
clOO 0.5 F - no significant findings pneumonia - measles
clOl 4.0 M - possible septicaemia septicaemia
cl04 6.0 M - cerebral malaria malaria
c!09 0.5 F - purulent meningitis pneumonia
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cl 17 2.9 M - cerebral malaria malaria
cl24 5.0 M - no significant findings pneumonia
HIV negative cases for Group B2 - c23,c50,c52,c57 and c93
c5 1.7 F + no significant findings CMV enteritis and pneumonia
c8 3.5 F + subtle widespread wm damage pyothorax post measles
c9 5.1 F + medullitis disseminated herpes
cl6 5.3 F + no significant findings pneumonia - interstitial
c24 5.0 M + measles encephalitis pneumonia CMV disseminated
c51 1.8 F + low grade lymphocytic infiltrate malaria fatty liver
c55 1.7 M + low grade lymphocytic infiltrate pneumonia strongyloidosis
c62 4.0 F + low grade lymphocytic infiltrate pneumonia
c70 2.1 F + low grade lymphocytic infiltrate pneumonia
c82 0.2 F + cerebellar infarct & microhaemorrhages pneumonia
c91 1.6 M + low grade lymphocytic infiltrate pneumonia strongyloidosis
cllO 0.4 M + toxoplasmosis pneumonia - measles
cl22 3.3 F + low grade lymphocytic infiltrate pneumonia
cl25 1.5 M + no significant findings pneumonia
cl26 1.5 F + no significant findings TB - miliary
cl29 0.4 F + low grade lymphocytic infiltrate pneumonia
cl 31 0.4 M + low grade encephalitis CMV enteritis
cl40 4.0 M + no significant findings pneumonia
cl50 0.4 F + no significant findings pneumonia
cl 57 0.2 M + purulent meningitis Pneumocystis pneumonia CMV
HIV positive cases for Group B2 - c5,cl25,cl26, cl40 and cl50
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Sections were stained with Luxol fast blue (LFB) and assessed for overall staining
on the light box (see Chapter 2), at a distance and in random distribution; on this
basis they were graded into 3 categories:
Grade 1 - marked local or general pallor
Grade 2 - moderate local or general pallor
Grade 3 - normal intensity and distribution of LFB
The results for the 3 groups were then tabulated and compared with their ages.
Assessment of Immunohistochemistry
Sections were examined blinded as to age, sex, HIV status and recorded pathology
findings. The immunostained sections were screened under low power to assess the
general pattern of staining and then under high power to examine any specific areas
of interest. Quantitative and/or qualitative assessment was then performed for the
individual immunostains according to different protocols, depending on the
complexity of the staining patterns.
The microscope used for routine screening was an Olympus BH2.
The image analysis equipment used was an Olympus BX40 microscope with an
automatic stage video linked to a computer, using Image-Pro 4.5 software supplied
by MediaCybernetics.
CD8: these sections were quantified by counting CD8 positive cells in the
perivascular and parenchymal zones, in basal ganglia and hippocampus. As it was
sometimes difficult to be certain of the exact location of the perivascular cells - some
might have been intra-luminal and others intra-mural - the term "vessel associated
cells" was used in some figures and tables. The counts were tabulated.
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CD20: in these sections the CD20 positive cells were counted and tabulated for the
perivascular zones and parenchymal zones of the basal ganglia and hippocampus.
CD14: these sections were assessed by a simple grading system for the whole section
and tabulated;
1 = sparse perivascular cells
2 = increased perivascular cells but no parenchymal staining
3 = slight parenchymal staining
4 = moderate parenchymal staining
5 = extensive and dense staining with or without added local
features, for example, nodules or necrosis.
CD16: these sections were assessed by image analysis and tabulated.
CD68: these sections were assessed by image analysis and tabulated.
HLA: the pattern of staining was found to be very similar to that for CD68 and no
formal quantitation was performed.
MBP: these sections were screened under low power for distribution of staining.
PAPP: these sections were screened for the presence and distribution of staining and
the results tabulated. A simple scoring system was adopted, from grades 1-3.
1 = minimal expression
2 = a small amount of positivity
3 = a moderate amount of staining either in extent or intensity.
GFAP: these sections were screened for evidence of increased GFAP activity in
terms of intensity and distribution. The grading categories ranged from 1-4 and the
results were tabulated.
1 = absent to minimal expression
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2 = slight expression
3 = moderate expression
4 = extensive and strong expression
Image Analysis Protocol
A total sampling section area of 4sq. mm was chosen following discussion with
experienced workers in this field. This equated well with the total area for 10
frames, using the xlO objective lens:
The single frame dimensions were -
Frame width = 740.441|am, height = 553.183p.m. and area = 409,585.3 sq.pm. Thus
the total area for 10 frames = 4.095 sq. mm.
Generally, 5 separate areas were sampled with 2 frames, side-by-side, per area.
Occasionally, if local tissue configuration dictated, for example if the internal
capsule fascicles were especially narrow, a different frame arrangement was chosen.
Sampling was as random and as wide as possible. The grey matter sampled was in
the caudate nucleus and the white matter in the internal capsule. In the hippocampus,
the grey matter sampled was that of the hippocampal and parahippocampal gyrus and
the white matter from adjoining tracts.
An image was captured within the chosen area and the following steps were taken.
The "count/size option" was selected from "measure" in the main soft-ware menu. In
this dialogue box the "manual" option was chosen for the command "select colours".
This opened another dialogue box named "segmentation". In this box, the sensitivity
was set at 4. The stained objects or areas of interest were highlighted using an on¬
screen pointer and the sequential selection allowed the stained areas or objects to be
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"filled" or captured. As regards cut-off, this was catered for by a reverse option that
allowed a return to the previously selected stained areas if minimally stained or
unwanted penumbral parts had been included. In this way staining that was
considered as background could be largely excluded .
The dialogue box was then closed and on return to the count/size box the stained
areas or objects were enumerated. Selection of the "view" option opened the
"statistics" dialogue box where the individual areas and sum total were recorded. For
each case, the result was expressed as the area stained in sq.pm per 4 sq.mm of
section area scanned - which did not change between cases.
In counting cells, a total sampling area of 4sq. mm was chosen and determined by
the use of an eyepiece graticule. Using a x20 objective lens, and a squared eyepiece
graticule, a sample field had an area of 0.785 sq.mm. Five fields of 0.785sq.mm and
one part field of 0.0754 sq.mm. gave a total area of 3.925 + 0.0754 = 4.0004 sq.mm.
Random fields were selected by using out-of-focus movement in between counting
areas.
4. 3 - Results
Overview of cases selected for this study
In tables 4.2.2 (basal ganglia) and 4.2.3 (hippocampus) the general neuropathology
pathology findings are documented for the separate HIV negative and positive cases,
showing that there are marked differences, as expected, between the two groups.
The group of HIV negative basal ganglia set included 4 cases of meningitis, 2
cases of possible septicaemia, 2 of malaria, and 11 cases for which there were no
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significant findings. The group of HIV positive basal ganglia set included 2 cases of
AIDS with toxoplasmosis, one of which showed HIVE at the original screening in
1997 (Bell et al. 1997), 1 case of meningitis, 1 case of measles encephalitis, 7 cases
showing low grade lymphocytic infiltrate and 5 cases for which there were no
significant findings.
For the hippocampus set, because some of the blocks corresponding to those of the
basal ganglia set were unavailable, some substitutions were necessary. For example,
the HIVE case cl52, and a case showing low grade lymphocytic infiltrate, cl28,
from the basal ganglia set were replaced in the hippocampus set with two cases
showing low grade lymphocytic infiltrate, c51 and c70. Four of the cases showing a
low grade lymphocytic infiltrate occurred in the youngest age group, aged 2 years or
less. The sexes are almost equally distributed in the set, 23 females and 19 males.
Staining Results
Haematoxylin and Eosin: Review of these sections confirmed the presence of
neuropathological findings reported in the original study (Figs 4.3.1 and 4.3.2). In
the original study describing the neuropathology of this paediatric African cohort




Table 4.3.1 Number of cases showing white matter pallor/gliosis in
original description (Bell et al. 1997)
HIV Negative Children HIV Positive Children
Age in months Gliosis and/or Pallor Age in months Gliosis and/or Pallor
l-14m (n = 36) 12 (33%) l-14m (n = 29) 6 (21%)
>15m (n = 42) 14 (33%) > 15m (n = 48) 7 (15%)
Luxol Fast Blue: These stained sections were very useful for displaying the general
tissue architecture. There was naturally a variation in tissue block boundaries given
the age range and the difficulties under which the post mortems were performed. In
the basal ganglia set, the internal capsule was present in all of the sections but other
structures, such as the corpus callosum, external capsule, septum and anterior
commissure, were variable in their inclusion. The comparison of sections on the
light box was used for an overall assessment of pallor. The results are shown in
Appendices 11 and 12.
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Table 4.3.2 - Results Mann-Whitney tests for LFB grades
LFB Grades
Basal Ganglia Hippocampus
Group At Group A2
(n=40) medians p values (n=40) medians p values
HIV -ve 2 HIV -ve 2
HIV +ve 2 p=0.666 HIV +ve 2 p=0.841
Group B1 (n=5) Group B2 (n=5)
HIV -ve 3 HIV -ve 2
HIV +ve 2 p=0.212 HIV +Ve 2 p=l .000
Table 4.3.2 shows the summary statistics for the LFB grades and no significant
difference was detected between HIV negative and positive grades in any of the
groups.
Myelin Basic Protein: The sections stained with myelin basic protein displayed the
white matter in the same way as Luxol fast blue and screening of these sections
provided no additional information.
P-APP: The grades for PAPP positivity are shown in Appendices 13 and 14, and
Fig 4.3.3 shows the pattern of staining when present.. Only about a third of HIV
negative and HIV positive cases showed evidence of PAPP reactivity and, in these, it
was mostly of limited extent and positivity - no tabulation is provided here but it
should be noted (see Appendix 13) that for the six HIV negative and six HIV positive
caes showing staining in the basal ganglia the grading results were significantly
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greater for the HIV negative cases p=0.029 (Mann-Whitney). In general, HIV
negative cases showed more positivity than HIV positive cases. There was no
obvious correlation with pathology, except that the case with meningoencephalitis
and infarcts, c54, showed grade 3 |3APP positivity. There was no obvious
relationship with GFAP reactivity. Only one of the two malaria cases was positive.
Case c93 showed neuronal positivity in the cortex and in the caudate nucleus.
Glial Fibrillary Acidic Protein: The general staining was satisfactory, all but one
section showing positivity. The pattern varied from a delicate pattern of restricted
expression, as in c42, to a strong and generalised reaction, Grade 4, as in cl21, in
which there was pronounced staining in the grey matter as well. The results of
grading were tabulated (Appendices 15 and 16). The pattern of GFAP positivity is
shown in Figs 4.3.4 and 4.3.5. The results of Mann-Whitney testing for GFAP
positivity in the basal ganglia (Group Al) and hippocampus (Group A2) of the 20
HIV negative and 20 HIV positive cases, and the subsets lacking pathology (Groups
B1 and B2) are shown in Table 4.3.2.and no significant differences were detected.
The means for the HIV positive cases were slightly greater than the corresponding
means for HIV negative cases in the basal ganglia, HIV positive 1.9 (0.79), HIV
negative 1.55 (0.69), and in the hippocampus, HIV positive 2.65 (1.09), HIV
negative 2 (0.95), which is suggestive of a slight trend but this did not reach
significance.
r




Group A1 Group A2
(n=40) medians p values (n=40) medians p values
HIV -ve 1 HIV -ve 2
HIV +ve 2 p=0.151 HIV +ve 2.5 p=0.120
Group B1 (n=5) Group B2 (n=5)
HIV -ve 2 HIV -ve 1
HIV +ve 1 p=0.908 HIV +ve 4 p=0.154
Table 4.3.3 shows the summary statistics for the GFAP grading and no
significant difference between HIV negative and positive cases was detected in



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Notes for Tables 4.3.4 and 4.3.5
1. Key - bg=basal ganglia, hippo=hippocampus, grd=grade, gm=grey
matter, wm=white matter, pvc=perivascular cells and par=parenchymal
cells
2. Asterisks,*, denote values not available for technical reasons
3. Decimal points in means and standard deviations generally to first point
if value below 10 otherwise to nearest whole number
4. For some CD 14 cases it was difficult to assign a grade because of
marked variation within the section - in these cases an intermediate
grade was given, e.g. 4.5.and the default value would be the upper
grade e.g.
5. Standard deviations are given in brackets after the means e.g.7.6 (5.7)
CD8: The results of cell counts are shown in Tables 4.3.4 and 4.3.5 and staining
patterns are illustrated in Figs 4.3.6 - 4.3.8. Perivascular CD8 cells were identified
and counted in almost all HIV negative cases, in basal ganglia and hippocampus,
and for both grey matter and white matter. The mean counts, with standard
deviations, for the basal ganglia grey and white matter were approximately equal,
respectively 7.6 (5.7) and 6.6 (5.1), but in the hippocampus the counts for the white
matter were appreciably higher - 10 (7) compared with 5 (5). An elevated count in
the grey matter was not necessarily accompanied by a similar rise in the white
matter, and vice versa, but quite often the counts are approximately equal. In the
basal ganglia set, 7 cases showed counts of 10 or greater. In the hippocampus, 10
cases show counts of 10 or more for the grey matter or white matter, or both. Some
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of these are cases in common with the basal ganglia set but there are differences, for
example in respect of the possible septicaemia cases - one showing higher values in
the basal ganglia set and the other in the hippocampus set. Parenchymal CD8 cells
were found in very few basal ganglia - in the white matter in five cases and in the
grey, in 4 cases. Most of these cases also showed higher perivascular counts. In the
hippocampus, the situation was much the same except there was a high count in the
grey matter case, clOl, which had signs of possible septicaemia. Perivascular cells
in the basal ganglia of HIV positive cases showed approximately equal counts in
grey and white matter. The respective means and standard deviations were 24 (15)
and 29 (22). Cases previously recorded as having a low grade lymphocytic infiltrate,
and the AIDS case with toxoplasmosis, cllO, showed particularly high CD8 counts
in the grey matter but so also did 2 cases with no recorded pathology. Generally the
counts for the white matter mirrored the grey matter findings. Counts for the HIVE
case, cl52, proved to be the highest for both grey and white matter. The lowest
counts were seen in cl52, which had a cerebellar infarct and microhaemorrhages,
and in cl21, which displayed cerebral oedema. A case with subtle widespread white
matter damage, c8, which proved later to have very high values in the CD68 results,
showed some elevation in the CD8 counts, but only in the basal ganglia. The counts
for the measles encephalitis case, c24, were below the means for grey matter and
white matter, for both the basal ganglia and hippocampus. In the hippocampus, the
mean counts for the grey matter, 24 (34) and white matter, 50 (62) differed
appreciably. The higher counts in the grey matter, like those in the basal ganglia,
were seen in the low grade lymphocytic infiltrate cases and, much higher, in the
AIDS case, cllO. The higher perivascular counts in the white matter generally reflect
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those in the grey but in some cases were appreciably greater, as in c91, a count of
244 against 114, and for cllO, a count of 196 against 117. The standard deviations
are greater than the means for the CD8 counts in the hippocampus. Parenchymal
CD8 counts in the grey and white matter of the basal ganglia were high but were
even more numerous in the white matter, 16 (34) and 56 (88) respectively. The
corresponding means for the hippocampus are 12 (26) and 17 (29). In all of these
counts, the standard deviations are greater than the means. Four cases showed
particularly high parenchymal counts in the grey matter. Two of these were AIDS
cases (cllO and cl52), c91 had a low-grade lymphocytic infiltrate, and cl57 had
purulent meningitis. Each of these had even higher counts in the white matter, some
by a factor of 2 or more. Three other cases had counts greater than 50 and all had
low-grade lymphocytic infiltrate cases. In the hippocampus, the highest count for the
grey matter was 114, in the AIDS case, cllO. The other cases with counts above the
mean of 12 (26) included 3 cases of low-grade lymphocytic infiltrate and the case of
purulent meningitis, cl57. White matter parenchymal counts revealed 4 cases that
had values above the mean of 17 (29), one being the AIDS case, cllO, as in the grey
matter counts above, and the other 3 all showed a low-grade lymphocytic infiltrate.
The Mann-Whitney tests (Table 4.3.6) comparing the counts for perivascular CD8
cells in HIV negative and positive groups, confirmed that they were significantly
greater in HIV positive basal ganglia in Group Al, (gm p=0.001 & wm p=0.000) and
for parenchymal CD8 cells, in both Group Al (gm p=0.001 & wm p= 0.000) and in
Group B1 for white matter only (p=0.034).
Results for the hippocampus (Groups A2 and B2) were similar. In Group A2,
perivascular CD8 cells were significantly more numerous in both grey and white
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matter (gm p=0.002, wm=0.006) as were parenchymal CD8 cells (gm p=0.003, wm
p=0.006). In Group B2, a significant increase in HIV positive cases was detected for
parenchymal CD8 cells only in the white matter (p=0.011). In Table 4.3.6,
perivascular is abbreviated to pv, and parenchymal to par, and significant values are
shown in bold type.
Figs 4.3.19, 4.3 20, 4.3 29 and 4.3.30 show these results in the form of boxplots for
basal ganglia and hippocampus. The scatterplots, Figs 4.3.39 and 4.3.40 show
reasonable correlation between the grey and white matter for both basal ganglia and
hippocampus but are distorted by outlying values.
Table 4.3.6 - Mann-Whitney test results for CD8 counts: basal ganglia
and hippocampus
CD8 Counts CD8 Counts








A1 HIV -ve 5 5
Group
A2 HIV -ve 3 9
pv cells HIV +ve 19.5 23 pv cells HIV +ve 11 32








A1 HIV -ve 0 0
Group
A2 HIV -ve 0 0
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par cells HIV +ve 1 13 par cells HIV +ve 2 4








B1 HIV -ve 5 7
Group
B2 HIV -ve 3 14
pv cells HIV +ve 17 20 pv cells HIV +ve 6 24








B1 HIV -ve 0 0
Group
B2 HIV -ve 0 0
par cells HIV +ve 1 10 par cells HIV +ve 0 21
p value p=0.251 p=0.034 p value p=0.441 p=0.011
CD20: Results are shown in Tables 4.3.4 and 4.3.5 and are summarised in Table
4.3.7. CD positive B lymphocytes (Fig.4.3.9) were counted in a total area of 4 sq.
mm. and in two categories, perivascular cells and parenchymal cells. The
perivascular group should more correctly be termed "vessel associated cells" in view
of the difficulty in determining the exact relationship of any particular cell with the
vessel wall of capillaries. In the basal ganglia of HIV negative cases there was a
very limited presence of B-cells, both in grey and white matter. Perivascular CD20
cells were detected more frequently in the white matter than in grey, with means
(standard deviations) of 5.6 (7.8) and 2.5 (3) respectively. In this group the only high
value was detected in a case of meningoencephalitis, c54. A similar response was
seen in the hippocampus set, where the white matter mean was 5.25 (7) against that
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for the grey matter 2.1 (3). The only other case with high values and common to both
was c60, a case reported previously as having no significant findings. A few positive
cells were detected in one of the cases of malaria in the basal ganglia set, cll7, and
in both in the hippocampus set. In general, parenchymal CD20 cells were rarely
seen and no formal analysis was attempted. In the basal ganglia of the HIV positive
cases, the highest count in the white matter was in the HIVE case, and lower counts
were seen in the low-grade lymphocytic infiltrate cases and case cl57 , with purulent
meningitis. No CD20 cells were seen in the other AIDS case, cllO, or in the measles
encephalitis case. In the hippocampus, higher counts are seen in the cases showing
low-grade lymphocytic infiltrate. The counts for the AIDS case, cllO, and for the
measles encephalitis case were minimal.
As regards analysis, it should be noted that the means for the grey matter vary little
between HIV positive and negative cases, in both the basal ganglia and
hippocampus, all being in the 2-3 range. For the white matter, mean values in the
basal ganglia are slightly less than those for the hippocampus, where the mean for
HIV negative cases is slightly more that for the HIV positive cases, 5.6 (7.8) as
opposed to 5.25 (7). The results are shown as boxplots in Figs 4.3.21, 4.3.22, 4.3.31
and 4.3.32. No result of statistical significance was recorded in the CD20 tables for
either basal ganglia or hippocampus - see Table 4.3.7.
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Table 4.3.7 - Mann-Whitney test results for CD20 counts: basal ganglia
and hippocampus
CD20 Counts CD20 Counts
Basal ganglia Mann-Whitney tests Hippocampus Mann-Whitney tests
gm medians wm medians gm medians
wm
medians
Group A1 HIV -ve 1.5 0 Group A2 HIV -ve 1.5 2.5
pv cells HIV+ve 2.5 0.5 pv cells HIV+ve 1 2.5
p=0.471 p=0.895 p=0.651 p=0.913
gm medians wm medians gm medians
wm
medians
Group B1 HIV -ve 2 0 Group B2 HIV -ve 2 1
pv cells HIV +ve 3 1 pv cells HIV +ve 0 1
p=0.832 p=0.908 p=0.158 p=0.295
CD14: The results are shown in Tables 4.3.4 and 4.3.5 and summarised in Table
4.3.8. For CD14 the staining was generally satisfactory (Fig. 4.3.10). In the HIV
negative cases, the CD14 grades for the basal ganglia and hippocampus are quite
similar for those cases that were common to Groups A1 and A2, and the means
(standard deviations) were 2.4 (1.2) and 2.3 (1.2) respectively. Generally the higher
grades of staining were related to the presence of significant pathology. In particular,
c54, a case with meningoencephalitis and infarcts, had a score of 5 for both basal
ganglia and hippocampus. The meningitis and malaria cases had scores above the
means in both sets, as did the possible septicaemia cases. In the basal ganglia of the
HIV positive cases, the mean score was 2.7 (1.2) and for the hippocampus, 2.5 (1).
The highest grades in both regions were in the AIDS cases, c82 with cerebellar
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infarcts and microhaemorrhages and cl57 with purulent meningitis. The grades for
the measles encephalitis case were likewise above the means. The cases with low
grade lymphocytic infiltration had scores in the middle to lower range.
Table 4.3.8 - CD14 grades: basal ganglia and hippocampus
CD14 Grades CD14 Grades


































The CD 14 results are also displayed in the boxplots, Figs 3.3.23, 3.3.24, 3.3.33 and
3.3.34.
CD16: The results are shown in Tables 4.3.4 and 4.3.5 and summarised in Table
4.3.9 and illustrated in. Staining quality was generally satisfactory (Fig 4.3.11) but in
5 cases, 3 HIV negative and 2 positive, the staining in the basal ganglia was so poor
as to preclude analysis. To balance the sets for analysis, one HIV positive case, c82,
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aged 0.2 years and with an original diagnosis of cerebellar infarct and
microhaemorrhages, was removed. This gave 17 pairs for comparison for CD 16
staining in the basal ganglia, a subset of Group A1 designated Group C (n=34). For
CD 16 staining comparisons in the hippocampus, Group A2 was used, as for all other
antibody screening.
The results for CD 16 staining in the basal ganglia of the HIV negative cases
showed mean values (standard deviations) in the white matter of 36 (31), and in the
grey matter, 25 (21). For the hippocampus, the corresponding means and standard
deviations were, for the white matter, 111 (211), and for the grey matter, 77 (84). In
the basal ganglia, two of the cases with higher values, c93 and cll3, had shown no
specific pathology on routine examination and another two, c33 and c77, were
possible septicaemia cases. Case c54, with meningoencephalitis & infarcts, also
showed higher values. The values for the malaria cases showed little difference from
the means. The reason for the difference in mean values between the basal ganglia
and the hippocampus is uncertain. It is possible that suboptimal staining in the basal
ganglia (which had made necessary the creation of a smaller subset, Group C) was a
contributory factor. Among the cases that were common to Groups C and A2, those
with high CD 16 values in the hippocampus generally paralleled those with elevated
values in the basal ganglia, except that the values were higher in Group A2. A
notable difference was that in the hippocampus, the values for one of the malaria
cases, cl04 with a grey matter value of 27 and a white matter value of 36, were little
different from, or even below, the means, while the other, cll7, showed a slight
increase (grey matter 166 and white matter 114). In the HIV positive cases, in both
basal ganglia and the hippocampus, the white matter generally shows a greater
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degree of activation than the grey. In the basal ganglia, the mean value (standard
deviation) for the white matter was 588 (867) and for the grey matter, 119 (267). In
the hippocampus, the corresponding values for white matter were 504 (1055) and for
grey, 267 (329).
Nevertheless, some very high values were seen for the white matter in the basal
ganglia, especially for the HIVE case, cl52, (3555), cl57, with purulent meningitis
(1500), and cl28, one of the cases showing low grade lymphocytic infiltrate (1343) .
Others in this category showed little evidence of activation apart from a high value
for the grey matter of c55 (637). The other findings of note were the relatively low
values for the other AIDS case, cllO, 31 and 395 for grey and white matter
respectively, and the measles encephalitis case, c24, 41 for grey matter, and 300 for
white matter.
In the hippocampus set, the higher values were generally in the cases that were
common to both sets, for example cases c8, (1053 and 385), and cl57, (633 and 712)
for grey and white matter respectively. The same was true for the lower values for
the case with measles encephalitis and for the AIDS case, cllO, 186 and 236
respectively for grey and white matter.
The differences for CD 16 staining values, between HIV positive and negative cases,
are statistically significant for the white matter in the basal ganglia, p=0.030, and the
grey matter and white matter in the hippocampus, p=0.037 and p=0.004 respectively.
However, comparison of HIV positive and negative cases in the small subsets,
Groups B1 and B2, failed to reveal significant differences for CD 16 staining values.
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The CD16 results are also displayed in the boxplots, Figs 4.3.25, 4.3.26, 4.3.35 and
4.3.36.
Table 4.3.9 - Mann-Whitney results for CD16 image analysis: basal
ganglia and hippocampus
CD16 image analysis CD16 image analysis
Basal ganglia Mann-Whitney tests Hippocampus Mann-Whitney tests
gm medians wm medians gm medians
wm
medians
Group C HIV -ve 18 32 Group A2 HIV -ve 36 37
HIV +ve 28 347.5 HIV +ve 142 208
p value p=0.447 p=0.03 p value p=0.037 p=0.004
gm medians wm medians gm medians
wm
medians
Group B1 HIV -ve 18 26 Group B2 HIV -ve 17 18
HIV +ve 15 95 HIV +ve 49 209
p value p=0.753 p=0.210 p value p=0.295 p=0.346
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Table 4.3.10 - CD68 results for the basal ganglia
BG - combined CD results
Code Age HIV CD14 CD68
CNS Pathology findings on routine
Staining
HIV negative cases grd gm wm
c33 1.6 F - 3 1,211 1,088 possible septicaemia
c42 5.0 F - 2 923 363 no significant findings
c50 1.6 F - 2 364 464 no significant findings
c54 0.4 M - 5 310 763 meningoencephalitis and infarcts
c57 5.0 F - 1 313 233 no significant findings
c59 1.6 M - 1 168 64 purulent meningitis
c60 1.5 F - 2 634 440 no significant findings
c67 4.0 F - 2 640 989 no significant findings
c74 1.5 F - 2 988 523 no significant findings
c76 1.6 M - 1 548 383 no significant findings
c77 0.3 F - 4 1,887 1,231 possible septicaemia
c89 0.5 F - 3 390 494 purulent meningoencephalitis
c93 1.5 F - 2 261 126 no significant findings
c94 0.5 M - 2 250 225 no significant findings
clOO 0.5 F - 1 225 131 no significant findings
clOl 4.0 M - 4 549 505 possible septicaemia
cl04 6.0 M - 4 676 341 cerebral malaria
cl09 0.5 F - 3 118 105 purulent meningitis
cl 13 0.4 M - 1 14 211 no significant findings
cl 17 2.9 M - 3 370 185 cerebral malaria
means 2.4 542 443
SD 1.2 441 336
HIV positive cases grd gm wm
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c5 1.7 F + 3 1,581 1,952 no significant findings
c8 3.5 F + 2 1,394 1,030 subtle widespread wm damage
c9 5.1 F + 1 1,027 1,100 medullitis
c24 5.0 M + 3 2,180 1,435 measles encephalitis
c55 1.7 M + 1 1,098 712 low grade lymphocytic infiltrate
c62 4.0 F + 1 698 592 low grade lymphocytic infiltrate
c82 0.2 F + 3 1,050 811
cerebellar infarct &
microhaemorrhages
c91 1.6 M + 2 1,592 1,193 low grade lymphocytic infiltrate
cllO 0.4 M + 4 1,125 985 toxoplasmosis
cl21 1.6 M + 3 431 420 cerebral oedema
cl22 3.3 F + 4 1,672 1,628 low grade lymphocytic infiltrate
cl25 1.5 M + 2 1,490 698 no significant findings
cl26 1.5 F + 1 298 269 no significant findings
cl28 1.8 F + 4 725 187 low grade lymphocytic infiltrate
cl29 0.4 F + 3 550 433 low grade lymphocytic infiltrate
c 131 0.4 M + 3 206 407 low grade encephalitis
cl40 4.0 M + 2 412 364 no significant findings
cl50 0.4 F + 3 1,076 812 no significant findings
cl52 6.4 M + 5 741 348 HIV encephalitis & toxoplasmosis
cl57 0.2 M + 4 1,408 922 purulent meningitis
means 2.7 1,038 815
SD 1.2 530 476
r
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Table 4.3.11 CD68 results for the hippocampus
Hippocampus - combined CD results
Code Age Sex HIV CD68 CNS pathology findings
gm wm on routine staining
c23 1.5 M - 807 568 no significant findings
c33 1.6 F - 3147 2169 possible septicaemia
c50 1.6 F - 155 244 no significant findings
c52 0.5 M - 49 209 no significant findings
c54 0.4 M - 966 1103 meningoencephalitis & infarcts
c57 5.0 F - 157 394 no significant findings
c59 1.6 M - 780 491 purulent meningitis
c60 1.5 F - 182 1295 no significant findings
c63 2.5 F - 1111 249 no significant findings
c77 0.3 F - 1162 1362 possible septicaemia
c86 1.8 F - 149 139 no significant findings
c89 0.5 F - 116 407 purulent meningoencephalitis
c93 1.5 F - 614 105 no significant findings
c94 0.5 M - 575 122 no significant findings
clOO 0.5 F - 436 426 no significant findings
clOl 4.0 M - 839 1406 possible septicaemia
cl04 6.0 M - 2356 1256 cerebral malaria
cl09 0.5 F - 163 349 purulent meningitis
cl 17 2.9 M - 984 870 cerebral malaria




c5 1.7 F + 1751 816 no significant findings
c8 3.5 F + 1698 1529 subtle widespread wm damage
c9 5.1 F + 476 858 medullitis
cl6 5.3 F + 662 810 no significant findings
c24 5.0 M + 4995 1003 measles encephalitis
c51 1.8 F + 399 331 low grade lymphocytic infiltrate
c55 1.7 M + 534 427 low grade lymphocytic infiltrate
c62 4.0 F + 621 361 low grade lymphocytic infiltrate
c70 2.1 F + 727 1564 low grade lymphocytic infiltrate
c82 0.2 F + 1014 736 cerebellar infarct & microhaemorrhages
c91 1.6 M + 4047 1500 low grade lymphocytic infiltrate
cllO 0.4 M + 1134 1477 toxoplasmosis
cl22 3.3 F + 1932 2310 low grade lymphocytic infiltrate
cl25 1.5 M + 1236 885 no significant findings
cl26 1.5 F + 454 477 no significant findings
cl29 0.4 F + 925 1229 low grade lymphocytic infiltrate
c 131 0.4 M + 474 247 low grade encephalitis
cl40 4.0 M + 593 810 no significant findings
cl50 0.4 F + 716 661 nothing significant




CD68: The results are shown in Tables 4.3.4 and 4.3.5 but extracted here for easy
reference as Tables 4.3.10 and 4.3.11, and summarised in Table 4.3.12 and illustrated
in Figs 4.3.12- 4.3.18. In Tables 4.3.4 and 4.3.5, and in Tables 4.3.10 and 4.3.11, the
HIV negative cases are grouped in the upper half, and HIV positive in the lower half.
A simple way of considering the individual results is to divide the Table arbitrarily
into 3 groups according to the CD68 values: low = 1 - 499, medium = 500 - 999,
and high = 1,000 and above.
The means and standard deviations for the HIV negative cases in the basal ganglia
grey matter were 542 (441) and 142(144) in Groups A1 and B1 respectively, and
those for the white matter, 443 (336) and 173 (160) respectively (see Table 4.3.4). In
the hippocampus, the corresponding means (Table 4.3.5) were in the medium range
for Group A2, 796 (783) for grey matter and 686 (565) for white matter, and in the
lower range for Group B2, 356 (333) for grey matter and 304 (180) for white matter.
The difference between Group A1 and Group A2 means was due largely to the
appreciably higher values for just two hippocampi (Group A2), which were not
matched by high values in the 2 corresponding basal ganglia. The most striking
results for individual HIV negative cases, in terms of high values in the basal
ganglia, were cases c33 (1,211 for grey matter and 1,088 for white) and c77 (1,877
for grey matter and 1,231 for white) (Table 4.3.10). For both these cases, the
pathology finding was possible septicaemia, a description based on the presence of
large numbers of polymorphonuclear leucocytes in large and medium sized vessels.
There was no recorded pathology within the brain itself in either of these cases. The
possible significance of this finding is addressed in Chapter 6. Another case of
possible septicaemia, clOl, was associated with more modest values, 549 and 505 for
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grey and white matter respectively, except in the hippocampus where the value for
the white matter was 1406 (Table 4.3.11). In the basal ganglia there were 6 cases
described as having no significant findings and for which the grey matter results fell
in the range categorised as medium. In four of these the values were higher than
those of the white matter. These cases, because of restricted block availability, did
not have a matching hippocampus in Group A2. Nevertheless, 6 hippocampus cases
had at least equivalent values for either grey or white matter, and three of these, c60,
c63 and cl24, had either grey or white matter values in the high range. The two cases
of cerebral malaria were both shared between the two sets, cl04 and cll7. In the
basal ganglia, the CD68 values were all in the low range except for that of the grey
matter in case cl04, 676. The values in the hippocampus were much higher, by a
factor of two to three. There were 4 cases of purulent meningitis or
meningoencephalitis and they were common to both sets. In two of these the results
were in the low range, falling below the HIV negative means for both Groups A1 and
2, and B1 and 2. For the basal ganglia, these cases were c59 and cl09, and for the
hippocampus, c89 and cl09.
In the HIV positive cases, strikingly higher CD68 values were seen, both in the
basal ganglia and in the hippocampus (Tables 4.3.10 and 4.3.11). In 12 cases, the
values for the grey matter were in the high range and for half of these, the
corresponding white matter results were also high. The means (standard deviations)
for Group Al, the basal ganglia, grey matter were 1038 (530) and for the white
matter, 815 (476). The corresponding values for Group A2, the hippocampus, grey
matter were 1355 (1250) and for the white matter, 987 (548). For Group BI, the basal
ganglia, the values were 971 (533) for grey matter and 819 (601) for white matter.
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For Group B2, the hippocampus, the values were 950 (537) for grey matter and 730
(163) for white matter
In the hippocampus, bearing in mind the slightly different case mix, there were
slightly fewer grey matter values (n=9) and slightly more white matter values (n=8)
in the high range than in the basal ganglia. Included in these (for both sets) were c8,
a case with subtle widespread white matter damage, and c24, the case of measles
encephalitis. The AIDS case with toxoplasmosis, cllO, which was common to both,
showed high values in the basal ganglia and in the grey matter of the hippocampus,
with medium values for hippocampal white matter. The other AIDS case, cl52, with
HIVE and toxoplasmosis, was part of the basal ganglia set only. Neither the value
for grey matter, 741, nor that for white matter, 348, fell in the high range.
There were 7 cases described as showing low grade lymphocytic infiltrate in each
set. Of those in the basal ganglia collection, four had grey matter values in the high
range while there were two high values in the hippocampus subset. For one case in
each group, both grey and white matter values were in the low range. There was only
one case ofmeningitis shared between the basal ganglia and hippocampus sets, cl57,
and in both sets it was associated with high values except for the white matter in the
basal ganglia, where a value of 922 was obtained. The grey and white matter values
of three HIV positive cases in the basal ganglia group were below the means for the
HIV negative group. These 3 cases were cl21, with cerebral oedema, as well as cl26
and cl40, both with no significant findings. In the hippocampus group, cl26, with
no significant findings, had values which approximated to the means and one case,
c!31, with low grade encephalitis, had values which were lower.
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The results of Mann-Whitney tests for CD68 immunostaining in the HIV negative
and positive basal ganglia and hippocampus are shown in Table 4.3.12. It can be
seen that for the basal ganglia, the activation was greater in the grey matter than the
white, for both HIV negative and positive groups, and that the differences between
HIV positive and negative grey and white matter in Group A1 are highly significant
(p=0.001 and p=0.000, respectively). Even in the small subset, Group Bl, the basal
ganglia grey matter of HIV positive cases, though not the white matter, showed
significantly more CD68 positivity than did the HIV negative cases (p=0.021). The
same pattern was true for the hippocampus but a statistically significant increase in
HIV positive cases was seen only in white matter in Group B2 (p=0.022).
The CD68 results are also displayed in the boxplots, Figs 4.3.27, 4.3.28, 4.3.37 and
4.3.38.
Table 4.3.12 Mann-Whitney test results for CD68 image analysis: basal
ganglia and hippocampus.
CD68 image analysis results CD68 image analysis results
Basal ganglia - Mann-Whitney tests Hippocampus - Mann-Whitney tests
gm medians wm medians gm medians
wm
medians
Group A1 HIV -ve 380 373 Group A2 HIV -ve 697 458
HIV +ve 1063 761 HIV +ve 826 837
p value p=0.002 p=0.009 p value p=0.091 p=0.468
Group Bl HIV -ve 364 383 Group B2 HIV -ve 157 244
HIV +ve 1076 698 HIV +ve 716 810
p value p=0.142 p=0.403 p value p=0.144 p=0.022
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HLA: the pattern obtained with anti-HLA antibody was almost identical to that
obtained with anti-CD 68 and no quantitative analysis has been attempted.
Summary of Immunohistochemical Results
Comparison of the CD 16 results in Tables 4.3.5 and 4.3.5 with those for CD 68
shows some notable parallel results. For example, the high levels of CD68
immunostaining for c8 and cl57 were seen to a lesser degree for CD16. This was
also the case for the low grade lymphocytic infiltrate case, cl22. Similarly high
CD 16 and CD68 values were seen in the cases with possible septicaemia and the
same was true for c54, with meningoencephalitis. Some equally marked differences
were also seen. For example, the very high CD68 values in the measles encephalitis
case, c24, were not reproduced in the CD 16 values. Of the malaria cases, cl04 had
the highest CD68 values in the hippocampus, whereas for CD16 it was cll7.
The results of all the Mann-Whitney tests for the immunostains for lymphocytes and
microglia/macrophages in FIIV positive and negative cases, and in the basal ganglia
and hippocampus, are summarised in Appendix 17 that combines the data shown in
Tables 4.3.6, 4.3.7, 4.3.8, 4.3.9 and 4.3.12.
For the Figures included below, BG denotes basal ganglia and HC denotes
hippocampus
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Fig. 4.3.1 Hippocampus - Haematoxylin & Eosin x200
Notes: Case cl 10 - an HIV positive case with AIDS showing a perivascular focus of
toxoplasmosis.
Fig. 4.3.2 Hippocampus - Haematoxylin & Eosin x200
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Notes: Case c70 - an HIVpositive case showing a pleomorphic perivascular cuff.
One of the cases listed as "low-grade lymphocytic infiltrate".
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Fig. 4.3.3 Basal Ganglia White Matter - pAPP x100
Notes: Case c93 - an HIV negative case showing evidence of axonal damage. A case
reported as "no significant findings" on routine screening.
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Notes: Case c94 - an HIV negative case described as "no significant findings" on
routine screening and showing increased perivascular GFAP expression
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Fig. 4.3.5 Basal Ganglia - Ependymal Surface - GFAP x100
Notes: Case cl57 - an HIV positive case with purulent meningitis and showing a
diffuse increase ofGFAP expression in the caudate nucleus.
Fig. 4.3.6 Hippocampus - Grey Matter - CD8 x400
Notes: Case cl04 - an HIV negative case with cerebral malaria. A longitudinal section of a
vessel showing congestion and a CD8 positive lymphocyte adherent to the endothelium -
long arrow, and malarial pigment in red cells - shorter arrows.
Fig. 4.3.7 Basal Ganglia - Internal Capsule - CD8 x100
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Notes: Case c91 - an HIV positive case, " low grade lymphocytic infiltration"
showing CD8 positive perivascular and parenchymal cells.
Fig. 4.3.8 Basal Ganglia - Lateral Angle of Ventricle - CD8 x100
Notes: Case c91 - the same case as above showing numerous CD8 positive cells in
subependymal layer.
Fig. 4.3.9 Basal Ganglia -White Matter - CD20 x100
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Notes: Case cl52 - HIV encephalitis and toxoplasmosis showing numerous
perivascular CD20 cells.
Fig. 4.3.10 Basal Ganglia -White Matter - CD14 x400
Notes: Case c89 - an HIV negative case with meningitis showing CD14 positive
perivascular cells and CD 14 negative macrophages/microglia - red arrows. Note the
difficulty in identifying individual stained cells (see note in first paragraph of materials and
methods)
Fig. 4.3.11 Basal Ganglia - Grey Matter - CD16 x200
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Notes: Case cl57 - an HIV positive case with meningitis - grey matter showing
diffuse CD16 positive macrophage/microglial expression.
Fig. 4.3.12 Hippocampus - Cortex - CD68 x40
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Notes: Case c33 - an HIV negative case with possible septicaemia
showing dense diffuse CD68 expression.
Fig. 4.3.13 Hippocampus - Cortex - CD68 x200
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Notes: Case c33 - same case as above at higher magnification








Notes: Case c89 - An HIV negative case with purulent meningitis
showing relatively little CD68 expression in the cortex.
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Fig. 4.3.15 Hippocampus -White Matter - CD68 x200
Notes: Case c33 - an HIV negative case with septicaemia showing
CD68 positive cells around a small vessel in longitudinal section.
Fig. 4.3.16 Hippocampus - Grey Matter/White Matter Junction CD68 x100
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Notes: Case c24 - an HIV negative case with measles encephalitis - CD68
immunostain showing the differing expression between grey matter bottom left
and white matter top right.





• lA I* -A • • *<4 '.SiA«" • • •
- ;*v/. *.
•V * *!?/:»• ;••V i*
- -ii 4
• *
# • v +1: * *
' ' l •
v* ^ ••• • •Wr v #*» 9 *-





• * * • •
• *V #
m asV. n • "*-• »»
Notes: Case c91 - an HIV positive case with low grade lymphocytic
Infiltrate - to show CD8 positive cells in choroid plexus.
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Notes: Case c91 - the same case as above to show CD68 positive cells in choroid
plexus.
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In the following charts the basal ganglia are denoted by "BG" or "bg" and
hippocampus by "HC" or "he". Grey matter by "gm" and white matter by "wm".
Boxes for HIV positive cases have a pink background.
Fig. 4.3.19 BG CD8 - Group A1
Boxplot of CD8 cell counts for Group A1 - gm and wm - HIV-ve & HIV+ve
































gm pvc- gm pvc+ gm par- gm par+ wm pvc- wm pvc+ wm par- wm par+
Boxplot of counts for perivascular and parenchymal cells in caudate nucleus (gm)
and internal capsule (wm)
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Fig. 4.3.20 BG CD8 Group B1
Boxplot of CD8 cell counts for Group B1 - gm and wm - HIV-ve & HIV+ve


















gm pvc- gm pvc+ gm par- gm par+ wm pvc- wm pvc+ wm par- wm par+
Boxplot of counts for perivascular and parenchymal cells in caudate nucleus (gm)
and internal capsule (wm)
Fig. 4.3.21 - BG - CD20 Group A1
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gm HIV-ve gm HIV+ve wm HIV-ve wm HIV+ve
Boxplot of perivascular cell counts only
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Fig. 4.3.22 BG CD20 Group B1

























Boxplot of perivascular cell counts only
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Fig. 4.3.23 BG CD14 Group A1
















grades for HIV-ve cases grades for HIV+ve cases
Boxplot of general (gm and wm) grades 1 -5
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Fig 4.3.24 - BGCD14 Group B1











for each box n=5 0 mean
grades for HIV-ve cases
median=2
grades for HIV+ve cases
Boxplot of general (gm and wm) grades 1-5
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Fig 4.3.25 BG CD16 Group C
Boxplot of CD16 immunostaining for Group C - gm and wm - HIV-ve & HIV+VE
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gm HIV-ve gm HIV+ve wm HIV-ve wm HIV+ve
Boxplot of image analysis for caudate nucleus (gm) and internal capsule (wm); graph
is with y-axis constraint of 1,600
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Fig. 4.3.26 BG CD16 Group B1
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Boxplot of image analysis for caudate nucleus (gm) and internal capsule (wm)
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Fig. 4.3.27 BG CD68 Group A1









gm HIV-ve gm HIV+ve wm HIV-ve wm HIV+ve
Boxplot of image analysis for caudate nucleus (gm) and internal capsule (wm)
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Boxplot of image analysis for caudate nucleus (gm) and internal capsule (wm)
Fig. 4.3.29 HC CD8 Group A2
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Boxplot of CD8 cell counts for Group A2 - gm and wm - HIV-ve & HIV+ve
perivascular and parenchymal cells
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Boxplot of perivascular and parenchymal cell counts
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Fig. 4.3.30 HC CD8 Group B2
Boxplot of CD8 cell counts for Group B2 - gm and wm - HIV-ve 8t HIV+ve
perivascular and parenchymal cells
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Boxplot of perivascular and parenchymal cell counts
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Fig. 4.3.31 HC CD20 Group A2 - boxplot of perivascular cell counts
only






gm-pvc- gm-pvc+ wm-pvc- wm-pvc+
266
Fig. 4.2.32 HC CD20 Group B2 - perivascular cell counts only
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Fig. 4.3.33 HC CD14 Group A2 - boxplot of general grades 1-5
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Fig. 4.3.34 HC CD14 Group B2 - boxplot of general grades 1-5
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Fig. 4.3.35 - HC CD16 Group A2 - boxplot of image analysis for grey
matter and white matter; graph has y-axis constraint to 1,500
Boxplot of CD16 immunostaining for Group A2 - gm and wm - HIV-ve & HIV+ve



















gm HIV-ve gm HIV+ve wm HIV-ve wm HIV+ve
Fig. 4.3.36 HC CD16 Group B2-
white matter
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boxplot of image analysis for grey and
Boxplot of CD 16 immunostaining for Group B2 - gm and wm - HIV-ve & HIV+ve
er
gm HIV-ve grn HIV+ve wm HIV-ve wm HIV+ve
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Fig. 4.3.37 HC C068 Group A2 - boxplot of image analysis for grey
matter and white matter
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Fig. 4.3.38 HC CD68 Group B2 - boxplot of image analysis for grey
matter and white matter
Boxplot of CD68 immunostaining for Group B2 - gm and wm - HIV-ve & HIV+ve
gm HIV-ve gm HIV+ve wm HIV-ve wm HIV+ve
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In the following scatterplots the HIV negative cases are in the upper half of the
figures and the HIV positive in the lower half. In the first figure, Fig.4.3.39, there is
no plot for CD8 parenchymal cells as only four values were recorded in the grey and
white matter, and only two of these were matched.
Fig 4.3.39 Scatterplots of CD8 counts for basal ganglia
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HIV negative cases (upper frame) - white matter vs grey matter for perivascular cells
only. HIV positive cases (lower frames) white matter vs grey matter for perivascular
(lower left) and parenchymal cells (lower right)
274
Fig 4.3.40 Scatterplots of CD8 counts for hippocampus
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White matter vs grey matter for HIV negative cases (upper frames) and HIV positive
cases (lower frames), perivascular cells (on left) and parenchymal cells on right)
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Fig 4.3.41 Scatterplots of CD16 vs CD68 immunostaining for basal
ganglia
Grey matter (upper left), white matter (upper right) for HIV negative cases. Grey
matter (lower left), and white matter (lower right) for HIV positive cases
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Fig. 4.3.42 Scatterplots for CD16 vs CD68 for hippocampus
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Limitations of the study
When analysing the data from this study there are several caveats that must be
acknowledged. Firstly the number of cases studied is relatively small and the brains
of the HIV negative children are not all entirely normal. Construction of the basal
ganglia and hippocampus subsets, determined by age and HIV status, necessarily
shows a differing spectrum of disease between the HIV negative and positive groups.
However, there appears to be a reasonable balance of pathology between the two
groups and a random array, in this sense, may provide a more valid approach to
comparison and analysis. Even if an attempt had been made to match conditions
between the HIV negative and positive groups, for example with bacterial
meningitis, there would have been difficulties. How could this be done in a
meaningful way without, at the very least, knowledge of the pathogen, the presence
or absence of co-existing disease, the duration of the illness and clinical findings?
Statistical analysis
The datasets for the Main Study generally did not conform to a normal distribution
and were all analysed by the non-parametric method, the Mann-Whitney test
(following a statistician's advice), and using Minitab statistical software. The data
were displayed using boxplots for both the basal ganglia and the hippocampi. The
problem of multiple analyses was discussed with a statistician who felt that the small
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scale of this study and the variability of the data were such that a more sophisticated
analysis was unlikely to yield more reliable results. Perhaps the best that can be said
is that the results obtained serve as pointers to a likely enhancement of immune
responses, particularly in the CD68 response in HIV positive subjects (in the
absence, apart from the cases of HIVE, of evidence of productive infection), but
that a larger survey would be required to confirm this. Nevertheless, given the degree
of pathology in the HIV negative group, some of it infective/inflammatory in nature,
the results for the HIV positive group are quite striking.
General Pathology Findings
The relevant general pathology findings are tabulated in Initial Study, Table 3.2.2
and this, the Main Study, Tables 4.2.2 and 4.2.3. They are, very briefly expressed,
the principal causes of death. Apart from distinctive conditions, such as malaria, it
seems unwise to attempt any correlation with the CNS findings. Without clinical and
laboratory data how could it be said that the pneumonia, which caused the death of
so many, was a "homogenous" condition
Inflammatory cells in the brain - summary of results
The CD8 results for the basal ganglia and hippocampus, Groups A1 and A2, (Table
4.3.6) revealed significantly higher values for perivascular and parenchymal cell
counts in the HIV positive sets. In the smaller Groups BI and B2 the only significant
results were for the parenchymal cell counts, which were greater in the white matter
of both HIV positive sets. The scatterplots (Figs 4.3.39 and 4.3.40, suggest a
reasonable degree of correlation between the perivascular cell counts for grey and
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white matter of HIV negative and positive cases in the basal ganglia. In the
hippocampus the situation is less clear cut, although values are greater in the HIV
positive group. In all, the presence of outliers tended to distort the graphs. The
correlation between the grey and white parenchymal cell counts for HIV positive
cases was similarly difficult to interpret.
No significant difference was detected for CD20 cell counts between HIV negative
and HIV positive cases, in either of the Groups for basal ganglia or hippocampus
(Table 4.3.7). Similarly, there was no significant difference between the CD14
grades for HIV negative and HIV positive cases in either Group A or B, in basal
ganglia or in hippocampus. Image analysis values for CD16 (Table 4.3.9) were
significantly higher in the white matter of HIV positive cases for Group C basal
ganglia, and in both grey and white matter of the hippocampus (GroupA2). No
significant difference was detected for Group B sets in either locus. A significant
increase in CD68 values was found in the basal ganglia of HIV positive cases
compared with HIV negative cases, in both grey and white matter. The only other
significant result was for Group B1 in the white matter of the hippocampus.
The scatterplots, Figs 4.3.41 and 4.3.42, for C16 values compared with those for
CD68 values in the basal ganglia show little evidence of correlation except perhaps
in respect of the grey matter in HIV positive cases. In the hippocampus the better
correlation is for the white matter of both HIV negative and positive cases.
In this study there were only two HIV positive cases that could be classified
definitely at the stage of AIDS. One, c91, was characterised by the finding of
cerebral toxoplasmosis and was common to both basal ganglia and hippocampus
groups. The other, c!52, was defined by HIVE and toxoplasmosis and this case was
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found only in the basal ganglia group. Without clinical details and CD4 counts it was
impossible to know how many cases of probable pre-AIDS were in the subsets, but it
may be inferred that at least some cases with a low grade lymphocytic infdtrate in the
brain had died before the onset of AIDS. If so, the degree of CD8 lymphocyte
infiltration may not be surprising but that of CD68 microglial activation is more
unexpected.
Discussion of Individual Staining Results
In general the Luxol fast blue staining did not reveal evidence of significant white
matter damage. The paler sections were usually those of children under the age of
one year. There did not appear to be any relationship with HIV status or pathology
findings. In view of the confounding factor of incomplete myelination, and the
uncertainty as to the ages of the children and their state of nutrition, it might be
unwise to place too much reliance on this data. In any case the assessment of subtle
grades of pallor is a highly subjective process.
Glial fibrillary acidic protein: There did not appear to be any clear-cut relationship
between the degree of activation and age, or pathological condition in HIV negative
or positive Groups. In the HIV negative group, strong GFAP expression was seen in
apparently normal cases and expression was not of the highest values in HIVE. In
any case the results in this study are in keeping with the relative lack of white matter
damage as in the LFB and PAPP grading.
P-amyloid pre-cursor protein (PAPP): The very limited positivity detected is in
keeping with the results for the LFB and GFAP grading results. The overall lack of
white matter reaction may be due to the early demise of these children before axonal
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and myelin damage had had time to develop. Examination of further cases in the
cohort might be helpful to confirm or refute the relative lack of white matter
change.if the study was extended.
Discussion of Lymphocyte Studies
The behaviour of lymphocytes with respect to the CNS was studied in the rat in
1991(Hickey et al. 1991). Naive T lymphocytes or lymphoblasts introduced into the
circulation were found to enter the CNS and reach peak levels within 12 hours and
leave in one to two days. The access of activated T-cells is more restricted but when
entry has been achieved the tendency is for them to remain, especially if their
cognate antigen is detected. Cerebral endothelial MHC class I antigen presentation is
thought to play a key part in their transit (Galea et al. 2007).
The twenty HIV negative cases provided a spectrum of conditions in which the
lymphocyte responses could be observed. In view of the background of systemic
disease in this cohort it was unlikely that any more than a few cases would reflect the
baseline levels for CD8 lymphocytes in this population. The counts for case c93 can
probably be taken as basal levels. Several of the cases with no significant findings on
initial examination showed elevated counts, for example, c50 and c67, and it seems
likely that systemic disease might account for these results. It is of interest that
individual cases show discrepancies between the CD8 and CD68 results. For
example, the case of possible septicaemia, c33, showed high values for CD68
expression but had low counts for CD8 lymphocytes, in both basal ganglia and
hippocampus. The finding that some of the cases of purulent meningitis, for example
c!09, had such low counts for CD8 cells might be explained by a short time course
282
for an overwhelming infection (but note the low CD68 results also). The CD8 cell
counts in the cases of cerebral malaria differed slightly, cll7 showing lower levels,
but both malaria subjects were older children (aged 2.9 and 6 years) and may have
developed a degree of immunity. These cases may suggest that different pathologies
may induce primarily a lymphocytic or macrophage response.
The immune responses to malaria are complex and may take years to develop fully
(Good et al. 2005). The role of CD8 lymphocytes has been investigated in
experimental cerebral malaria in mice and depletion of CD8 T-cells or splenectomy
have been shown to have a protective effect (Hermsen et al. 1998). One way in
which CD8 cells are thought to contribute to the pathogenesis of cerebral malaria is
by increased adherence to the cerebral capillary endothelium (Nitcheu et al. 2003)
(Fig. 4.3.6). The lower counts in c!17 may therefore be of prognostic significance.
The role of CD8 T-cells in the CNS in HIV positive cases, appears on available
evidence likely to be multifactorial. HIV-specific cytotoxic T-cells are present in the
sera of HIV infected individuals (Walker et al. 1987) and are involved in the
suppression of HIV in the acute and chronic stages of the infection (Brander and
Riviere 2002) . They are also known to be infected from early in the infection
(Livingstone et al. 1996) . The question of timing of viral entry into the CNS, and
therefore a lymphocytic presence, is one of continuing debate (McCrossan et al.
2006). Certainly significant numbers of perivascular CD8 lymphocytes are present
in the brains of HIV infected pre-symptomatic individuals (Bell et al. 1993) while an
underlying low level of pro-virus is detected by limiting dilution nested PCR
(McCrossan et al. 2006). The relationship is considered to be one of control by the
CD8 lymphocyte population and the precise factors which lead to the loss of control
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and the development of productive infection remain undefined. The root cause of
progression of HIV/AIDS is generally accepted to be the increasing degree of
immune suppression. In this regard, the introduction of HAART has resulted in some
changes which are not well understood. One of these is the continuing inflammation
in the CNS, as detected by macrophage/microglial activation in an autopsy study
(Anthony et al. 2005) in post-HAART subjects (which, as in this present study,
focused on the basal ganglia and hippocampus). The other is the as yet incompletely
explained and lethal phenomenon of the immune reconstitution inflammatory
response (IRIS) in which, in association with HAART, there is a great influx of CD4
and CD8 lymphocytes to the CNS (Miller et al. 2004).
The twenty HIV positive cases in this study were probably infected perinatally.
The two cases that had progressed to definite AIDS were aged 0.4 and 6.4 years and
illustrate the age spectrum in childhood AIDS, from the many who succumb in the
first two years to those who survive to mid to late childhood. The bimodal
distribution of AIDS presentation in children in the USA is not considered to be so
applicable to children in sub-Saharan Africa because of the high background of
infectious disease.
An increased quota of perivascular and parenchymal CD8 cells was confirmed in
HIV positive cases in this study. As mentioned earlier, the number of pre-AIDS
subjects in this study is unknown but it is considered that some, at least, of the cases
displaying low-grade lymphocytic infiltrates were at this stage of HIV infection.
Indeed 4 of the 6 cases had high parenchymal counts in the basal ganglia and all had
high perivascular cell counts in both grey matter and white matter. Four of these
children were under the age of two years at death. It is concluded that the level of
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CD8 influx reflects the balance of disease and adaptive response in the particular
child at the time of death, recognising that no two human subjects are the same.
The rarity of CD20 cells in the parenchyma of HIV negative cases, both for the
basal ganglia and hippocampus, is in accordance with what is known for the normal
adult nervous system - namely that they are present, but in very small numbers
(Anthony et al. 2003). There is no reason to suppose that children should differ in
this respect. The elevated counts in cases such as c50, with no significant findings,
c54, a case of meningoencephalitis with infarcts, and c60, with no significant
findings, suggest responses to both local (in the case of c54) and remote (c50, c60)
stimuli.
Among the HIV positive cases, the case of measles encephalitis, c24, is remarkable
for the absence of CD20 positive cells in either the basal ganglia or hippocampus.
Furthermore, although there are elevated CD8 cell counts, these are quite modest
compared with those for other cases in the CD8 HIV positive group. Measles is
usually accompanied by a brisk immune response in the blood, involving both CD8
T cells (cytotoxic T lymphocytes) and CD20 cells (B lymphocytes). Also, in
encephalitis (non-HIV), there may be significant numbers of CD20 cells in both the
parenchymal and perivascular compartments (Anthony et al. 2004). Perhaps there
was a reason other than HIV for this B cell absence, such as severe malnutrition,
which is known to impair the immune response (Whittle 1996)
A similar lack of CD20 response, striking in the case of the basal ganglia and more
limited in the case of the hippocampus, applied in the AIDS case, cllO. But in this
case there were high parenchymal and perivascular CD8 counts in both the basal
ganglia and hippocampus. In the other AIDS case, c!52, a fairly high count was seen
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in the basal ganglia white matter, with a negligible response in the grey. These
results should be seen in the context of what is known about the B-cell numbers in
the brain in AIDS and HIVE, namely that they tend to fall to below normal levels in
the progression towards AIDS (Anthony et al. 2004).
Several of the cases showing low-grade lymphocytic infiltrate had CD20 counts
above the means for the group. For instance, in the basal ganglia of c55 and c62 and
in the hippocampus of c62, c70 and c91, the counts are several times greater than the
means. Increases in numbers of CD20 lymphocytes in the brain of HIV positive
adults may herald the pre-AIDS phase (Anthony et al. 2003). Perhaps this increase
in CD20 counts in the brain is a surrogate marker for the imminent onset of AIDS in
some of these cases, especially where there are also high values for CD68
expression, for example c55 and c91.
Discussion of the Macrophage and Microglial Markers
The grades for CD14 immunostaining in the HIV negative cases tended to be
higher in the cases where there was evidence or suspicion of intravascular or
perivascular infection. In particular, these included the possible septicaemia cases,
and the cases of meningitis and of malaria. This is in keeping with the role of CD 14
cells as gate-keepers of the CNS. In the HIV positive cases higher values were seen
in both AIDS cases and some of those with low- grade lymphocytic infiltrates. As in
the HIV negative group, the case of purulent meningitis has higher grades.
The results for CD16 quantitation appeared to parallel those obtained for CD68 and
the results are considered together. In the HIV negative cases, the difference in CD
68 values between basal ganglia and hippocampi may simply reflect a natural
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variation in disease expression from one brain region to another, as was found in
another study which identified a similar variation in inflammatory response in HIV
infection in the basal ganglia and hippocampus (Anthony et al. 2005).
The molecular mechanisms that determine inflammatory cell access to the CNS
appear to vary with respect to both stimulus and site - whether this be cerebrum or
spinal cord, grey matter or white, and this subject was examined in a review in 2005
(Engelhardt and Ransohoff 2005). These considerations may apply to other cases
such as cerebral malaria, as in cl04. The values for CD68 expression in this case
were much higher in the hippocampus than in the basal ganglia. Another factor is
that severity of malarial disease in West African children is known to be strongly
correlated with serum levels of TNFa (Kwiatkowski et al. 1990) and thus with
potential damage to the blood brain barrier. The highest values recorded in the HIV
negative group for both sets were those for the possible septicaemia cases c23 and
c77. As there was no corresponding significant rise in the lymphocyte counts these
results can be interpreted as a rapid response to an acute systemic infection. However
the results for the cases of purulent meningitis introduce a paradox. These results
were in the low or medium range of values and yet the infection was clearly both in
very close proximity and intense (compare Figs. 4.3.12. and 4.3.14). The explanation
for this is uncertain without knowledge of clinical or laboratory findings. In part it
may be explained by differing pathogens or time courses, an impaired state of
immunity due to causes other than HIV, and perhaps even attributable to changes in
the integrity of the blood brain barrier.
In the HIV positive cases, CD68 staining was significantly accentuated, compared
with the negative cases. Of the 2 definite AIDS cases, cllO, with toxoplasmosis and
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aged 0.4 years, showed generally high levels of staining while the other, cl52, with
HIVE showed only moderate CD68 staining (despite high values for CD14 and
CD 16), These two cases were not really comparable. Firstly there was the age
difference - the infant could be seen to be in a rapid progressors group, possibly
signifying intra-uterine infection. The supposition was that the toxoplasmosis was
congenital. In contrast, the older child had HIVE, and the relatively modest CD68
staining levels were perhaps surprising, but the prominent CD14 and CD 16 results
were in keeping with what is known of responses in HIVE.
High levels of CD68 expression were seen in about half of the cases showing
a low-grade lymphocytic infiltrate and in most of these there was also increased
expression of CD 16. Four of the six cases in this category were under the age of 2
years at death and it is likely that some if not most of these cases in this category
were cases of pre-AIDS
Some of the cases with no significant findings on initial examination showed high
levels of activation and presumably the causes for these were systemic, possibly
infection in the pulmonary or gastro-intestinal systems.
In this discussion of the macrophage/microglial contribution to the inflammatory
responses of the CNS, reference is briefly made to the part probably played by the
choroid plexus. A study of the choroid plexus in HIV infection showed that of 25
AIDS cases, 70% contained T lymphocytes and 50% contained monocytes
(Falangola et al. 1995). Almost half contained HIV positive monocytes and it was
suggested that this finding supported the hypothesis that HIVE might develop from
such a source. In this study the choroid plexus was frequently seen in hippocampus
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sections and both lymphocytes and macrophages were detected in the plexus, by
CD8 and CD68 immunostains respectively (see Figs. 4.3.17 and 4.3.18)
With regard to the results obtained from the B Groups, (n=10, 5 HIV negative and
5 HIV positive), in which it was hoped that the effects of other confounding
pathology would not affect results due to HIV alone, it is noted that, for the most
part, the results fell short of significance apart from CD8 and CD68 comparisons,
reflecting the large differences for these parameters in the larger groups. This was
probably due to the small sizes of Groups B1 and B2 but unfortunately few of the
original cohort were in the category of having no significant neuropathology on
routine examination.
General Discussion of Results
The results for the markers of macrophages and lymphocytes confirm that there is
significant entry of inflammatory cells into the CNS and activation of the microglial
population, in the absence of detectable intrinsic infection by HIV. Furthermore
there is influx and activation in HIV negative cases, even without manifest disease of
any kind in the CNS and, paradoxically, there is little or no response in the presence
of intense local surrounding infection, as in the HIV negative cases with purulent
meningitis. Despite these potentially confounding factors, there is significant
microglial upregulation in the HIV positive group.
In the past few years there has been sustained interest (Perry 2007; Perry et al.
2007), in the question of microglial activation in relation to systemic disease and the
cognitive correlates, especially in respect of neurodegenerative disorders, such as
Alzheimer's disease. It has been shown that even minor infective illness elsewhere
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in the body can alter CNS function and lead to behavioural change. Of course such
an alteration could be due to neuro-synaptic interference (Epstein and Gendelman
1993) and the evidence suggests that the microglial population is involved and may
indeed be the prime mover through cytokine release. The main question seems to be
one of access to the brain parenchyma in several contexts - why do only a proportion
of AIDS cases suffer from CNS involvement? Why, if there are significant
responses to minor systemic illness, is there so little involvement when there is
intense local inflammation, as in meningitis - even allowing for a short time course in
such illnesses? The answer must lie, at least in part, in the blood brain barrier. Just
as there is regional specialization in capillary endothelium (Engelhardt and
Ransohoff 2005), might there not also be genetic influences at work conferring
resistance or otherwise to immune cell access ?
The intense microglial activation detected by CD68 staining in the cases of
possible septicaemia serves to focus attention on the dynamics of immune cell
responses, which occur in most diseases affecting the CNS (Kreutzberg 1996).
However the role of immune activation in the pathogenesis of many CNS conditions
remains unclear (Weiner and Selkoe 2002). It is a widely held opinion that the
effects of microglial activation are malign in HIV infection, and it is thought the
damage in HIV encephalopathy is due to cytokine secretion by activated
macrophages (Yoshioka et al. 1995). The principal molecule involved is TNF-a.
The role of macrophage activation in CNS disease has been explored in mice by a
technique known as microglial paralysis, which involves genetic manipulation such
that microglia are developed that are incapable of producing proinflammatory
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cytokines. In such mice, the response to facial nerve section was blocked and the
response in experimental allergic encephalitis suppressed (Heppner et al. 2005).
Since the introduction of HAART and the great improvement in mortality figures,
there have been fewer large studies on the neuropathology of HIV infection in
children or adults (Vallat-Decouvelaere et al. 2003), and not many address the
problem of microglial activation. A recent post mortem study on adult brains
examined microglial activation, detected by CD68 immunostaining, in the setting of
drug abuse. The results for the normal controls were by image analysis (pixels per
unit area) in the 200-1000 range (Arango et al. 2004). The highest levels, for HIVE
subjects who were drug abusers, were in the 2,000 to 4,500 range, and for HIV non-
drug users the range was similar but with lower means.
In the present study macrophages with a rectangular nuclear profile were seen in
both HIV negative and positive cases that showed a high level of activation
(Fig.4.3.10). Some of these were positively stained by the macrophage/microglial
markers and others were not. There was, and still is, debate concerning the naming
and the origins of these cells (Dickson et al. 1991). They are variously described as
"activated" or "amoeboid", and they may be derived from both microglia and
perivascular macrophages. Their appearance, especially in the white matter, is
suggestive of determined movement, and tissue culture studies have revealed their
dynamic properties (Esiri 1996).The very early responses of microglia to changes in
the CNS have been revealed by in-vivo experiments involving two-photon laser
scanning microscopy (Nimmerjahn et al. 2005). In this technique cortical microglia
in mice were visualized directly, both in their resting and early activated state. At
rest, microglial processes were seen to be in a constant state of expansion and
291
retraction of the protrusions on these processes. After a micro-injury induced by a
two-photon laser, the processes of neighbouring microglia were observed to enwrap
the zone of damage whilst retracting the processes that extended in the opposite
direction. The authors emphasised that the function of microglia is primarily one of
neuroprotection and that the effects ofmicroglial activation depend on the nature and
intensity of the stimulus.
In general, in viral infections of the CNS, macrophages, CD8 T-cells and natural
killer cells tend to move into the parenchyma, whereas B-cells and CD4 T-cells
usually remain in a perivascular position (Esiri 1997). In the HIV negative cases in
this study there was little parenchymal distribution of CD8 T-cells, but in the HIV
positive group, as noted above, both AIDS cases showed appreciable numbers
(Tables 4.3.4 and 4.3.5). However large numbers were also seen both in grey and
white matter of the cases with low grade lymphocytic infiltrate, and this is rather
different from the findings in another study in which CD8 T-cells were rare or absent
in non-HIVE cases (Petito et al. 2006). If, as these authors propose, CD8 T-cells
could be an important biomarker for productive brain infection by HIV-1, it might be
inferred that some, at least, of the cases in the low grade lymphocytic infiltrate
category are in the pre-AIDS phase. Another study which considered grading of CD8
cells in the parenchyma showed a significant presence of CD8 lymphocytes in the
hippocampus in both pre-symptomatic and HIVE cases, but slightly lower in AIDS
(Anthony et al. 2005).
In conclusion brief mention is made of two other conditions which feature in the
main study, cerebral malaria and measles encephalitis.
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Cerebral malaria is a serious cause of death world-wide, causing up to 2 million
deaths annually (Medana et al. 2001). The pathophysiology is not well understood,
particularly as the CNS is not actually invaded by the parasite, which remains intra¬
vascular. In the past, hypoxia due to obstruction in the microcirculation was thought
to be the major factor, but now the focus is on damage to the blood brain barrier
(BBB) and the secondary sequelae associated with protein seepage and increased
inflammatory cell access (Szklarczyk et al. 2007). The two cases included in this
study show significant immune activation only in one. The difference may simply be
due to a shorter time course or co-existing disease.
Measles encephalitis is seen infrequently in Europe and the USA, now that effective
immunisation programmes are in place. In the developing world, measles is still a
major cause of morbidity and mortality, but in Africa the estimated mortality has
fallen, due largely to the introduction of community based immunisation
programmes, that have contributed 72% of the total global disease reduction
(Wolfson et al. 2007) The high level of inflammation shown in the single case in this
study underlines the severity of the response to viral infections other than HIV
infection. The results of a small study, also based in Abidjan, suggested that HIV
positive children might be more susceptible to CNS involvement by measles virus
(McQuaid et al. 1998).
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Conclusions
1 Very limited evidence of white matter damage was detected in this study by the
methods used, namely Luxol fast blue routine staining and immunostaining using
GFAP and [3APP.
2. Compared with HIV negative children, positive children had significantly higher
levels of microglial activation in the white matter of both basal ganglia and
hippocampus, as detected by CD 16 immunostaining.
3. Compared with HIV negative children, positive children had significantly higher
levels of macrophage/microglial activation in the grey and white matter of the
basal ganglia, and in a small subset of the hippocampus, by CD68 immunostaining.
4. Compared with HIV negative children, positive children had significantly higher
levels of lymphocyte infiltration in both grey and white matter of the basal ganglia
and hippocampus, and in both perivascular and parenchymal loci.
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Chapter 5: The APOE Study
5.1- Introduction
History: major milestones in the understanding of APOE and its
relationship to human disease
Darwin's publication in 1859 of "The Origin of Species" (this year marking the
250th anniversary of publication) resulted in a completely new understanding of all
living things. The concept of "survival of the fittest" described how the members of a
population who are better adapted to their environment tend to flourish and pass on
their advantageous traits. The mechanism of this "passing on" was to be explained in
a simple and lucid way by Mendel in 1856 as a result of his experiments on the
breeding characteristics of the edible pea. In 1953 Watson and Crick published their
proposal of the double helix structure for DNA, which now underpins our present
understanding of molecular biology (Watson and Crick 1953).
A further fundamental discovery, which has transformed the field of molecular
genetics by facilitating the amplification of DNA from a single molecule to a
hundred billion copies of itself in a few hours, was the discovery of what is now
known as the polymerase chain reaction (PCR) (Mullis et al. 1986). In essence this
is the catalysed incubation of oligonucleotide fragments with the enzyme DNA
polymerase.
Since these studies the field of genotyping has expanded enormously, and
molecular biology now allows a very sophisticated understanding of the genetic
determinants of disease. In the field of neuroscience many studies have attempted to
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link genes with disease. In Alzheimer's disease (AD) one of the strongest genetic
links has been shown to be the apolipoprotein (APOE) gene, found on chromosome
19 (Burke and Roses 1991). This gene encodes a protein of the same name. Here the
convention of APOE is adopted for the gene and ApoE for the protein.
Biochemistry and Genetics
Lipoproteins are macromolecules involved in the transport of lipids, such as
cholesterol and free fatty acids, in the bloodstream. The name apolipoprotein is
derived from the use of the Greek prefix, Apo - off, from, away - and refers to the
protein moieties on the surface of the macromolecule. On this basis several different
apolipoproteins are recognized, of which ApoE is of particular interest because of its
involvement in CNS homeostasis and disease. ApoE is a complex molecule with a
molecular weight of 34 KD and is composed of 299 amino acids (Rail et al. 1982).
The APOE gene exists in three allelic forms and codes for corresponding protein
isoforms, ApoE 2, 3 and 4, which differ in their arginine and cysteine content
(Zannis et al. 1981). The alleles are known as APOE s2, APOE e3 and APOE e4.
This allelic variation allows six genotypes - three homozygous (s2/s2, s3/s3 and
s4/e4), and three heterozygous (s2/s3, 82/e4 and £3/e4). The distribution of the
alleles has been the subject ofmany studies. For example a study in Scotland found
the following distribution in adults aged 45-60 years - s2 in 8%, s3 in 77% and s4 in
15% (Cumming and Robertson 1984).
The e3 allele is the commonest variant and occurs at a frequency of 60-80% in most
Western populations. The frequency of APOE s4 is fairly constant at 10 -12%
throughout southern and western Europe but reaches 30% in Scandinavia (Mahley
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and Rail 2000). In Africa the overall distribution APOE alleles is different from
Caucasian populations with APOE e2 found in 11.6%, APOE s3 in 70.6% and APOE
s4 in 17.8%. The frequency of APOE s4 varies from 9% to 41% across Africa
(Zekraoui, 1 - 1997) and in Nigeria, West Africa, a frequency of 22-29% was
recorded for APOE s4.
It is now well established that there is a strong association between the
development of AD and possession of one or more APOE s4 alleles (Corder et al.
1993). In contrast, no such association was found between APOE s4 and AD in
elderly Nigerians (Osuntokun et al. 1995).
The issue as to which is the ancestral allele is pertinent to the West African
population on which this study is based. In the early years it was considered likely
that it was the APOE s3 allele because of its frequency (Mahley 1988). However,
since Africa was the site of origin for mankind and shows a higher frequency of
APOE s4, there are reasons to conclude that this is the more likely candidate.
Supporting evidence comes from gene sequencing in non-human primates (Hanlon
and Rubinsztein 1995), and from other African studies (Zekraoui et al. 1997). It is
possible that possession of APOE s4 alleles may have conferred a selective
advantage in the form of increased capacity to survive in an environment so rich in
pathogens, particularly the protozoal group (Sinnis et al. 1996).
Physiology
ApoE protein is expressed in a variety of cells in different organs including the
liver, kidneys, spleen and brain. The protein is involved in cholesterol metabolism,
cell repair and especially in immune activation. The integral role of APOE in lipid
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metabolism underlies an association with the development of atheroma and the
pathogenesis of ischaemic heart disease. The level of ApoE protein in the blood is
30-70 pgm/ml; most of this is produced in the liver. High levels are also expressed
in the brain (Mahley and Rail 1999). A study in which tissues were screened for
ApoE messenger RNA (mRNA) found high concentrations in all areas of the brain,
as in the liver, in keeping with active protein production (Elshourbagy et al. 1985).
A further study showed that ApoE protein was associated exclusively with astrocytes
(Boyles et al. 1985), either within these cells or on astrocyte processes ending at the
glia limitans or on blood vessels. This finding has been confirmed (Fujita et al.
1999).
In AD the hallmark at microscopical level is the presence, in the cerebral cortex, of
senile plaques and neurofibrillary tangles. Microglia are frequently seen in
association with these plaques and a causative role has been suspected (Mackenzie et
al. 1995). The main constituent of the plaques is Amyloid-P, a 39-43 amino-acid
polypeptide. It is derived from cleavage of beta-amyloid pre-cursor protein ((3APP).
Microglial activation seems to occur especially near plaques expressing a high level
of PAPP (Griffin et al. 1995).
The relationship between amyloid-P and ApoE protein has been the subject of
much discussion. High affinity binding occurs with ApoE 4 protein, resulting in the
formation of insoluble high-molecular weight compounds and, in vitro, dense
amyloid monofibrils (Sanan et al. 1994). ApoE 3 protein binding and molecular
elaboration occurs to a lesser degree (Wisniewski et al. 1994). Amyloid protein
deposition is known to occur in the brain after head injury (Roberts et al. 1991) and
this is more prevalent in those with APOE s4 allele(s) (Nicoll et al. 1996).
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The relationship between the APOE gene and AD posed the question as to whether
or not there would prove to be a relationship between the APOE gene and HIV-
associated dementia. A retrospective autopsy study investigating the APOE
genotype of 132 HIV positive individuals (Dunlop et al. 1997) showed no association
between HIV encephalitis (HIVE) and different APOE alleles. The following year
the results of a clinical study on 42 HIV-infected subjects, followed for up to five
years, were published. This study showed that there was a twofold excess of patients
with the APOE e4 among those who developed dementia (Corder et al. 1998). It was
concluded that a partly genetically determined pathway might be common to AD and
HIV associated dementia (HAD) or alternatively, a gene-virus interaction might be
operating to accelerate AD pathogenesis.
Lipoproteins were shown to have a role in immune regulation in 1976, when a low
density lipoprotein was shown to be capable of inhibiting lymphocyte proliferation
(Curtiss and Edgington 1976). ApoE protein was then shown to be the most
important lipoprotein in this respect (Hui et al. 1980).
Since 1997 there has been increasing interest in the relationship between APOE,
ApoE protein and (3 amyloid derivatives on the one hand, and the innate immune
system of the CNS on the other. In tissue culture experiments using neuronal-glial
preparations, the secretion of tissue necrosis factor alpha (TNFa) was shown to be
related in a dose-dependent way to the presence or absence of ApoE protein
(Laskowitz et al. 1997). In another study, soluble APP alpha (sAPP-a), a secreted
derivative of PAPP, was used to investigate the inflammatory responses of microglia
(Barger and Harmon 1997). Pre-treatment of microglial cultures with sAPP-a was
found to upregulate activation markers and to increase production of neurotoxins.
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This response was blocked by prior application of ApoE 3 but not by ApoE 4. The
differential secretion of nitric oxide (NO), a potent neurotoxin produced by
macrophages and microglia, was explored in relation to the different ApoE isoforms
in 2002. The findings were that more NO was produced by macrophages from
humans carrying the APOE e4 allele were found to produce more NO than those
from APOE e3 individuals (Colton et al. 2002).
Turning to in vivo studies, it appears that microglia tend to be associated with
dense amyloid plaques rather than diffuse plaques, suggesting that microglial
activation occurs later rather than earlier in AD (Vogelgesang et al. 2002). In 2003 a
report was published on the relationship between astrogliosis and APOE in
transgenic mice, and the response to injected lipopolysaccharide (LPS). Enhanced
astrogliosis was shown in both the control and APOE e3 transgenic mice, but no
effect was noted in APOE deficient and APOE s4 transgenic mice (Ophir et al.
2003). Further studies using transgenic mice have confirmed the relationship
between the different APOE genotypes and the degree of microglial activation, and
that an apparent inhibitory effect associated with APOE s3 was gene dose dependent
(Vitek et al. 2007).
The dynamics of the influence of the APOE genotypes on innate immune responses
in the CNS are still a matter of debate. In 2000 the view was expressed that APOE
s2 and APOE s3 were active in repair processes and neuroprotection, and that APOE
e4 was relatively inactive (Mahley and Rail 2000). Since then a modified view, that
APOE e4 is associated with, and possibly a promoter of, neuroinflammation has
seemed as likely a proposition (Vitek 2007). To our knowledge, there has been no
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previous investigation of a possible association between HIV associated microglial
activation and APOE genotype.
Accordingly the hypothesis for this part of the study was that possession of one or
more APOE e4 alleles accentuates HIV associated microglial activation.
The aims of this study were:
1. To extract DNA and determine the APOE allelic distribution, using PCR
and subsequent restriction enzyme digestion applied to the 40 cases from the
main study, and subsequently to 20 extra cases.
2. To relate the degree of inflammatory change in each case, as detected by
CD68 and CD 16 immunohistochemistry, to the different APOE genotypes.
5.2 - Material and Methods
First, the forty cases used in the Main Study (basal ganglia subset) (see Chapter 4)
were subjected to DNA extraction, and subsequent PCR if the first step was
successful, as described in Chapter 2. Of these 40 cases, 20 were HIV positive and
20 were negative. Subsequently, a further 10 HIV positive and 10 negative cases
were selected within the age range of the Main Study set. Thus, genotyping was
attempted on 60 cases in total.
In addition, immunohistochemistry for CD68 and CD 16 was undertaken on paraffin
sections of the basal ganglia in the selected cases, as described in Chapter 2.
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Quantitation of microglial activation in these sections was undertaken as described in
Chapter 4.
The data for this study was analysed using Minitab soft ware. The chi-square test
was used in the analysis of the APOE allele frequencies, and the Mann-Whitney test
for the image analysis data.
5.3 - Results
Of the 40 cases derived from the Main Study, 33 proved amenable to downstream
PCR analysis on first extraction (Figs 5.3.1 & 5.3.2). The remaining 7 cases were re-
extracted and 4 of these proved amenable to DNA amplification by PCR. Of these
37 cases in which APOE genotypes were determined, 19 were HIV negative and 18
HIV positive. A further set of twenty cases, 10 HIV negative and 10 HIV positive,
was examined and of these successful genotyping was achieved for 4 in the HIV
negative group and 6 in the HIV positive group. In all, APOE genotypes were
ascertained in 23 HIV negative and 24 HIV positive cases (Table 5.3.1).
Fig. 5.3.1 shows an example of PCR amplification of the APOE gene, revealing a
product of 220bp. Figure 5.3.2 shows subsequent restriction enzyme digest of the
PCR products using Hhal to reveal the APOE genotype. The size of cleaved
products in the metaphor gel is used to determine the genotype. The APOE z2 allele
produces two main fragments of 91 bp and 81 bp length. Digestion of the e3 allele
results in fragments of length 91bp, 48bp and 33bp, while s4 produces fragments of
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72bp, 48bp, 34bp and 19bp. There are also two smaller fragments common to all
alleles: these are 18bp and 16bp in length.
Fig. 5.3.1 - APOE PCR: Agarose gel showing initial extraction of gene
product
Fig. 5.3.2- Restriction enzyme digest of APOE PCR products
3/4 3/3 3/4 3/4
91 bp — —
72bp
48bp
Key: Lane 1 and 2 control cases.
3/3 3/3 3/3 3/4 3/3
Table 5.3.1 shows the frequency of APOE e2, s3 and e4 alleles in the study cohort
compared with data taken from the Scottish population.
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Table 5.3.1 shows the frequency of APOE s2, s3 and s4 alleles in the study cohort
compared with data taken from the Scottish population.
Table 5.3.1 - Frequency of APOE alleles in the African cohort compared















* Data taken from Cumming & Robertson 1984
A comparison of the HIV negative African cases with the Scottish data shows a
significant difference in the allele frequencies (X2=22.45, p=<0.001). In particular
the s4 allele was more than twice as common in HIV negative African children as in
the Scottish population. In addition, there was a significant difference between allele
frequencies in the two African groups, HIV positive and negative (X2=8.97,
p=0.011).
Technically satisfactory immunohistochemical staining for the markers of
microglial activation, CD68 and CD 16, was achieved in most but not all the
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genotyped cases, including 21 of 23 HIV negative and 23 of 24 HIV positive cases
analysed for CD68 expression, and 18 of 23 HIV negative and 21 of 24 HIV positive
cases for CD16 expression.
Table 5.3.2 shows the case by case data for APOE genotype and
microglial/macrophage quantitation in the selected series as well as the CNS and
general pathology findings. The cases successfully genotyped from the 20 extra cases
are marked in blue.
The APOE genotypes in the two HIV negative cases in which
immunohistochemistry was not successful were APOE e3/e4 and APOE e4/e4, and











































































































































































































































































































































































































































































































































Table 5.3.3 shows data for mean and median values of CD68 and CD16
quantitation, stratified against APOE genotype, for HIV negative African children.
Only 3 genotypes were observed in the 21 cases studied, e3/e3, e3/e4 and e4/e4. For
CD68 minimal differences in microglial quantitation were observed in the white
matter in different APOE genotypes. However greater divergence was noted in the
grey matter where the median value for subjects with an e3/e3 genotype was 364
compared to 548 for those with a e3/e4 genotype. Only minimal differences in CD 16
expression were observed between different genotypes. The e4/e4 genotype was
excluded from statistical analysis as there were insufficient numbers to allow
satisfactory comparison. None of the comparisons in these HIV negative children
reached significance.
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Table 5.3.3 - Correlations between APOE genotype and

















437 363 523 0.659
(371) (444) (539)
n=7 n=8 n=3





WM 24 36 32 0.862
(98) (37) (52)
Key: Values given are median with mean in brackets, GM - Grey Matter, WM - White
Matter, p values - Mann Whitney Test
Table 5.3.4 shows data for CD68 and CD16 quantitation stratified against APOE
genotype for HIV positive African children. Although there appeared to be APOE e4
dose related trend for increased CD68 expression in both grey and white matter,
these differences did not reach statistical significance when s3/e3 and e3/s4 cases
were compared. For CD 16 expression in the grey matter there was little difference
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between subjects with e3/e3 and e3/e4 genotypes. The e4/e4 cases were excluded
from statistical analysis because of small numbers.
Table 5.3.4 - Correlations between APOE genotype and




e2/e3 e3/e3 e3/e4 e4/e4
P value for comparison
of 3/3 and 3/4
genotypes
1






OVo 1592 0 105
(1027) (478) (922) (1607)
n=23
WM
1100 377 592 1193 0.071
1100 (363) (800) (1146)
n=l n=T3 n=5 n=2
CD16
GM
50 31 14 21 0.692
50 (107) (105) (21)
n=21
WM
116 100 450 156 0.844
116 (284) (379) (156)
Key: Values given are median with mean in brackets, GM - Grey Matter, WM - White
Matter, p values - Mann Whitney Test
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Fig 5.3.3 CD16 quantitation in basal ganglia in different APOE
genotypes - HIV negative (grey boxes) and HIV positive cases (pink
boxes)
Boxplot for CD16 image analysis - basal ganglia gm and wm - ApoE genotypes
<$> A*& £ JtT
A> A? A* AT
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6> 6> <5> d>N & v ^
CD16 values for gm and wm according to genotype and HIV status
A*
£
Fig 5.3.3 - this boxplot illustrates the results for CD16 immunostaining of the grey and
white matter of the basal ganglia, separated according to APOE genotype and HIV status -
the HIV positive boxes are coloured pink. CD staining values are those obtained from
image analysis - expressed as the area stained in sq. mu out of a total of 4 sq. mm of
section.
The x-axis labels denote grey matter and white matter partition with respect to the
genotypes s3/s3 and s3/s4, so that CD16g3/3 identifies the box expressing the values for
the grey matter of those cases found to have an APOE e3/e3 genotype. CD16w3/3
identifies the values for the white matter of those with the same genotype - and so on.
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Values for cases with an s2e3 or s4s4 genotype have been excluded due to small numbers.
On the graph the mean values have been added. Any outlying values are indicated by an
asterisk - *. For the HIV positive cases mean connect line joins the means for the grey
matter values of the 3/3 and 3/4 genotypes and the same applies to the means for white
matter.
Fig 5.3.4 CD68 quantitation in basal ganglia in different APOE
genotypes - HIV negative (grey boxes) and HIV positive cases (pink
boxes) image
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CD68 values for gm and wm according to genotype and HIV status
Fig 5.3.4 - this boxplot illustrates the results for CD68 immunostaining of the grey and
white matter of the basal ganglia and the same principles of labelling apply as for Fig 5.3.3.
A mean connect line links the boxes for grey and white matter separately for HIV negative
and positive cases of different APOE genotype.
5.4 - Discussion and Conclusions
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These results show that there are statistically significant differences between APOE
allele distributions in the African paediatric cohort and in the Scottish population and
between the HIV negative and positive children. It is acknowledged that the numbers
of African cases genotyped in this study are very small and may not be representative
of the population in the Ivory Coast. However the findings in the present study,
notably the excess of APOE 4 cases, are in line with what is known of adult West
African distributions, where the APOE s4 frequency may approach 30% (Zekraoui et
al. 1997).
For HIV negative children the levels of inflammation, as detected by both CD 16
and CD68, differ little between the e3/e3, e3/e4 and e4/e4 genotypes although there
is a trend for the CD68 microglial expression to be greater in grey matter in cases
with one or more APOE e4 alleles. For HIV positive children, the corresponding
values are generally higher with a similar trend for increase in APOE e4 cases, albeit
in the white matter, but these shifts did not amount to significance. It is worth noting
that the APOE e4/e4 cases were excluded for statistical analysis because of small
numbers. The conclusion is that this study has not been able to demonstrate that the
APOE genotype influences the degree of microglial activation in the CNS, either in
HIV negative or positive African children. It may be that there is no difference - it
should not be assumed that the relationship between microglial activation and APOE
genotype demonstrated in AD in Caucasians should necessarily also occur in HIV
infection. It may also be that possession of APOE e4 alleles does not have the same
implications in African populations, as exemplified by the study that was unable to
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detect a relationship between the APOE s4 allele and AD in elderly West African
males (Osuntokun 1995). Alternatively, there might prove to be a difference but one
which could only be shown by examination of a much larger number of subjects.
Among the cases genotyped, HIV negative individuals were fairly balanced
against HIV positive children in terms of pathology, both at systemic and CNS
levels.
A major difficulty encountered in this study was that of the extraction of DNA
from the paraffin wax preserved tissue although this is a recognized method for DNA
extraction from archival material (Dunlop et al. 1997). Nevertheless it is well
recognised that formalin fixation inhibits the extraction of DNA and subsequent
amplification by PCR (Rogers et al. 1990). It is thought that formalin causes cross
linkage between DNA and proteins, which may inhibit efficient DNA extraction.
Formalin is also known to cause single strand breaks in DNA, which may inhibit
efficient DNA replication by PCR (Grafstrom et al. 1983).
The small number of cases is acknowledged as a limitation of the current study,
and more extensive sampling of the whole paediatric cohort might provide more
robust data. Confirmatory evidence of the association between the APOE e4 allele
and enhanced neuroinflammation might be found in the adult Abidjan autopsy
cohort, as well as providing additional information on the APOE allelic distribution
in this African population. The difference between the allele frequencies for HIV
negative and HIV positive children is noted - the s4 allele being almost 50% lower
in HIV positive children. Even among the 3 cases excluded from the correlations
because of unsatisfactory immunohistochemical staining, it is noted that both the
HIV negative cases possessed APOE s4 alleles whereas the excluded HIV positive
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case had an APOE s3/s3 genotype, in keeping with the apparent greater frequency of
s4 alleles in the former group. It seems unlikely that being HIV positive would
influence the dynamics of gene extraction. A bias however could operate at a very
early stage - even to affect the vulnerability of an HIV positive foetus, heterozygous
or homozygous for the s4 allele, and thereby the frequency at birth and in the
neonatal period. However the numbers are too small to draw any firm conclusions
and only a larger survey could clarify this interesting finding.
In concluding this account of the APOE study the results of a few pertinent studies,
and their possible applications to neurodegenerative and neurotraumatic human
disease, are considered.
Since the effect of APOE on lymphocyte function was investigated in 1980 (Hui et
al. 1980) many experimental studies, especially on transgenic mice, have explored
the dynamics of the relationship between the APOE polymorphisms and the immune
system, particularly in respect of the innate neuroinflammatory response. The
absolute importance of APOE was demonstrated in 1999 when it was shown in a
study of APOE knockout mice that resistance to systemic infection was impaired. In
addition, circulating pro-inflammatory cytokine TNFa levels were increased 4-5 fold
in response to bacterial endotoxin lipopolysaccharide (LPS) injection in these mice
(de Bont et al. 1999). As an interesting corollary to this finding, a recent paper has
described the beneficial effects of ApoE-derived peptides administered to APOE e2,
s3 and s4 targeted replacement mice that were subjected to experimental closed head
injury (Wang et al. 2007). In these mice, treatment resulted in reduced microglial
activation and early inflammatory events, raising the possibility of a therapeutic
application of ApoE protein in human cases of head injury.
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The physiological basis for this effect was investigated in 2001, when both in-vitro
and in-vivo studies showed that ApoE protein down-regulated CNS production of
TNFa and 11-1(3 following the application of LPS (Lynch et al. 2001). The authors
thought that this effect of ApoE was specific, and could account for the role that it
appears to play in neurological injury and disease.
The effects of differing APOE alleles on the neuronal responses to microglial
activation were tested in an experiment using dissociated cultures of glia and neurons
from targeted replacement mice bearing the APOE s2, s3 and e4 alleles (Maezawa I
- 2006). The degree of neuronal damage was found to be greatest in association with
the microglia possessing APOE s4, and least with the APOE s2 microglia.
In 2007, a further study on the APOE isoforms and inflammation was published.
In a series of experiments, Vitek et al (2007) defined several key features of the
APOE gene-modulated macrophage/microglial inflammatory responses using in-
vitro and in-vivo models. Microglial cultures from both heterozygous and
homozygous targeted replacement mice were studied and it was shown that APOE
e3/e3 and APOE e4/e4 microglia exhibited different morphologies. The former
showed a partial ramified shape with extended processes, and the latter the amoeboid
morphology shown earlier to be associated with activation (Perry and Gordon 1988).
Vitek et al. confirmed that production of inflammatory mediators was greatest in
APOE e4/e4 microglial cultures. In addition, they showed that peripheral
macrophages shared in this APOE genotype-specific effect. Measurement of
supernatant nitrite levels in the cultures revealed a gradation which was shown to be
APOE gene-dose dependent - the levels being highest in the APOE e4/e4 microglial
cultures. They considered the idea that the effect of APOE e4/e4 microglia might be,
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in part at least, due to reduced production of ApoE protein, thereby depriving the
neuropil of its beneficial effects. This concept had previously been proposed in 2001
(Ramassamy et al. 2001). They found, by comparing ApoE protein expression in
brain lysates of APOE e3/e3 and APOE e4/e4 mice that the levels in the former were
significantly higher than in the latter. A final finding of interest was that the innate
inflammatory response in aged mice tended to be higher in animals with an APOE
e4/e4 genotype compared with APOE e3/e3 animals, as detected by TNFa levels in
response to injected LPS in 60-week old mice.
The idea that the innate immune response, as linked to the APOE genotype, and
which is considered important for survival in human populations exposed to high
levels of pathogens (Finch and Morgan 2007), should become disadvantageous in the
elderly is noted (Vitek et al. 2007). However, biological mechanisms that might
operate in the elderly at one latitude need not operate at another, where different
conditions of climate and diet obtain. Indeed, in West African elderly males, as
noted at the beginning of this chapter of this chapter, no association was found
between dementia and the APOE e4 allele (Osuntokun et al. 1995). While
interpreting the present data with caution, it may be that links between APOE
genotype and microglia observed in Caucasians are not operative in African
populations. However the quantitative results for microglial activation do suggest
that such a link might be established with a larger study. Finally, when analyzing the
distribution of alleles in an autopsy cohort, it should also be considered that the genes
being examined might influence survival in this disease-prone population.
Accordingly, an autopsy cohort may not necessarily reflect the surviving population.
Conclusions
1. The distribution ofAPOE alleles in this African cohort, whilst significantly
different from that of the Scottish population, and significantly different
between HIV positive and negative children, is in keeping with what is
known ofWest African distributions.
2. The results of this study of the relationship between APOE allelic variants
and the neuroinflammatory response show a trend for increased activation in
APOE e4 HIV positive cases that does not however reach significance. To
our knowledge this is the first study of this relationship in African subjects.
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Chapter 6: General Discussion and Conclusions
Introduction
When, in 1991, the authors of the paper " Disease in children infected with HIV in
Abidjan, Cote d'lvoire" (Lucas et al. 1996) started their work they must have been
aware of the daunting task that they were about to undertake. There could have been
no comparison with contemporary mortuary pathology practice in Europe, either in
terms of the harrowing human material and its unremitting volume or the conditions
under which they would work, in the absence of air conditioning in a humid tropical
city. Nor should the risks of infection, not just from HIV, but also from tuberculosis
pass without mention. The documentation of the study alone could scarcely be
imagined from the succinct presentation in the paper.
The data gathered at that time remain as a unique archive, both as a resource of
HIV material, and also of a spectrum of diseases, both non-tropical and tropical.
Many of the non-tropical illnesses are seen in stages of their natural history not
described since the pre-antibiotic era in the West. Of course deaths due to meningitis
and pneumonia are still recorded in this country but they are few in comparison and
most will have had the appropriate treatment. The high frequency of HIV infection
noted in the original paper (Lucas et al. 1996) - during the period of the study 80 of
the 408 (20%) children brought to the mortuary were HIV positive - underlines the
high incidence of HIV infection in infants and children in sub-Saharan Africa. In
South Africa alone an estimated 50,000 HIV infected children are born each year
(Prendergast et al. 2007).
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In 1997, with the publication of the paper " The Neuropathology of HIV-infected
African Children in Abidjan, Cote d'lvoire' (Bell et al. 1997) the communication of
the findings of what was the very first cross-sectional post-mortem survey ofHIV in
Africa, was completed.
Now, the present study documents three different aspects of the neuropathology. It
suffers from several limitations and perhaps the most important is that it was
undertaken in the absence of clinical data (there was very little clinical, laboratory or
radiological information available to the original authors) or general post mortem
findings. Furthermore, no spinal cords were available and thus no conclusions can be
drawn as to motor or sensory disability suffered in the months before death. One
consistent feature is the remarkably good preservation of the tissue, which was linked
to the short death-to-postmortem interval. The decision to study only 40 cases in the
Main Study- about a quarter of the whole cohort - has meant smaller numbers for
statistical analysis but a reasonably representative sample was obtained by selection
on age groups and a detailed survey of inflammatory change has proved possible.
As noted in the introduction to the Main Study there was a differing disease
spectrum between the HIV negative and HIV positive groups though a reasonable
balance of cases with, and without, significant pathology is thought to obtain. In the
original description of the neuropathology of the cohort (Bell et al. 1997), 8 of the 78
HIV positive cases were described as having HIV specific pathology, including 4
cases of HIV encephalitis (HIVE) and 4 cases of leucoencephalopathy. Two of these
are subjects in the present study, - one case ofHIVE in the Initial Study and another
in the Main Study. The abstraction of 5 HIV negative and 5 positive cases which
appeared within nuimal limits lieuropathulugically, was an attempt to analy se while
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mailer abnormalities, lymphocytic infiltrates and microglial/macrophage activation
in cases free of the confounding factor of disparate disease, thus permitting an
assessment of the effects ofHIV infection alone on these parameters.
The Initial Study
The usefulness of the initial study may be open to question, not only because of the
difficulty in the separation of the glial populations and in reliable counting in the
presence of oedema or possible shrinkage, but also because of the natural variation in
cell numbers as they appear at different levels in the neuraxis, in different fibre tracts
and in different orientations of these fibres. However, the cell counts proved to be
reasonably consistent between cases, suggesting that they may reflect an accurate
picture of cell subsets in the white matter. Even in the small numbers of cases in this
study, a statistically significant difference was detected in cell numbers between the
HIV positive and negative cases, the HIV positive counts being the larger. This
increase was detected in counts for nuclei posited on their shape or position or GFAP
positivity to belong to a class of oligodendrocytes, astrocytes,
microglia/macrophages and endothelial cells.
In particular, the numbers of nuclei of GFAP positive cells were increased in the
HIV positive cases compared with those that were negative. These results are in
agreement with other studies which show that astrocytic hyperplasia is not just
confined to the end stage of HIV infection, but occurs throughout the course of the
infection in adults (Gray et al. 1996) (Weis et al. 1993). Astrocytosis was also a
frequent finding in childhood AIDS encephalopathy (Sharer et al. 1986). One cause
of proliferation of astrocytes was investigated in an in-vitro study in 1990 (Selmaj et
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al. 1990), which found that serum free TNF-a produced a mitotic response in
cultured astrocytes. There was no evidence of cytotoxicity or of proliferation of
oligodendrocytes, suggesting that the effect was cell type specific. However, the
Main Study showed no evidence of upregulation of GFAP expression in HIV
positive cases and this apparent discrepancy is discussed below.
The observed differences in total cell numbers between HIV positive and negative
cases reflect increases in all cell types. The reasons for an increase in apparent
oligodendrocytes in HIV positive cases are unclear, particularly in the absence of
white matter damage as shown in the Main Study, and would require further
examination to confirm the finding. However the lack of recognised cell markers for
accurate identification of oligodendrocytes remains a stumbling block.
The increase in microglial numbers in HIV positive cases is unsurprising, is borne
out by the results in the Main Study and is in keeping with the results of all other
studies of HIV/AIDS. However this is the first time that such a finding has been
reported for African cases.
The finding that capillary endothelial cell nuclei appear increased in numbers in
HIV positive cases compared those of HIV negative cases was unexpected and may
signify a subtle inflammatory response. A hundred years after the first microscopical
description of inflammation by the German experimental pathologist, Julius
Cohnheim (1839-1884), the molecular basis for the changes he observed was
investigated (Pober 1988).The first of such studies examined the responses to TNF-a,
IL-1, IL-6 and IFN-y, produced locally by leucocytes, and these included increased
BBB permeability and hypertrophy and proliferation of endothelial cells with
associated accumulation of intracellular organelles (Stolpen et al. 1986),(Cavender et
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al. 1989). In 2001, HIV gpl20 was shown to be an activator of brain endothelial cells
in children, resulting in increased expression of the endothelial adhesion factors,
ICAM-1 and VCAM-1 (Stins et al. 2001). A circulating, virally derived molecule,
such as HIV gpl20, could induce a proliferative response in endothelial cells and
thus account for the apparent increase in numbers of endothelial cells detected in this
study. However there are other possible reasons for this result. Firstly, the orientation
of the myelin might favour more capillaries being displayed in longitudinal section
and thus increasing the numbers of nuclei available to be counted. This seems to be
an unlikely explanation since the selection of the areas sampled applied equally to
HIV negative and positive cases. Secondly, the endothelial cell nuclei in HIV cases,
exposed to molecules such as gpl20, might in their activation have become
hypertrophied and therefore more visible. Finally, relatively more small vessels may
have been affected by vasodilatation in HIV positive cases, rendering their lining
endothelial cells more obvious.
The Main Study
This in-depth survey of the inflammatory changes in the brains of African children
reveals a wide variation of responses to the infectious diseases that were responsible
for their deaths. In most cases, the terminal illnesses are likely to have been of just a
few days duration and so the reactions of the adaptive immune system, as judged
here by the CD 8 and CD20 lymphocyte counts, may have been evolving in many of
the subjects. These reactions are subject to many influences, including age, the state
of nutrition and hydration, and the co-existence of other disease(s). The polyclonal
B-cell activation known to occur during the course of HIV infection is supported in
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this study by the finding of B-cells in most of the cases showing low-grade
lymphocytic infiltrate and in one of the AIDS cases. Their numbers do not
necessarily signify effective function and the impaired humoral immunity associated
with HIV infection leads to reduced resistance to bacteria such as H.influezae and S.
pneumoniae, which may have caused the deaths of some of these children.
The striking numbers of CD8 lymphocytes in the parenchyma of the brains of the
AIDS cases and, of course, those defined by the presence of low-grade lymphocytic
infiltrate, suggests that this may represent a response to the presence of HIV infected
cells undetected by immunocytochemical methods, as described in a recent paper
(McCrossan et al. 2006). By the same token, the numbers seen in the parenchyma in
other HIV positive cases, such as those in the category with no significant findings
on routine staining, may have a similar explanation.
Investigation of the white matter in the main study did not reveal significant myelin
damage, in either the basal ganglia or hippocampus. Similarly there was no evidence
of a significant upregulation of GFAP expression in HIV positive cases compared
with negative. The results of the Initial Study (albeit in a different group of cases)
suggested that significant GFAP positive astrogliosis would be detected in the HIV
positive cases in the Main Study and this proved not to be the case. The reasons for
the relative lack of GFAP response may be that some of the subjects in the Main
Study were less mature than those in the Initial Study and therefore perhaps less
capable of mounting an astroglial response. But, in addition, it is noted that cell
counting methods reflect cell numbers, whereas GFAP immunostaining indicates
upregulated protein expression. Thus the two results may not be as incompatible as
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they appear at first sight. In general, it seems from these results that white matter
damage is not a major feature ofHIVAIDS in untreated African children.
The microglial population of the brain is generally considered to be the local arm of
the innate immune system and there is little doubt that evolution has ensured that not
only is the territory fully covered by a elaborate spatial gridwork of cells, but also
that there is very fine functional tuning (Nimmerjahn et al. 2005). The CD68 and
CD 16 responses detected in this study can be seen as a snapshot of a mixture of both
acute and chronic activation and involving both macrophage (perivascular and
bloodstream derived) and microglial populations. The magnitude of these responses,
irrespective of the cause, for example in the septicaemia cases in the HIV negative
group, constitutes a threat to the CNS. Firstly, in HIV infected individuals the
passage of infected monocyte/macrophages is facilitated and secondly, the
homeostasis of the parenchyma is prejudiced by cytokine production by activated
macrophage/microglia (Glass and Wesselingh 2001). From the CD68 and CD 16
results, this study confirms that, even in the context of heightened risk of brain
disorders seen in these African children regardless of their HIV status, HIV infection
is accompanied by significant activation of microglia and macrophages, constituting
the innate immune system.
The importance of these processes, in both the short term survival of the individual
and in longer term cognitive functioning, is such that any factor that might influence
either process could be critical in determining the outcome. The result of the APOE
study is clearly relevant in this regard, given the current interest in dementia and the
part that APOE might play in its pathogenesis.
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The APOE Study
The main limitation of the APOE study is the number of genotyped cases and any
conclusions must be tempered with caution, to be re-examined in the contest of a
larger study. However the finding of raised numbers of APOE s4 cases in the groups
overall are in keeping with what is known of African populations. Within this study,
the finding of lower numbers of APOE e4 alleles in the HIV positive group is
intriguing and might suggest some degree of protection from HIV in individuals
bearing this allele although the result is just as likely to be a chance finding.
The results of the APOE study show that within both HIV negative and positive
groups, higher levels of CD 16 and CD68 expression are generally associated with the
APOE e4 genotype (although it is important to note that the results did not achieve
significance) and this tends to support the view that possession of an s4 allele is
likely to be associated an increased level of neuroinflammation. More specifically,
the experimental finding that the 4/4 genotype is associated with increased levels of
TNF-a production (Vitek et al. 2007) is of contemporary interest in respect of
Alzheimer's disease. For several years monoclonal antibodies against inflammatory
cytokines, in particular anti-TNF-a, have been used in the treatment of diseases that
have a major inflammatory component, such as rheumatoid arthritis. This approach,
termed cytokine modulation, is reserved for severe forms of the disease and a drug
called Etanercept is one of the more commonly prescribed preparations (BNF 2007).
In 2007, a paper was published in which a remarkable improvement in cognitive
functioning was reported in patients suffering from Alzheimer's disease following
the injection of Etanercept into the peri-spinal venous system (Tobinick 2007). This
potentially revolutionary discovery awaits further evaluation in controlled trials. If
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substantiated, this finding supports the hypothesis that there is a "pre-structural" and
potentially reversible stage in the development of Alzheimer's disease and that this
may operate at synaptic level. A similar approach may prove of value in HIV
associated dementia (HAD), since a study in 1993 showed that the levels of TNF-a
mRNA in the white matter of AIDS patients are significantly greater in HAD than in
AIDS patients without dementia, or in controls (Glass et al. 1993).
The novel finding that the degree of neuroinflammation in this African paediatric
cohort may have a relationship to the ApoE e4 allele is of great interest since genetic
influences can operate at many levels in determining susceptibility or resistance to
disease. Recent views on the location and structure of the blood brain barrier (BBB)
suggest that the favoured, if not exclusive, point of transit for inflammatory cells
entering the CNS is through the post-capillary venules (Bechmann 2006), and that
this is seen as the first step in entry. This passage is apparently made with ease by
monocytes in the course of their normal patrolling behaviour. The second step,
which involves crossing the perivascular space and the glia limitans, is subject to
strict structural and functional constraints. The dynamics of this passage have been
explored using a mouse model, and the finding was that mice deficient in CD95
(CD95L is a death ligand expressed constitutively on astrocyte end feet) showed
much lower numbers of apoptotic T-cells in experimental allergic encephalitis (EAE)
than did control mice (Sabelko et al. 1997). Perivascular apoptosis is a well
recognized feature of neuroinflammation (Pender et al. 1991). ApoE is also
expressed on the surface of astrocyte end feet (Boyles et al. 1985) (Fujita et al.
1999) and could therefore affect events at the BBB. If immune cell access to the
CNS were influenced by ApoE that in turn could affect the level of cytokine
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production and the associated tissue disturbance in both Alzheimer's disease and
HAD.
Possible Future Extensions of this Study
The results provided by this study are derived from a small part of the original
cohort, and it would be of value in the future to document more of the
neuroinflammation in this unique archive. Another useful investigation would be to
compare the systemic findings and causes of death, described in 1996, with the
findings of this study and to extend the APOE survey to the African adults who died
in Abidjan. It would also be of great interest to investigate the BBB with
immunostaining for evidence of breakdown in HIV positive cases in this cohort,
using a marker of tight junctions (ZO 1), and with anti-fibrinogen immunostaining to
detect serum leakage.
The APOE study would require larger numbers to provide more definite evidence
of a relationship between the e4 allele and the severity of neuroinflammation in
HIV/AIDS in these children.
Epilogue
The material on which this study is based underlies the sad story of HIV/AIDS,
especially in children in Africa, but in adults as well and throughout the whole
developing world. Even apart from HIV infection it is salutary to reflect on the fact
that many of the infants and children in this cohort died of diseases, which, in the
West, respond readily to the appropriate treatment.
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However, the latest information (UNAIDS - 2007) is that in some parts of Africa,
including the Cote d'lvoire, the prevalence of HIV infection has shown a decline
over the last few years. In 2007 there were an estimated 1.7 million (1.4 - 2.4) new
infections in sub-Saharan Africa - a significant reduction since 2001. An estimated
22.5 million (20.9 - 24.3) people are living with HIV in Africa and this accounts for
68% of the global total. Elsewhere the figures are not encouraging. In Eastern Europe
and Central Asia the number of people living with HIV has increased by 150% in
2007 to 1.6 million (1.2 - 2.1 million). In Asia the fastest growing epidemic is
Indonesia. Overall, however the global prevalence has levelled, and the number of
new infections has fallen. HIV prevention programmes are considered to have
contributed to this improvement. For 2007 the global total of people estimated to be
living with HIV was 33.2 million, 2.5 million were thought to have become newly
infected and 2.1 million to have died.
Universal access to diagnosis and prevention of mother-to-child transmission are
seen as the most important interventions to reduce the number of infected children
(Prendergast et al. 2007). Antiretroviral therapy programmes, where they have been
available in Africa have usually been successful. In 2004, 544 children in Cote
d'lvoire were started on HAART and a year later 84% were still attending for
follow-up (Wemin 2006).
In 2003 it was estimated that 10 million children were dying each year worldwide
(Black et al. 2003) of malnutrition and infectious disease. Without public health
programmes and political commitment that number is unlikely to fall. The hope is
that the goodwill and offers of financial help for the economic development of
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countries such as Africa, expressed at the G8 summit in Gleneagles in 2005, will
ensure a better future for the world's children.
Conclusions
1. In a small group of this cohort of African children, studied at autopsy, HIV
infection was shown to be associated with generalised hyperplasia of both
glia and endothelial cells in the white matter
2. A significant increase in the degree and extent of neuroinflammation has been
demonstrated in HIV positive children especially in respect of the basal
ganglia region and despite a high level of co-present pathology in the brains
of both HIV negative and positive children.
3. No white matter abnormality was detected in these developing brains as a
result of HIV infection.
4. The distribution of APOE alleles in this African cohort, whilst significantly
different from that of the Scottish population, and significantly different
between HIV positive and negative children, is in keeping with what is
known ofWest African distributions
5. A trend towards increased activation of the inflammatory response was
detected in APOE s4 HIV positive children.
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7. Initial Study - comparison of sampling methods
8. Initial Study - means and standard deviations of counts
9. a. Initial Study - data for cell count groups 1-3
b. Initial Study - data for cell count groups 4-6
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11. Main Study - Table of LFB grades for basal ganglia
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361
Appendix 1 Monoclonal ABC Method
1. De-wax sections in xylene - two 5 minute immersions.
2. Immerse in 99% ethanol (74 op) - twice for 5 minutes each
3. Immerse in 70% alcohol - twice for 5 minutes each
4. Immerse in picric acid for 20 minutes
5. Wash in running tap water until all the picric acid is removed
6. Immerse in hydrogen peroxide for 10 minutes (50 mis hydrogen
peroxide and 450 mis distilled water for 20 minutes (100 mis methanol
+ 25 mis 3% H O ) (blocks endogenous peroxidase enzyme)
7. Wash in water
8. Perform antigen retrieval if required (unmasks antigens which may have
been affected by fixation)
9. Wash in water
10. Place sections in sequenza rack with TBS
11. Wash in xl TBS buffer for 5 minutes
12. Treat with normal rabbit serum (NRS) (1 ml NRS to 4 mis TBS 10
minutes
13. Incubate with primary antibody diluted in NRS for 30 minutes (omit
from negative control)
14. Wash in buffer 2x5 minutes
15. Incubate in biotinylated rabbit anti-mouse immunoglobulins diluted in
NRS for 30 minutes
16. Prepare ABC according to Manufacturer's instruction, 30 minutes prior
to use
17. Wash in buffer 2x5 minutes
18. Incubate in ABC for 30 mins
19. Wash in buffer 2x5 minutes
20. Treat with DAB for 1 - 2 minutes
21. Counterstain in Haematoxylin
22. Dehydrate, clear and mount
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Appendix 2 Polyclonal ABC Method
23. De-wax sections in xylene - two 5 minute immersions.
24. Immerse in 99% ethanol (74 op) - twice for 5 minutes each
25. Immerse in 70% alcohol - twice for 5 minutes each
26. Immerse in picric acid for 20 minutes
27. Wash in running tap water until all the picric acid is removed
28. Immerse in hydrogen peroxide for 10 minutes (50 mis hydrogen
peroxide and 450 mis distilled water for 20 minutes (100 mis methanol
+ 25 mis 3% H O ) (blocks endogenous peroxidase enzyme)
29. Wash in water
30. Perform antigen retrieval if required (unmasks antigens which may have
been affected by fixation)
31. Wash in water
32. Place sections in sequenza rack with TBS
33. Wash in xl TBS buffer for 5 minutes
34. Treat with normal swine serum (NSS) (1 ml NSS to 4 mis TBS 10
minutes)
35. Incubate with primary antibody diluted in NSS for 30 minutes (omit
from negative control)
36. Wash in buffer 2x5 minutes
37. Incubate in biotinylated swine anti-rabbit immunoglobulins diluted in
NSS for 30 minutes
38. Prepare ABC according to Manufacturer's instruction, 30 minutes prior
to use
39. Wash in buffer 2x5 minutes
40. Incubate in ABC for 30 mins
41. Wash in buffer 2x5 minutes
42. Treat with DAB for 1 - 2 minutes
43. Counterstain in Haematoxylin
44. Dehydrate, clear and mount
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Appendix 3 Tyramide signal amplification (TSA) method
45. De-wax sections in xylene - two 5 minute immersions.
46. Immerse in 99% ethanol (74 op) - two 5 minute immersions
47. Immerse in 70% alcohol - two 5 minute immersions
48. Immerse in picric acid for 20 minutes
49. Wash in running tap water until all the picric Acid is removed
50. Immerse in hydrogen peroxide for 10 minutes (50 mis hydrogen
peroxide and 450 mis distilled water for 20 minutes (100 mis methanol
+ 25 mis 3% HO) (blocks endogenous peroxidase enzyme)
51. Wash in water
52. Perform antigen retrieval if required ( unmasks antigens which may
have been affected by fixation)
53. Wash in water
54. Place sections in sequenza rack with TBS
55. Wash in xl TBS buffer for 5 minutes
56. Treat with normal rabbit serum (NRS) (1 ml NRS to 4 mis TBS 10
minutes
57. Incubate with TNB for 10 mins
58. Incubate with primary antibody diluted in NRS for 30 minutes (omit
from negative control)
59. Rinse in TBS 2x5 minutes
60. Incubate in biotinylated rabbit anti-mouse immunoglobulins diluted in
NRS for 30 minutes
61. Rinse with TBS 2x5 mins
62. Incubate with streptavidin HRP for 30 mins (dilute 1 in 500 in TNB)
366
63. Rinse with TNT 2x5 mins
64. Incubate with biotinylated tyramide for 10 mins
( lpL biotinylated tyramide in 300pL boric acid solution. Boric acid
solution is 3mls boric acid + 1 p.1 hydrogen peroxide)
65. Rinse with TNT 2x 5 mins
66. Incubate with streptavidin HRP for 30 mins
67. Rinse with TBS 2x5 mins
68. Wash with water
69. Incubate with DAB for 1 - 2 mins
70. Wash with water
71. Counterstain with haematoxylin
72. Dehydrate clear and mount
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Appendix 4 Immunohistochemistry notes
1. Slides racks should be agitated once or twice when in xylene, alcohols and
picric acid
2. Picric acid breaks formalin bridges - see ApoE chapter
3. Antigen retrieval methods are given in immunostain tables in text.
Their aim is to unmask antigen epitopes hidden by formalin fixation
4. TBS is TRJS-HC1 buffered saline Ph 7.6 - TRIS (hydroxylmethyl)
aminomethane 0.6 gm, sodium chloride 8.1 gm, 1 M HC1 3.8mls and
distilled water to 1,000 mis - see reagent sheet
5. The biotinylated secondary antibody attaches the primary antibody to the
peroxidase labelled streptavidin-biotin compound ABC.
6. ABC is Avidin Biotin Complex
7. DAB is diaminobenzidine - a chromogenic agent which labels
immunoreactive sites a brown colour when oxidised in the presence of
streptavidin bound horse radish peroxidase
8. The tyramide signal amplification (TSA) method is used when there are
low levels of antigen in the tissue. The principle is that the primary
antibody signal can be amplified by the interaction of tyramide with
horseradish peroxidase (HRP), which generates large numbers ofHRP
molecules, This in turn enhances the amount of colour on the addition of
DAB thereby increasing the ability to detect smaller amounts of the
antigen.
9. TNB and TNT are buffers - see reagent sheet
368
















































Appendix 6 Solutions for immunohistochemistry and PCR
Solutions
Immunohistochemistry:
Tris buffered saline (TBS) xl
Tris-HCL, PH7.6 0.05M
NaCl 0.15M
Made up in dHiO
TNT Tris HCL pH7.5 0.1M
NaCl 0.15M
0.05% Tween 20
TNB Tris HCL pH7.5 0.1M
NaCl 0.15M
0.5% blocking reagent
Biotinylated tyramide 4ml Boric acid 50mM
lOmg Biotinamidocaproic acid 3-
sulpho-N-Hydroxysuccinimide ester
3mg tyramine Hydrochloride
Hydrogen peroxide 10% v/v
Made up in dH20
Ethanol 99%
75%
Made up in dH20
PCR:
Loading buffer Glycerol 49.9% v/v
lOxTBE 49.9% v/v
Bromophenol blue (BPB) 0.2% w/v
Ethidium bromide (Et Br) 1 % w/v
Made up in dH20
Tris-Borate-EDTA (TBE) xlO
Tris 10.8% w/v
Boric acid 5.5% w/v
0.5M EDTA, pH 8.0 4% v/v
Made up in dH20
lkb ladder
(in lOmM Tris-HCL, pH7.5, 50mM NaCl, 0
200pg/ml
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Appendix 7 Initial study - the sampling methods compared
Initial study - the sampling methods compared.
First method Second method
1 derivation - total to cover 1 sq.mm total to cover l/5th of lsq. mm
2 frames in x =2 frames in x =1
3 frames in y =2 frames in y = 1
4 width = 328.37 p width = 164.18p
5 height = 246.59p height = 123.29p
6 area = 80975.24 sq.p area = 20243.8sq.p
7 image tiled — in 4 frames single - untiled image
8 sample - 12.35 fields sample - 10 fields
9 equation - equation -
12.35 images =lsq.mm. 10 images = 202438 sq.p
."..for area 1 sq.mm multiply by 4.94
Total area actually scanned =1 sq.mm Estimation of area scanned = 1 sq.mm
Appendix8
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Appendix 10 Table of the means for the HIV negative cases c61-c40 (n=4)
Initial study - the means of the HIV negative cases compared for CNS areas.
mean mean mean
CNS area C1.0 % CI. 1 % C1.2 % Totals
Cx.gyral core 797 90% 58 6% 32 4% 887
Cx. U fibre z. 807 89% 61 7% 36 4% 904
Temp, lobe 775 90% 52 6% 36 4% 863
Int.Cap. 708 92% 43 6% 19 2% * 770
Cerebellum 648 85% 74 10% 39 5% «* 761
rounding 800 60 30




percentages 90% 6% 4%
89% 7% 4%
90% 6% 4%
Int.Cap. ** 92% 6% 2%
Cerebellum * 85% 10% 5%
mean percentages -approximate 90% 6% 4%
Notes * internal capsule - oblique fibre orientation - fewer nuclei?
** cerebellum - oedema - nuclear fallout? Reduced numbers?
C1.0=round nuclei - CI. 1 =GFAP positive cells - C1.2= rectangular nuclei
Means of 4 HIV -ve cases
















Levels: convexity to cerebellum
Appendix 11 Table of basal ganglia Luxol fast blue light- box grades 376
A B C D E F
1 Basal ganglia LFB light-box grades
2 Code No Age Sex HIV Grd CNS pathology findings on routine staining
3
4 HIV negative cases
5 c54 0.4 M - 1 meningoencephalitis and infarcts
6 c94 0.5 M - 1 no significant findings
7 c100 0.5 F - 1 no significant findings
8 c104 6.0 M - 1 cerebral malaria
9 c109 0.5 F - 1 purulent meningitis
10 c113 0.4 M - 1 no significant findings
11 c59 1.6 M - 2 purulent meningitis
12 c77 0.3 F - 2 possible septicaemia
13 c89 0.5 F - 2 purulent meningoencephalitis
14 c93 1.5 F - 2 no significant findings
15 c117 2.9 M - 2 Lcerebral malaria
16 c33 1.6 F - 3 possible septicaemia
17 c42 5.0 F - 3 no significant findings
18 c50 1.6 F - 3 no significant findings
19 c57 5.0 F - 3 no significant findings
20 c60 1.5 F - 3 no significant findings
21 c67 4.0 F - 3 no significant findings
22 c74 1.5 F - 3 no significant findings
23 c76 1.6 M - 3 no significant findings
24 c101 4.0 M - 3 possible septicaemia
25
26 Mean=2.15 p=0.666 (Mann-Whitney)
27 SD=0.875
28
29 HIV positive cases
30 c5 1.7 F + 1 no significant findings
31 C82 0.2 F + 1 cerebellar infarcts & micro-haemorrhages
32 cllO 0.4 M + 1 toxoplasmosis
33 cl29 0.4 F + 1 low grade lymphocytic infiltrate
34 cl31 0.4 M + 1 low grade encephalitis
35 C24 5.0 M + 2 measles encephalitis
36 c62 4.0 F + 2 low grade lymphocytic infiltrate
37 cl21 1.6 M + 2 cerebral oedema
38 cl22 3.3 F + 2 low grade lymphocytic infiltrate
39 cl25 1.5 M + 2 no significant findings
40 C126 1.5 F + 2 no significant findings
41 C140 4.0 M + 2 no significant findings
42 cl50 0.4 F + 2 no significant findings
43 C157 0.2 M + 2 purulent meningitis
44 c8 3.5 F + 3 subtle widespread wm damage
45 c9 5.1 F + 3 medullitis
46 c55 1.7 M + 3 low grade lymphocytic infiltrate
47 c91 1.6 M + 3 low grade lymphocytic infiltrate
48 C128 1.8 F + 3 low grade lymphocytic infiltrate





54 Note of grading: l =minimal stain intensity or extent.
55 2=moderate stain intensity or extent.
56 3=normal or almost normal stain intensity or extent
Appendix 12 Table of hippocampus Luxol fast blue light-box grades 377
A B c D E F
1 Hippocampus LFB light-box grades
2 Code No Age Sex HIV Grd CNS Pathology findings on routine staining
3
4 HIV negative cases
5 c52 0.5 M - 1 no significant findings
6 c54 0.4 M - 1 meningoencephalitis & infarcts
7 c60 1.5 F - 1 no significant findings
8 c77 0.3 F - 1 possible septicaemia
9 c94 0.5 M - 1 no significant findings
10 c100 0.5 F - 1 no significant findings
11 c109 0.5 F - 1 purulent meningitis
12 c23 1.5 M - 2 no significant findings
13 c33 1.6 F - 2 possible septicaemia
14 c50 1.6 F - 2 no significant findings
15 c63 2.5 F - 2 no significant findings
16 c89 0.5 F - 2 purulent meningoencephalitis
17 c57 5.0 F - 3 no significant findings
18 c59 1.6 M - 3 purulent meningitis
19 c86 1.8 F - 3 no significant findings
20 c93 1.5 F - 3 no significant findings
21 C101 4.0 M - 3 possible septicaemia
22 C104 6.0 M - 3 cerebral malaria
23 c117 2.9 M - 3 cerebral malaria
24 C124 5.0 M - 3 no significant findings
25
26 Mean=2.05 p=0.840 (Mann-Whitney)
27 SD=0.89
28
29 HIV positive cases
30 c51 1.8 F + 1 low grade lymphocytic infiltrate
31 c82 0.2 F + 1 cerebellar infarct & microhaemorrhages
32 c110 0.4 M + 1 toxoplasmosis
33 c150 0.4 F + 1 nothing significant
34 c157 0.2 M + 1 purulent meningitis
35 c5 1.7 F + 2 no significant findings
36 c9 5.1 F + 2 medullitis
37 c16 5.3 F + 2 no significant findings
38 c55 1.7 M + 2 low grade lymphocytic infiltrate
39 c62 4.0 F + 2 low grade lymphocytic infiltrate
40 c70 2.1 F + 2 low grade lymphocytic infiltrate
41 c91 1.6 M + 2 low grade lymphocytic infiltrate
42 c126 1.5 F + 2 no significant findings
43 c129 0.4 F + 2 low grade lymphocytic infiltrate
44 c131 0.4 M + 2 low grade encephalitis
45 c8 3.5 F + 3 subtle widespread wm damage
46 c24 5.0 M + 3 measles encephalitis
47 c122 3.3 F + 3 low grade lymphocytic infiltrate
48 c125 1.5 M + 3 no significant findings





54 Note of grading: l =minimal stain intensity or extent.
55 2=moderate stain intensity or extent.
56 3=normal or almost normal stain intensity or extent
Appendix 13 Table of basal ganglia pAPP grades 378
A | B C I D | E F
1 Basal ganglia PAPP grades
2 Code No Age Sex HIV grd CNS pathology findings on routine staining
3
4 HIV negative cases
5 c42 5.0 F - 0 no significant findings
6 c50 1.6 F - 0 no significant findings
7 c57 5.0 F - 0 no significant findings
8 c59 1.6 M - 0 purulent meningitis
9 c67 4.0 F - 0 no significant findings
10 c74 1.5 F - 0 no significant findings
11 C76 1.6 M - 0 no significant findings
12 C77 0.3 F - 0 possible septicaemia
13 c89 0.5 F - 0 purulent meningoencephalitis
14 c94 0.5 M - 0 no significant findings
15 C100 0.5 F - 0 no significant findings
16 C101 4.0 M - 0 possible septicaemia
17 C104 6.0 M - 0 cerebral malaria
18 cll3 0.4 M - 0 no significant findings
19 cll7 2.9 M - 1 cerebral malaria
20 c33 1.6 F - 2 possible septicaemia
21 c60 1.5 F - 2 no significant findings
22 cl09 0.5 F - 2 purulent meningitis
23 c54 0.4 M - 3 meningoencephalitis and infarcts
24 c93 1.5 F - 3 no significant findings
25
26 Mean = 2.17 p=0.029 (Mann-Whitney)
27 SD=0.75
28 1 1
29 HIV positive cases
30 c5 1.7 F + 0 no significant findings
31 c8 3.5 F + 0 subtle widespread wm damage
32 c9 5.1 F + 0 medullitis
33 c62 4.0 F + 0 low grade lymphocytic infiltrate
34 c82 0.2 F + 0 cerebellar infarcts & micro-haemorrhages
35 c91 1.6 M + 0 low grade lymphocytic infiltrate
36 cllO 0.4 M + 0 toxoplasmosis
37 C121 1.6 M + 0 cerebral oedema
38 cl22 3.3 F + 0 low grade lymphocytic infiltrate
39 cl25 1.5 M + 0 no significant findings
40 C128 1.8 F + 0 low grade lymphocytic infiltrate
41 cl31 0.4 M + 0 low grade encephalitis
42 C140 4.0 M + 0 no significant findings
43 cl57 0.2 M + 0 purulent meningitis
44 C24 5.0 M + 1 measles encephalitis
45 c55 1.7 M + 1 low grade lymphocytic infiltrate
46 cl26 1.5 F + 1 no significant findings
47 C129 0.4 F + 1 low grade lymphocytic infiltrate
48 C150 0.4 F + 1 no significant findings






55 Notes:grd=overall grade of staining. l=minimal, 2=moderate and 3=maximal.
Appendix 14 Table of hippocampus BAPP grades 379
A | B | C | D E F
1 Hippocampus - pAPP grades
-> Code No Age Sex HIV grd CNS pathology findings on routine staining
3
4 HIV negative cases
5 c23 1.5 M - 0 no significant findings
6 c50 1.6 F - 0 no significant findings
7 c52 0.5 M - 0 no significant findings
8 c57 5.0 F - 0 no significant findings
9 c59 1.6 M - 0 purulent meningitis
10 c86 1.8 F - 0 no significant findings
11 c89 0.5 F - 0 purulent meningoencephalitis
12 c94 0.5 M - 0 no significant findings
13 c100 0.5 F - 0 no significant findings
14 c101 4.0 M - 0 possible septicaemia
15 c104 6.0 M - 0 cerebral malaria
16 c33 1.6 F - 1 possible septicaemia
17 c77 0.3 F - 1 possible septicaemia
18 c109 0.5 F - 1 purulent meningitis
19 c124 5.0 M - 1 no significant findings
20 c54 0.4 M - 2 meningoencephalitis & infarcts
21 c63 2.5 F - 2 no significant findings
22 c93 1.5 F - 2 no significant findings
23 c117 2.9 l_M - 2 cerebral malaria
24 c60 1.5 F - 3 no significant findings
25
26 Mean = 1.2 p=0.585 (Mann-Whitney)
27 SD=0.71
28
29 HIV positive cases
30 c5 1.7 F + 0 no significant findings
31 c8 3.5 F + 0 subtle widespread wm damage
32 c9 5.1 F + 0 meduliitis
33 c16 5.3 F + 0 no significant findings
34 c51 1.8 F + 0 low grade lymphocytic infiltrate
35 c82 0.2 F + 0 cerebellar infarct & microhaemorrhages
36 c122 3.3 F + 0 low grade lymphocytic infiltrate
37 c125 1.5 M + 0 no significant findings
38 c131 0.4 M + 0 low grade encephalitis
39 c150 0.4 F + 0 nothing significant
40 c24 5.0 M + 1 measles encephalitis
41 c110 0.4 M + 1 toxoplasmosis
42 c126 1.5 F + 1 no significant findings
43 c129 0.4 F + 1 low grade lymphocytic infiltrate
44 c140 4.0 M + 1 no significant findings
45 c157 0.2 M + 1 purulent meningitis
46 c62 4.0 F + 2 low grade lymphocytic infiltrate
47 c70 2.1 F + 2 low grade lymphocytic infiltrate
48 c91 1.6 M + 2 low grade lymphocytic infiltrate
49 c55 1.7 M + 3 low grade lymphocytic infiltrate
50
51 Mean = 1.5
52 SD=0.71
53 1
54 Notes:qrd=overall grade of staining. l =minimal, 2=moderate and 3=maximal.
Appendix 15 Table of basal ganglia GFAP staining grades 380
A | B | C | D | E F
1 Basal ganglia - GFAP grades
2 Code No Age Sex HIV Grade CNS pathology findings on routine staining
3
4 HIV negative cases
5 c33 1.6 F - 1 possible septicaemia
6 c42 5.0 F - 1 no significant findings
7 c54 0.4 M - 1 meningoencephalitis and infarcts
8 c67 4.0 F - 1 no significant findings
9 C74 1.5 F - 1 no significant findings
10 C76 1.6 M - 1 no significant findings
11 c77 0.3 F - 1 possible septicaemia
12 c89 0.5 F - 1 purulent meningoencephalitis
13 clOO 0.5 F - 1 no significant findings
14 clOl 4.0 M - 1 possible septicaemia
15 cl04 6.0 M - 1 cerebral malaria
16 C50 1.6 F - 2 no significant findings
17 c57 5.0 F - 2 no significant findings
18 c59 1.6 M - 2 purulent meningitis
19 c93 1.5 F - 2 no significant findings
20 cl09 0.5 F - 2 purulent meningitis
21 C113 0.4 M - 2 no significant findings
22 cll7 2.9 M - 2 cerebral malaria
23 c60 1.5 F - 3 no significant findings
24 c94 0.5 M - 3 no significant findings
25
26 Mean=1.55 p=0.151 (Mann-Whitney)
27 SD=0.69
28
29 HIV positive cases
30 c8 3.5 F + 1 subtle widespread wm damage
31 c9 5.1 F + 1 medullitis
32 c55 1.7 M + 1 low grade lymphocytic infiltrate
33 c91 1.6 M + 1 low grade lymphocytic infiltrate
34 C125 1.5 M + 1 no significant findings
35 cl40 4.0 M + 1 no significant findings
36 C150 0.4 F + 1 no significant findings
37 c62 4.0 F + 2 low grade lymphocytic infiltrate
38 C110 0.4 M + 2 toxoplasmosis
39 C122 3.3 F + 2 low grade lymphocytic infiltrate
40 C126 1.5 F + 2 no significant findings
41 C128 1.8 F + 2 low grade lymphocytic infiltrate
42 C129 0.4 F + 2 low grade lymphocytic infiltrate
43 C131 0.4 M + 2 low grade encephalitis
44 C152 6.4 M + 2 HIV encephalitis & toxoplasmosis
45 c5 1.7 F + 3 no significant findings
46 c24 5.0 M + 3 measles encephalitis
47 c82 0.2 F + 3 cerebellar infarcts & micro-haemorrhages
48 C121 1.6 M + 3 cerebral oedema




53 Notes: grade l=abserit to minimal expression.
54 grade 2=slight expression
55 grade 3=moderate expression
56 grade 4=extensive and strong expression
Appendix 16 Table of hippocampus GFAP grades 381
A | B | C | D | E F
1 Hippocampus - GFAP grades
2 Code No Age Sex HIV grade CNS pathology findings on routine staining
3
4 HIV negative cases
5 c23 1.5 M - 1 no significant findings
6 c33 1.6 F - 1 possible septicaemia
7 c50 1.6 F - 1 no significant findings
8 c52 0.5 M - 1 no significant findings
9 c54 0.4 M - 1 meningoencephalitis & infarcts
10 c89 0.5 F - 1 purulent meningoencephalitis
11 c94 0.5 M - 1 no significant findings
12 c63 2.5 F - 2 no significant findings
13 c86 1.8 F - 2 no significant findings
14 c101 4 M - 2 possible septicaemia
15 c104 6 M - 2 cerebral malaria
16 c124 5 M - 2 no significant findings
17 c57 5 F - 3 no significant findings
18 c59 1.6 M - 3 purulent meningitis
19 c60 1.5 F - 3 no significant findings
20 c77 0.3 F - 3 possible septicaemia
21 c93 1.5 F - 3 no significant findings
22 c100 0.5 F - 3 no significant findings
23 c117 2.9 M - 3 cerebral malaria
24 c109 0.5 F - 4 purulent meningitis
25
26 Mean=2 p=0.120 (Mann-Whitney)
27 SD=0.95
28
29 HIV positive cases
30 c16 5.3 F + 1 no significant findings
31 c55 1.7 M + 1 low grade lymphocytic infiltrate
32 c140 4 M + 1 no significant findings
33 c5 1.7 F + 2 no significant findings
34 c24 5 M + 2 measles encephalitis
35 c51 1.8 F + 2 low grade lymphocytic infiltrate
36 c70 2.1 F + 2 low grade lymphocytic infiltrate
37 c82 0.2 F + 2 cerebellar infarct & microhaemorrhages
38 c110 0.4 M + 2 toxoplasmosis
39 c122 3.3 F + 2 low grade lymphocytic infiltrate
40 c8 3.5 F + 3 subtle widespread wm damage
41 c9 5.1 F + 3 medullitis
42 c62 4 F + 3 low grade lymphocytic infiltrate
43 c91 1.6 M + 3 low grade lymphocytic infiltrate
44 c125 1.5 M + 4 no significant findings
45 c126 1.5 F + 4 no significant findings
46 c129 0.4 F + 4 low grade lymphocytic infiltrate
47 c131 0.4 M + 4 low grade encephalitis
48 c150 0.4 F + 4 no significant findings




53 Notes: grade l=absent to minimal expression.
54 grade 2=slight expression
55 grade 3=moderate expression
56 grade 4= extensive and strong expression
Appendix 17 Table of summary statistics for the Main Study 382
A | B C | D |E| F | G | H I
1 Basal ganglia and hippocampus - summary of Mann-Whitney test results
2
3 CD8 counts CD8 counts
4 basal ganglia Mann-Whitney tests hippocampus Mann-Whitney tests
5 gm medians wm medians gm medians wm medians
6 Group A1 HIV -ve 5 5 Group A2 HIV -ve 3 9
7 pv cells HIV +ve 19.5 23 pv cells HIV +ve 11 32
8 p value p=0.001 p=0.000 p value p=0.002 p=0.000
9
10 gm medians wm medians gm medians wm medians
11 Group A1 HIV -ve 0 0 Group A2 HIV -ve 0 0
12 par cells HIV +ve 1 13 par cells HIV +ve 2 4
13 p value p=0.011 p=0.000 p value p=0.003 p=0.006
14
15 gm medians wm medians gm medians wm medians
16 Group B1 HIV -ve 5 7 Group B2 HIV -ve 3 14
17 pv cells HIV +ve 17 20 pv cells HIV +ve 6 24
18 p value p=0.115 p=0.060 p value p=0.172 p=0.071
19
20 gm medians wm medians gm medians wm medians
21 Group B1 HIV -ve 0 0 Group B2 HIV -ve 0 0
22 par cells HIV +ve 1 10 par cells HIV +ve 0 21
23 p value p=0.251 p=0.034 p value p=0.441 p=0.011
24
25
26 CD20 counts CD20 counts
27 basal ganglia Mann-Whitney tests hippocampus Mann-Whitney tests
28 gm medians wm medians gm medians wm medians
29 Group A1 HIV -ve 1.5 0 Group A2 HIV -ve 1.5 2.5
30 pv cells HIV+ve 2.5 0.5 pv cells HIV+ve 1 2.5
31 p=0.471 p=0.895 p=0.651 p=0.913
32
33 gm medians wm medians gm medians wm medians
34 Group B1 HIV -ve 2 0 Group B2 HIV -ve 2 1
35 pv cells HIV +ve 3 1 pv cells HIV +ve 0 1
36 p=0.832 p=0.908 0.158 p=0.295
37
38
39 CD14 grades CD14 grades
40 basal ganglia Mann-Whitney tests hippocampus Mann-Whitney tests
41 medians
42 Group A1 HIV-ve 2 Group A2 HIV-ve 2.25
43 HIV+ve 3 HIV+ve 2
44 p=0.338 p=0.490
45
46 Group B1 HIV-ve 2 Group B2 HIV-ve 2




51 CD16 image analysis CD16 image analysis
52 basal ganglia Mann-Whitney tests hippocampus Mann-Whitney tests
53 gm medians wm medians gm medians wm medians
54 Group C HIV -ve 18 32 Group A2 HIV -ve 36 37
55 HIV +ve 28 347.5 HIV +ve 142 208
56 p value p=0.447 p=0.03 p value p=0.037 p=0.004
57
58
59 gm medians wm medians gm medians wm medians
60 Group B1 HIV -ve 18 26 Group B2 HIV -ve 17 18
61 HIV +ve 15 95 HIV +ve 49 209
62 p value p=0.753 p=0.210 p value p=0.295 p=0.346
63
64 |
65 CD68 image analysis results CD68 image analysis results
66 Basal ganglia - Mann-Whitney tests Hippocampus - Mann-Whitney tests
67
68 gm medians wm medians gm medians wm medians
69 Group A1 HIV -ve 380 373 Group A2 HIV -ve 697 458
70 HIV +ve 1063 761 HIV +ve 826 837
71 p value p=0.002 p=0.009 p value p=0.091 p=0.468
72
73
74 Group B1 HIV -ve 364 383 Group B2 HIV -ve 157 244
75 HIV +ve 1076 698 HIV +ve 716 810
76 p value p=0.142 p=0.403 p value p=0.144 p=0.022
77
78 Notes: for Groups A1 and A2 n=20
79 for Groups B1 and B2 n=5
80 for Group C n=17
81 I i
